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Mesenchymal stem cells are multipotent cells that have the ability to differentiate 
down multiple lineages as well as secrete trophic and anti-inflammatory factors. These 
qualities make MSCs a promising cell source for cell-based therapies to treat a variety of 
injuries and pathologies. Biomaterials are often used to control and direct stem cell 
behavior by engineering a desired environment around the cells. Recent research has 
focused on using the naturally derived sulfated glycosaminoglycan (GAG), heparin as a 
biomaterial due to its negative charge and ability to sequester and bind positively charged 
growth factors. Engineering a heparin coating that can mimic the native heparan sulfate 
proteoglycan structure found at cell surfaces can be used as a novel platform to present 
GAGs to cells to direct cell behavior. The overall goal of this dissertation was to develop 
GAG-based coatings on MSC spheroids in order to study the role of heparin and its 
derivatives on MSC culture applications. 
To investigate the role of heparin in coating form on MSC behavior, the ability of 
the coating to sequester positively charged growth factors was characterized. Given the 
role of sulfation in the negative charge density of heparin and growth factor interactions, 
a desulfated heparin coating was develop and used to examine how presentation of 
coatings with native and no sulfation levels could potentiate response to growth factors in 
the surrounding environment. Additionally, heparin and growth factor binding in coating 
presentation was explored to develop a novel platform to assemble MSC-based 
microtissues. Together these studies provided valuable insight into a novel approach to 








 Mesenchymal stem cells (MSCs) are multipotent cells commonly obtained from 
bone marrow and adipose tissue that have the ability to differentiate down bone, 
cartilage, muscle, marrow, tendon/ligament and connective tissue lineages [1]. 
Additionally, MSCs have the ability to secrete trophic and anti-inflammatory factors that 
can promote angiogenesis, modulate extracellular matrix (ECM) remodeling, modulate 
immune cell activation or suppression and promote cell recruitment [1-4]. These qualities 
make MSCs a promising cell source for cell-based therapies to treat a wide range of 
pathologies. Currently, MSCs are being used in 374 clinical trials that aim to treat 
diseases and injuries that involve bone/cartilage, heart, neural, kidneys, lung, liver tissues 
and autoimmune pathologies [5, 6]. Although the number of clinical trial has increased 3-
fold since 2011, approximately 90% of these trials remain in Phase 1 or 2 and no Food 
and Drug Administration (FDA)-approved Biologics License Applications (BLAs) for 
MSC-based products currently exist [5].  
 To improve current therapies, recent research efforts have employed using MSC 
formed into aggregates as a platform for MSC-based treatments. The benefits of MSC 
aggregates have been shown in preclinical studies, in which administration of three-
dimensional (3D) MSC aggregates in a porcine model have improved cell retention 
survival and integration in myocardial transplantation [7]. Additionally, in in vitro 
studies, MSC aggregates have shown to possess enhanced ability to differentiate down 
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osteogenic and adipogenic lineages as well as secrete trophic and anti-inflammatory 
factors [8]. Because single cell administration of MSCs often result in low engraftment, 
MSC aggregates can also be formed into microtissues as a means increase retention of 
cells upon delivery to a site of injury [9, 10]. Additionally, since the adherent MSCs are 
formed into 3D aggregates with cell-cell contacts with each other, they can be cultured in 
dynamic systems that are amenable for large scale processing [11]. While MSC 
aggregates have promising potential for future cell based-therapies, it has been shown 
that when aggregated, MSCs have limited proliferative capacity [12, 13]. Therefore, 
although this aggregated culture platform is amenable for scale up processes, its ability to 
support cell expansion is limited [14]. Additionally, due to the 3D organization of the 
densely packed cells together in an aggregate, the resulting microenvironment is 
biochemically and molecularly heterogeneous and the cells on the interior of the 
aggregate may not be exposed to the same nutrients or factors as the cells at the surface 
of the aggregate [15]. Efforts to improve upon these strategies to overcome these 
limitations may lead to the development of future MSC aggregate-based therapies.  
 To address limitations that exist in MSC aggregate culture, biomaterials can be 
used as a method to control and direct behavior by engineering a desired environment 
around the cells. Recent research has focused on using naturally derived 
glycosaminoglycans (GAGs) as a biomaterial for tissue engineering and drug delivery 
applications [16, 17]. Heparin, the most sulfated GAG, has anti-coagulant activity, plays 
a role in organizing basement membrane and can act as a coreceptor to bind and 
sequester positively charged growth factors, cytokines, and chemokines and enhance 
ligand-receptor signaling [18]. Engineering of a heparin coating that can mimic the native 
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heparin sulfate proteoglycan structure found at cell surfaces can be used as a novel 
platform to present GAGs to cells to direct cell behavior. Because it is known that 
interactions with growth factors is dependent on the sulfation pattern present [19, 20], 
there is an opportunity to examine how non-native sulfation patterns can play a role in 
potentiating growth factor signaling and response in MSCs. In addition to modulating 
growth factor response with heparin-derived coatings, there is also an opportunity to alter 
cell behavior by exploiting heparin’s ability to bind positively charged growth factors. By 
taking advantage of this property, molecular interactions could then be translated to not 
only direct cellular response to growth factors in the surrounding environments, but also 
direct cell behavior in microtissue assembly. The role of heparin and its derivatives in 
coating form on cell response and culture has not been previously examined and can 
provide insight into novel techniques to develop effective MSC-based therapies. The 
engineering of the immediate cells microenvironment at its surface can be used to 
enhance and direct cell fate and behavior in many different applications for tissue 
engineering MSC based therapies.  
 
1.2 Research Objectives 
 The objective of the research presented in this dissertation was to develop 
heparin-based coatings on MSC spheroids in order to study the role of heparin and its 
derivatives on MSC culture for the improvement of stem cell-based therapies. To develop 
an understanding of this novel approach to control cell behavior, MSCs were coated with 
heparin and its ability to sequester positively charged protein and the subsequent cellular 
response was examined. Given the importance of sulfation in the negative charge density 
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of heparin, a platform was developed to explore its role in growth factor interaction 
through the desulfation of heparin. These materials were used to examine how 
presentation of coatings with native and no sulfation levels could potentiate the mitogenic 
response to the growth factor fibroblast growth factor-2 (FGF-2) and the chondrogenic 
response to transforming growth factor beta-1 (TGF-β1) and subsequently cell 
proliferation and differentiation, respectively. Additionally, to explore other usages of 
these coatings, the interactions between heparin and a peptide sequence presenting the 
specific binding site found on FGF-2 (HEPpep), was explored to develop a novel 
platform to assemble MSC-based microtissues. The goal of these studies was to provide 
insight into the presentation and interaction of heparin that alter stem cell behavior 
regarding proliferation, differentiation or aggregation. The central hypothesis of this 
research was that engineering heparin-based coatings would allow for the ability to direct 
cell behavior in MSC spheroids by regulating the response to the surrounding cues 
(growth factors or peptide interactions) in the environment. The characterization and 
effects of this heparin coating on cell surfaces within MSC spheroids was explored in the 
following three specific aims:  
  
Hypothesis I: Using a layer-by-layer method will facilitate coating MSC spheroids with 
heparin and subsequently a bioactive heparin binding growth factor. 
Specific Aim I: Develop and characterize a multilayer heparin coating for biomolecule 
presentation to human MSC spheroids. 
MSCs have been used as cell therapies to aid in regeneration of a variety of 
injured tissue. Moreover, MSCs aggregated into small spheroids have enhanced anti-
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inflammatory properties over single MSCs grown in monolayer [21]. However, MSC-
based therapies may be rendered ineffective due to lack of control over cell fate after 
introduction into a complex or harsh injured environment. We aimed to develop a heparin 
coating for MSC spheroids to potentially allow for simultaneous delivery of both cells 
and a soluble factor to direct cell differentiation. Heparin, a negatively charged 
glycosaminoglycan that can sequester and release positively charged proteins, was 
grafted onto cell surfaces through deposition of biotin and avidin as intermediate layers. 
Fluorescent imaging provided characterization of heparin coatings at different 
concentrations, confirmation of a loaded protein and effects on cell viability within the 
MSC spheroid. Additional characterization was performed through a particle exclusion 
assay to examine heparin coating effects on the native pericellular matrix of MSCs, 
through a monocyte anti-inflammatory coculture assay to reveal heparin coating effects 
on MSC spheroid anti-inflammatory properties, and through a mink lung epithelial cell 
line bioactivity assay to determine the bioactivity of TGF-β1 loaded onto coated cell 
surfaces.  
 
Hypothesis II: A fully sulfated heparin coating will result in higher cell number in 
response to FGF-2 and to greater chondrogenic differentiation in response to TGF-β1 in 
MSC aggregates, compared to a desulfated heparin coating and a noncoated control, due 
to stronger electrostatic interactions with the positively charged growth factor within the 
vicinity of the cells.  
Specific Aim II: Determine response of human MSC aggregates to growth factors in the 
culture media after coating with heparin of high and low sulfation levels. 
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 MSC micromass culture has been traditionally used to study chondrogenic 
differentiation, however, recent interest in smaller MSC aggregates (500-1000 cells) with 
smaller diameters has increased because of their ability to be used as injectable therapies 
treatment of cartilage injuries and disease [22]. Although MSC spheroids can be a 
promising platform for effective cell-based therapies, the challenge of lack of 
proliferation in spheroid culture may hinder the scale-up of aggregate systems. 
Additionally, due to the 3D structure of formed aggregates, exogenous growth factors 
supplemented to the culture medium may not be exposed the entire cell population, 
especially the cells found on the interior of the aggregate. The incorporation of sulfated 
GAGs, like heparin, can be used as a potential vehicle to promote growth factor 
availability due to the negatively charge that local electrostatic interaction with positively 
charged proteins. Additionally, because the interaction between heparin and its growth 
factors depends on the presence of the negatively charged sulfate groups, desulfation of 
the GAG can modulate the interaction with a positively charged protein. Therefore, the 
objective was to characterize heparin MSC coatings of two different sulfation levels 
(native sulfation and fully desulfated) and study the effect of these coatings on MSC 
response in the presence of two different growth factors supplemented to the culture 
media. To evaluate the coating effect, MSC aggregates were coated with either heparin or 
desulfated heparin and then cultured in serum-free media containing FGF-2 or TGF-β1. 
Over 14 days in vitro, cell number was determined using a DNA assay, and over 21 days 
in vitro, cell morphology was characterized using histological staining and chondrogenic 
differentiation was evaluated using quantitative reverse transcription polymerase chain 
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reaction (RT-PCR) and immunohistochemical (IHC) staining for chondrogenic 
extracellular (ECM) components.  
 
Hypothesis III: MSC spheroid building blocks coated with HEPpep and heparin will 
assemble due to the specific interaction between the peptide sequence and the GAG to 
form microtissue constructs with different cell populations.  
Specific Aim III: Determine effect of HEPpep and heparin cell coating on MSC spheroid 
microtissue assembly in a dynamic culture system.  
Another application of MSCs is their use in microtissues as either an in vitro 
model system or in vivo tissue repair replacement [23, 24]. Formation of these 
microtissues can be performed by using a “bottom-up” method, in which smaller building 
blocks of multiple cell types are assembled together to construct a larger tissue. To 
recapitulate complex structure of tissues, multiple cell types are often incorporated in 
specific spatial confirmations that mimic both homotypic and heterotypic cell interactions 
found in native tissues. The objective of this study was to investigate the use of HEPpep 
and heparin coatings on MSC spheroids assembly to form multi-cellular microtissues in a 
dynamic suspension culture system. It was envisioned that HEPpep coated spheroids 
would interact and assemble with heparin coated spheroids to form multi-cell type 
constructs in dynamic culture. First, HEPpep and heparin coatings and their effect on cell 
viability of MSC spheroids were characterized. Additionally, the specificity of these 
coatings was assessed by culturing together spheroids coated with different peptide 
sequences and GAGs for 24 hours. Finally, system parameters such as ratio of cell 
populations and surface area availability were varied to observe effects on assembly of 
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HEPpep coated and heparin coated spheroids and their interactions within the system by 
measuring assembled construct size, composition and interfacial area between two 
populations over the course of 3 days.  
 
1.3 Significance and Scientific Contributions 
 The studies in this dissertation provide significant insight into the role of a novel 
presentation of the naturally derived GAG, heparin in coating form on MSC spheroid 
culture. Using a layer-by-layer technique, a method to graft heparin and subsequently 
facilitate protein sequestration onto cell surfaces was developed. The new technology of a 
heparin cell coating provides a new platform to present both GAGs and a sequestered 
growth factor to cells. The released growth factor from the heparin coating can also 
signal to surrounding environments, demonstrating that this heparin coating can also act 
as a carrier to deliver a therapeutic growth factor in addition to the stem cells to help 
regeneration and repair tissues.  
In addition to the establishment of a heparin coating, the use of biotin and avidin 
as intermediate layers allow for the grafting of other biotinylated species on cell surfaces, 
therefore, other heparin derivatives, such as desulfated heparin can also be coated onto 
cell surfaces. The versatility of this system enabled investigating the effects of GAG 
species with native and no sulfation levels on cell surfaces and how it potentiates the 
response of the aggregated cells to the growth factor in the environment, specifically, 
MSC proliferation and chondrogenic differentiation. Desulfation of heparin provided 
insight into how coatings of different sulfation patterns can promote response to 
positively charged growth factors to ultimately direct cell behavior. These studies 
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provided evidence that pairings of different GAGs and growth factors can be used to 
tailor a MSC response to target and treat different pathologies. The knowledge gained in 
these studies, in turn, may advance the development of novel cell based therapies that 
modifies stem cell response using a combination of growth factors and GAG sulfation 
patterns for effective usage in a specific application.    
 Finally, the development of heparin and HEPpep coatings reveal insights into 
heparin and heparin binding peptide interactions that can be utilized to self-assemble 
microtissues from small building blocks in a dynamic culture system. By simply 
culturing heparin coated and HEPpep coated spheroids together in one system, the 
specific interaction between the coatings on each cell population can be exploited to 
promote assembly to form a population of microtissues containing multiple cell types. 
This platform provides insight into a novel technique to assemble microtissuses in one 
system under dynamic culture by harnessing the interactions that can be engineered at 
cell surfaces. This research highlights that a GAG-based coating for MSC spheroids can 
be used for different culture applications, ranging from proliferation to differentiation to 
microtissue formation. Together these findings represent a novel technology that 
modulates molecular interactions at cell surfaces through exploitation of the heparin 





BACKGROUND AND LITERATURE REVIEW 
 
2.1 Mesenchymal Stem Cells 
2.1.1 Mesenchymal Stem Cell-Based Therapies  
 Adult bone marrow contains multipotent progenitor cells referred to as 
mesenchymal stem cells (MSCs) [1]. In the bone marrow, MSCs are isolated from the 
mononuclear layer after separation by density gradient centrifugation. These cells are 
cultured in media containing fetal bovine serum to allow for the MSCs to adhere to tissue 
culture plastic, exhibiting a fibroblast-like morphology [25]. Population doubling time is 
dependent on donor and playing density, however, these cells divide rapidly and are 
relatively easy to expand in culture [4, 26, 27]. This cell type exhibits two important 
qualities that make them a promising source for cell-based therapies. First, MSCs are able 
to differentiate into numerous mature cell types, such as those from bone, cartilage, 
muscle, bone marrow stroma, tendon and ligament, fat, dermis, and connective tissues [1, 
2, 26, 28]. Therefore, this cell type is able to regenerate multiple tissues through the 
practices of tissue engineering. Second, MSCs also secrete a broad spectrum of trophic 
factors that can be classified as immunoregulatory and proangiogenic [1, 3, 29, 30]. 
These factors can be harnessed to promote a microenvironment in diseased or injured 
tissue that is favorable for repair and regeneration.  
Since MSCs can differentiate into end-stage cell types, they have been used in 
tissue engineering practices to reform and regenerate tissues in tissue-specific 
biomaterials or when implanted into different tissue sites [1, 2, 4, 5, 26]. When cultured 
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in the correct environments containing lineage specific cues either by seeding on 
scaffolds, introducing growth factor cues or mechanical cues, MSCs can respond and 
begin to mature into the tissue specific cell type and produce tissue specific extracellular 
matrix (ECM) [31]. Typically, MSCs are characterized by their ability to different down 
three main lineages:  osteogenic, adipogenic and chondrogenic [32-36]. Each pathway is 
achieved by culture under different conditions in vitro. To induce osteogenic 
differentiation in MSC, cells are cultured in the presence of dexamethasone, ascorbic acid 
and β-glycerol phosphate [35, 37, 38]. The master osteogenic transcription factor Runx2, 
activates and regulates osteogenesis as the targeted  signaling pathway for growth factors 
such as TGF-β1, bone morphogenic proteins (BMPs), Wingless type (Wnt) and 
Hedgehog, all of which have been shown to induce bone differentiation [39-41]. 
Assessment of osteogenic different in MSCs is typically performed by measuring alkaline 
phosphatase (ALP) activity, gene expression of Runx2, collagen I and ALP, protein 
production of collagen I and ALP, and mineralization of calcium deposits over the course 
of 21 or 28 days  [12, 35, 37-39, 42].  
Adipogenic differentiation in MSCs is achieved by culture in the presence of 
insulin, isobutylmethylxanthanine, dexamethasone and hydrocortisone over the course of 
3 weeks [43-45]. The transcription factor, peroxisome proliferator-activated receptors-γ 
(PPARγ) is known to be a master regulator of promoting adipogenesis and represseing 
osteogenesis in MSCS [42]. The binding of PPARγ to various ligands, including long 
fatty acid chains and thiazolidinediones (TZDs) induce the transactivation of the 
transcription factor [46]. Additionally, studies using PPARγ deficient mice have 
demonstrated increased bone mass and decreased fat storage [47]. Adipogenic 
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differentiation in MSCs is typically measured by gene expression analysis of PPARγ and 
lipoprotein lipase (LPL), as well as, Oil Red O staining for fatty deposits over the course 
of 21 days [43, 44].  
For chondrogenic differentiation, MSCs are typically formed into pellets of 
aggregates of approximately 250,000 cells, to recapitulate embryonic limb bud 
development of high cell density environments [48-50]. Chondrogenic culture media 
contains dexamethasome, ascorbate acid, sodium pyruvate, insulin-transferrin-selenous 
acids and the growth factor TGF-β1 or TGF-β3 [49-53]. Other factors that have been 
implicated in inducing chondrogenic differentiation include the growth factors BMP-6 
and insulin growth factor-1 (IGF-1) and mechanical stimulation in the form of dynamic 
compression [54, 55]. It is also known that activation of the transcription factor Sox9 can 
regulate the expression of downstream signaling molecules that result in the expression of 
chondrocytic markers, such as collagen II and aggrecan [53, 56, 57]. Additionally, MSC 
chondrogenesis is also accompanied with expression of cartilage oligomeric matrix 
protein, fibromodulin, and deposition of sulfated glycosaminoglycans [48, 52].  
Other differentiation pathways, such as myogenesis and tendonogenesis in MSCs 
have also been achieved via in vitro culture. Myogenesis has been induced by culturing 
MSCs in media containing platelet derived growth factor-BB (PDGF-BB) and TGF-β or 
culturing MSC on bladder derived ECM [58, 59]. The smooth muscle cell phenotype has 
been characterized by measuring expression and deposition of collagen IV, desmin and 
myosin [59]. Tenogenic differentiation has been induced by culturing MSCs in 
environments undergoing mechanical strain and in the presence of growth differentiation 
factor (GDF) proteins [46]. The expression of the transcription factor, scleraxis, has been 
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used as an early marker of tendon lineage commitment [60, 61]. Other measurements of 
the protein collagen I and collagen III, as well as the expression of tenascin-C, biglycan 
and decorin, molecules all present in native tendon tissue, have been examined to 
determine tendon differentiation [60-62].  
In addition to differentiation, when subjected to biochemical or mechanical cues, 
MSCs can also secrete specific bioactive factors that create an environment favorable for 
regeneration and repair [1]. This environment containing trophic factors can promote 
activity that inhibits scarring, inhibit apoptosis, stimulate angiogenesis, and stimulate 
mitosis of tissue intrinsic stem cells [63]. MSCs and conditioned medium from MSCs in 
growth have shown do have strong immunosuppressive effects by inhibiting T-cell 
recognition and proliferation and tumor necrosis factor-α (TNF-α) and interferon-λ (INF-
γ) production [64-66]. MSCs also secrete anti-inflammatory cytokines, such as 
interleukin-6 (IL-6) and IL-8 that can alter antigen-presenting maturation, induce T-cell 
unresponsiveness, and suppress the secretion of inflammatory molecules by activated 
monocytes [28, 30, 67-69].  
 In the NIH clinical trial database, there are 374 registered clinical trials using 
MSCs [6]. Over the past 4 years, there has been a 3-fold expansion over the existing 
number; however, the distribution of the number of trials by phase has remained the 
same, with the majority of them in Phase 1 or 2 [5]. Additionally, of the Phase 3 trials , 3 
have reported completion  with results that have shown that MSCs are safe in treatment 
of myocardial infarction, cartilage defects and spinal cord injury (clinicaltrials.gov) [70]. 
One Phase 4 study that uses allogeneic umbilical cord blood MSCs  is currently recruiting 
patients to treat aplastic anemia [6]. These trials are currently MSC clinical trials include 
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treatments for bone, cartilage, and heart, diabetes, lung and liver organ regeneration, and 
repair of neurodegenerative disease and injury [5]. Some limitations in MSC-based 
therapies are the donor and tissue source diversity, manufacturing diversity in culture 
parameters (serum, oxygen tension, cryopreservation), and the lack of a standard 
characterization of MSCs [5, 71]. 
  
2.1.2 Mesenchymal Stem Cell Aggregates  
Although MSCs have canonically been defined as plastic adherent cells, it was 
revealed that 2D culture can alter the native phenotype after multiple passages and 
extended expansion [8, 11]. Using conventional in vitro culture techniques of tissue 
culture plastic substrates, MSC eventually lose their ability to self-renew, replicate, form 
clonal colonies and differentiate into the numerous lineages after successive passages and 
often before adequate cell numbers for transplantation is obtained [72, 73]. This has led 
to recent studies examining MSCs assembled into tightly packed clusters of 500-100,000 
cells to mimic an in vivo microenvironment and better preserve MSC phenotype and 
innate properties [8, 14, 74]. The formation of the 3D aggregates have shown to enhance 
regenerative properties, such as differentiation potential and secretion of trophic factors, 
as well as improve cell retention, survival and integration in animal models [11, 75-78].  
Recent studies have shown that 3D aggregate culture can enhance the 
differentiation potential of MSCs. While pellet culture has long been used to induce 
chondrogenic differentiation from MSCs [76], recent studies have also revealed that 
human bone marrow MSCs formed into aggregates exhibit a 2-5-fold increase in 
osteogenic gene expression of osteocalcin, osteopontin, ALP and Runx2 when compared 
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to MSCs cultured in 2D [78, 79]. Additionally, aggregate form increased Oil red O 
staining and adipogenic gene expression of PPAR-γ, LPL and aP2 3-fold in MSCs when 
compared to 2D monolayer [79]. When cultured in aggregate form, it has been 
demonstrated that cell-cell contacts can improve adipogenic and osteogenic 
differentiation through increased gap junction or cadherin signaling. In chondrogenic 
differentiation, the widely used micromass culture provides cell-cell contacts that are 
required to activate Notch signaling to initiate chondrogenesis [8]. ECM protein secretion 
of collagen, fibronectin and laminin also appears to increase when MSCs are cultured in 
3D clusters, which can also help regulate differentiation potential of MSCs [80]. Overall, 
the increased differentiation potential and ECM production can enhance cell survival and 
the therapeutic effect in wound healing and tissue repair [81].   
Another advantage of MSC aggregate culture is the enhanced secretion of anti-
inflammatory and proangiogenic factors [21, 28, 82]. It was shown that the enhanced 
secretion of the anti-inflammatory cytokine TNF-α stimulated gene protein-6 (TSG-6) by 
MSC aggregates was a major mechanism in the beneficial effects of MSC administration 
in mice with myocardial infarctions [83, 84]. Additionally, MSC aggregate containing 
between 50k-250k cells can increase secretion of prostaglandin E2 (PGE2), which in turn 
can modulate macrophage response [82]. Anti-inflammatory effects were also observed 
with small MSC spheroids containing 200-1000 cells, in which immunomodulatory 
factors secretion of PGE2, transforming growth factor- β1 (TGF-β1), IL-6 and 
indoleamine 2,3-dioxygenase (IDO) activity was greater when compared to MSCs 
cultured in monolayer [85]. Other trophic factors that are secreted in elevated amounts 
when MSCs are cultured in high density clusters include vascular endothelial growth 
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factor (VEGF), fibroblast growth factor-2 (FGF-2), hepatocyte growth factor (HGF), 
CXCR4, monocyte chemotactic protein-3 (MCP-3), stromal cell derived factor (SDF-1) 
and angiogenin [11, 83, 86]. Combined, these qualities elicit strong interest in the field of 
culturing and utilizing MSCs in aggregate form for potential therapeutic regimens.    
Compared to single cell administration, MSC aggregates offer numerous 
advantages to improve low retention and engraftment in preclinical animal studies [8]. 
These advantages include having upregulated secretion of trophic and anti-inflammatory 
factors that enhance therapeutic efficacy, secreting factors and producing ECM to create 
a microenvironment that protects the cells in a cytotoxic injury site, and improving cell 
adhesion and retention due to the increased cell-cell contacts and ECM production [78, 
87, 88]. These characteristics have contributed to MSC aggregates demonstrating positive 
outcomes in multiple animal in vivo models of regenerating bone and cartilage, wound 
healing, neoangiogenesis and cardiac transplantation [76].  
Various methods and culture platforms have been used to generate and study 
MSC aggregates. Formation methods include self-assembly on nonadherent or treated 
surfaces, hanging drop, forced aggregation, and microfabrication or microwells. 
Nonadherent or low-attachment surfaces culture MSCs in suspension so that the cells 
spontaneously adhere to each other forming 3D aggregates [8]. Although this method is 
easy to implement in the laboratory, formed aggregates are typically in variable size, low 
viability and low efficiency [12, 89]. In surface treated methods, typically, MSCs are 
seeded on a positively charged membrane, such as chitosan, that do not support substrate 
adhesion; therefore MSCs adhere to each other to form aggregates [90, 91]. Cell 
aggregation in the hanging drop method occurs when MSCs are suspended in separate 
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droplets and cultured on an inverted surface, during which, cells form a sphere in the 
apex of the drop [92]. During forced aggregation, cells are spun down into separate wells 
in a 96-well plate and allow cells to attach to each other [93]. Lastly, microwells typically 
seed cells in an array of micropatterned wells to separate small aggregates or 
micropatterned regions that are nonadherent to promote self-adherence [77, 94]. These 
methods utilize spatial confinement or mechanical forces to increase cell-cell contacts to 
control for aggregate size and cellular composition [95]. The formation of MSC 
spheroids used in the experiments of this dissertation was performed by using the 
commercialized microwell product, AggreWells
TM
. This platform has shown to support 
cell viability in high through manner through control of initial aggregate size and 
aggregate cell number [11, 96].  
For culture of formed aggregates, the use of dynamic cultures via rotary orbital 
shakers or spinner flasks have shown to minimize aggregate fusion, improved nutrient 
delivery and increased MSC viability [97, 98]. Bioreactor systems such as stirred tank, 
rotating wall, and perfusion bioreactors, have also been used to cultivate MSC aggregates 
for long term periods [98]. The dynamic setting appeared to enhance their biological 
function, and supported increased secretion of factors such as VEGF, HGF and FGF-2 
from MSCs [6, 8, 99]. For clinical applications, high doses of cell numbers (on the order 
of 10
9
 per administration) are typically required; therefore bioreactor systems that 
provide homogenous environment with control over parameters such as oxygen tension, 
pH and nutrient feeding are utilized [100]. However, when aggregated, the proliferation 
potential of MSC aggregates is rather limited and increased compaction has been 
observed during prolonged culture [14]. It is believed that proliferation is inversely 
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related to aggregate size due to diffusion limitations, thus large aggregates have reduced 
proliferation potential when compared to smaller aggregates. Additionally, regardless of 
size, due to the 3D environment in a tightly packed and dense cluster, the resulting MSC 
microenvironment is biochemically and molecularly heterogeneous [101, 102]. Further 
studies are needed to both understand the mechanisms behind the limited proliferation 
capacity, as well as develop methods and techniques to improve it in MSC aggregates.  
 
2.1.3 Mesenchymal Stem Cell Chondrogenesis 
During development, MSCs proliferate and differentiate into chondrocytes 
secreting cartilage ECM. These chondrocytes can undergo hypertrophy during the final 
stage of development and produce proteins necessary for calcification in the subchondral 
bone [103]. Because chondrocytes have low proliferation capacity and low metabolic 
activity, MSCs are of high interest as a promising source of cells for cartilage tissue 
engineering.  
MSC chondrogenic differentiation has been achieved by culturing cells in the 
presence of growth factors from the TGF-β superfamily, ascorbate and dexamethasone 
[104]. Traditional methods of chondrogenesis have mimicked embryonic limb bud 
development in high cell density pellet culture because a key factor in successful 
differentiation down a chondrogenic lineage is presence of cell condensation, which is 
also a natural progression observed during cartilage formation in vivo [105-107]. 
Common markers for chondrogenic differentiation include ECM markers collagen II, 
aggrecan, and cartilage oligomeric matrix protein (COMP), as well as the Sox9 
transcription factor [51, 108, 109]. Glycosaminoglycan deposition is also observed to 
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increase during in vitro pellet culture as MSCs differentiate down a chondrogenic lineage 
[49, 106, 107, 110]. While large aggregates have been used to study this process, one 
limitation includes the formation of undifferentiated or necrotized central core, leaving 
only the outside layer of cells to undergo differentiation [21]. This has led more recent 
studies to focus on the use of smaller MSC aggregates for a platform for tissue 
engineering for cartilage restoration [111].   
Additional studies have shown that MSCs can also differentiate when cultured on 
scaffolds or hydrogels [112-114]. Both natural and synthetic scaffolds, such as collagen 
II, silk/chitosan, poly(lactic-co-glycolic) acid or poly(epsilon-caprolactone), have all 
supported MSC chondrogenic differentiation, seen through upregulation of cartilage 
specific ECM gene markers and GAG deposition [112, 113, 115]. Additionally, 
implantation of these MSCs on scaffolds has shown evidence of in vivo cartilage 
regeneration in rabbit and caprine models [115, 116].  
MSCs have also been cultured in hydrogels containing naturally derived ECM or 
synthetic polymers [51, 117-120]. MSCs encapsulated in 3D network of collagen II, a 
major component of hyaline cartilage, has been shown to increase expression of Sox9, 
collagen II, aggrecan and COMP in a time dependent manner when cultured in the 
presence of TGF-β1 and dexamethasone [51]. Similarly, when MSCs were encapsulated 
in collagen I hydrogels, which is clinical used for matrix-based autologous chondrocyte 
transplantation, and cultured in the presence of TGF-β1 or BMP-2, MSCs exhibited 
distinct, chondrocyte-like cell morphology, sulfated proteoglycan-rich ECM and collagen 
II deposition was detected [119]. Gene expression for collagen II, collagen X, and 
aggrecan were also all upregulated [119]. In synthetic hydrogels that incorporate collagen 
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mimetic peptides into a poly (ethylene glycol) (PEG) network, MSCs exhibit enhanced 
secretion of cartilage specific ECM when compared to PEG only hydrogels [117, 118]. 
This has also been observed when MSCs are cultured in chondroitin sulfate (CS) 
containing hydrogels, in which cells in CS-based bioactive hydrogels supported 
aggregation of cells and expressed increased expression of cartilage gene markers such as 
Sox9 and aggrecan [120]. Overall, the use of different hydrogel networks has shown to 
support in vitro chondrogenic differentiation in MSCs, indicating that the surrounding 
cell-ECM environment around MSCs can play a role in guiding MSC fate.   
Another method to induce chondrogenic differentiation in MSCs is by subjecting 
them to dynamic compressive loading [121-123]. This mechanical stimulation 
recapitulates the in vivo knee environment that supports cyclic loading at the joint. It has 
been observed that MSCs seeded in agarose hydrogels and subjected to 10-20% strain 
lead to significantly greater proteoglycan synthesis and produced constructs with greater 
mechanical strength when compared to agarose gels that were not loaded [121-123]. It 
has been speculated that the dynamic compression regimen facilitates the diffusion of 
growth factors, such as TGF-β1, throughout the entire construct [124]. Culturing MSCs 
in a load bearing environment in in vitro systems can be utilized as a preculture technique 
to induce chondrogenic differentiation prior to implantation for cartilage tissue repair.    
Lastly, in in vitro systems, chondrogenic differentiation of MSCs can also be 
enhanced by hypoxic culture (< 5% O2), during which gene expression markers of Sox9, 
aggrecan, collagen I and II and X were upregulated in comparison to MSCs cultured in 
normoxic conditions (21% O2) [125]. It is suggested that exposure to hypoxic conditions 
results in the  translocation of the transcription factor hypoxia-inducible factor-1α (HIF-
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1α) from the cytosol to nucleus and can upregulate the expression of cartilage-related 
genes in MSCs [126]. Given that cartilage tissue resides in low oxygen environments, 
HIF-1α has also been implicated in maintaining chondrocyte phenotype and preventing 
hypertrophy of differentiated cells [127].  
 
2.1.4 Mesenchymal Stem Cell-Containing Microtissues   
 Microtissues that exhibit complex physiological microenvironments can readily 
be used as a building material for in vivo tissue repair or can be implemented as an in 
vitro tissue model [74, 128-130]. They often require the assembly of multiple cell types 
to better mimic realistic tissue structure. Cell-cell contacts between different cell 
populations are important in microtissues because they can provide contact dependent 
signals between cells and can provide cues to induce cells to perform a certain function  
and properly organize to better recapitulate specific niche environments [131].  
Microtissue models can recapitulate tumor microenvironments for drug screening 
and have been typically executed in cellular arrays or microfluidic devices that provide a 
means to culture cells in either two-dimensions or three-dimensions. These arrays are 
used to study effects of different conditions, such as drug dosage, on the resulting cellular 
response, such as viability, to determine safety and toxicity [132]. In more complex 
systems, tissue matrix arrays that combine extracellular matrix (ECM) and cells can be 
used to investigate cell function, such as proliferation and differentiation, in response to 
different environments. Such approach enables high-throughput analysis of many factors 
to determine optimal conditions to achieve a desired cellular response [129, 133, 134].  
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For tissue repair purposes, assembled 3D microtissues aim to exhibit similar 
characteristics as the complex physiological microenvironments for efficient integration, 
both functionally and morphologically, with the defect tissue [9, 74, 130]. For example, 
cardiac spheres formed from aggregating cardiomyocytes and cardiac muscle tissue has 
been used to form contractile constructs that can be implanted for treatment of 
myocardial infarctions [23]. Microtissues are advantageous in tissue repair applications 
because they are not as prone to clearance compared to single cells and can produce 
proangiogenic factor that enable pre-vascularization or induce angiogenesis post 
implantation, ultimately, can improve engraftment when delivered [128].  
MSCs have been extensively used in numerous microtissue applications, 
including cartilage, hepatic, vascularized tissues and bone marrow niches [23, 130, 135-
137]. For cartilage tissue engineering, it has been shown that MSCs cultured with 
chondrocytes results in constructs that decreased deposition of collagen X, a marker for 
MSC hypertrophy, increased glycosaminoglycan (GAG) deposition and higher Young’s 
modulus and dynamic moduli when compared to constructs without MSCs [107, 138]. 
The presence of the progenitor cells also have been shown to prevent dedifferentiation 
and maintain functional phenotype in chondrocytes. For hepatocyte culture, microtissues 
containing MSCs and hepatocytes have results in maintenance of the functional 
phenotype of the hepatocytes, as seen through urea and albumin secretion [139-141]. 
Additionally, the use of MSCs cultured in 3D can further improve hepatocyte phenotype, 
and ultimately can be used in strategies for liver regeneration and bioartificial liver-assist 
devices [142, 143]. In vascularized tissue, MSC and cardiomyocyte can be formed into 
small myocardial spheroids that secrete VEGF and support vascularization in injured 
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myocardial tissue [23, 128]. Implantation of these contractile constructs has been shown 
to improve function in myocardial infarction models in a number of animal models and 
ongoing clinical trials. Due to their numerous usages, MSCs can be used in many 
different microtissue applications.  
To assemble microtissues with multiple cell types, previous methods have used 
encapsulation in hydrogels, scaffold-free technologies and microfluidic devices. 
Hydrogel encapsulation has been used to control organization of cell populations by 
encapsulating different cell types into separate sections of a hydrogel or seeding all cell 
types in a mixed population in one single hydrogel [144-146]. Hydrogel microtissues 
have been used to examine the cross talk and interactions between MSC, osteoblast and 
adipocyte populations cultured in different regions [145]. Additionally, a hybrid 
hydroxyapatite and alginate hydrogel containing chondrocytes has been developed to 
form osteochondral constructs that can support the formation of a calcified cartilage-like 
matrix for the interfacial tissue engineering between bone and cartilage [147].  
The other option of scaffold-free technologies uses centrifugation or gravity to 
force cells into aggregate form. Multiple cell types are typically mixed together and 
cultured together in one aggregate [148, 149]. Scaffold-free microtissues containing small 
spheroids of different cell types as the building block can also be formed by the 
incorporation of magnetic microparticles that direct the assembly of spheroids upon 
application of a magnetic field [150]. Aggregated microtissues have previous been used 
to form hepatocyte tissue containing hepatocytes and fibroblasts or cardiospheres 
containing cardiomyocytes and MSCs [9, 10].  
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Lastly, microfluidic systems have been used to form high throughput arrays of 
small microtissues [24, 129, 151-154]. Spatial organization of different cell types is 
typically achieved by introducing different cell types into the small specialized devices 
sequentially to allow for each cell type to interact ad bind with each other [24, 134, 155, 
156]. This platform facilitates control over the formation of the construct and culture 
parameters of media exchange and flow rate and can ultimately resemble a complex and 
accurate in vivo tissue environment [153, 154]. 
 
2.2 Heparin 
2.2.1 Glycosaminoglycans  
 Glycosaminoglycans (GAGs) are a class of lineage polysaccharides that are found 
throughout the entire human body and located on cell surfaces, inside cells and in the 
ECM [157, 158]. Their functions include maintaining hydrostatic pressure by osmotically 
attracting water in cartilage, regulating cell function by controlling growth factors at cell 
surface proteoglycans, as well as acting as co-receptors to modulate biological 
environment at cell surfaces or in the ECM [159]. Sulfated GAGs, such as heparin, 
heparin sulfate, chondroitin sulfate, dermatan sulfate, and keratin sulfate bear negative 
charge throughout its repeating disaccharides [158]. Non-sulfated GAGs, such as 
hyaluronic acid, also exists as the GAG with the lowest net negative charge [160]. GAGs 
can attract and bind positively charged proteins through both electrostatic interactions, as 
well as carbohydrate specific sequences [161]. Based on their multiple functions and 
ability to bind proteins, GAGs have been used as a biomaterial for controlled delivery of 




2.2.2 Heparin Structure and Biosynthesis 
 Heparin is a linear GAG polymer composed of repeating iduronic acid and 
glucosamine units [158, 165]. It contains the highest amount of N- and 2-O sulfate groups 
as well as numerous carboxyl groups, making it the most highly negatively charged 
polysaccharide structure. Heparin molar mass can range from 3-30 kDa, with an average 
around 15 kDa. Each disaccharide unit contains approximately 2.7 sulfate groups, located 
at the 6-O or N- position on the glucosamine unit and 2-O position on the iduronic unit 
[20].  
 Heparin is structurally similar to its proteoglycan counterpart, heparan sulfate 
(HS) [20, 166]. Heparin is typically found in mast cell granules and HS is present in 
many tissues and located on cell surfaces or in the ECM as a part of the proteoglycans 
perlecan and agrin [167, 168]. Both heparin and HS play a role in cell adhesion, protein 
storage and can interact with numerous growth factors [169]. Biosynthesis of heparin 
begins with non-sulfated polysaccharides attached to a protein core. Then, 
sulfotransferases couple sulfate groups to the repeating subunits and proteases eventually 
release heparin from the protein core, resulting in the free floating form of heparin 
utilized in clinical and biomaterial applications [170].  
 
2.2.3 Heparin-Protein Interactions 
 Heparin is clinically used as an anti-coagulant and is of great pharmacological 
importance in hemostasis due to its ability to interact with antithrombin [19, 20]. This 
protein is a member of the serpin family of proteases, many of which are known to also 
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bind heparin. This binding causes a conformational change in the protein and enhances 
the rate at which it inactivates thrombin and Factor Xa [171]. Additionally, the heparin 
chain acts as a template that can bring together antithrombin and thrombin physically to 
facilitate the inhibition. Studies have shown that only 5 sugar residues in heparin actually 
bind to antithrombin with high affinity [172]. This interaction with antithrombin provides 
a basis for heparin’s anti-coagulant activities [171].  
Heparin is also known to interact with many different families of growth factors, 
including FGFs, HGFs, VEGF, insulin-like growth factor binding proteins, and TGF-β 
[20, 166]. Summarized here are the protein interactions observed with FGF-2 and TGF-
β1, as these are the growth factors used throughout this dissertation. The well-known 
interaction between heparin and FGF has been used in chromatography technologies to 
purify the growth factor due to their strong affinity [173]. FGF-2 has a very high affinity 
for heparin and has potent mitogenic activity in cells that express the corresponding FGF 
receptor [173]. Cell surface HS is known to bind both FGF-2 and the FGF-2 receptor to 
facilitate the formation of a ternary complex and promote dimerization of the ligand-
receptor complex [174]. Both the binding and mitogenic response is greatly stimulated by 
heparin or HS [175]. Similar to the interaction with antithrombin, binding of heparin to 
the protein requires a small portion of the overall polysaccharide chain, in which the 
binding sequence for FGF-2 consists of a pentassachride [176]. However, a longer 
oligosaccharide containing 10 units is required to trigger biological mitogenic response 
[175]. Within this binding site, only one N- and the 2O- sulfate group on the adjacent 
iduronic acid are required to bind the growth factor [174, 176, 177]. Unlike the 
antithrombin interaction, no conformation change occurs upon binding, which is 
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consistent with the idea that heparin serves to dimerize the FGF-2-FGF-2 receptor 
complex to activate the subsequent signaling pathway. It has been shown that the removal 
of those sulfate groups, decreases the affinity for the growth factor and the mitogenic 
response is no longer stimulated when desulfated forms of heparin are present [178]. This 
interaction demonstrates the importance of the sulfate groups and contributions of the 
electrostatic interaction to the binding and signaling capacity of heparin.  Heparin 
complexation has also been shown to protect growth factors from enzymatic degradation 
or denaturation [179-182]. This results in increased bioactivity and a stronger mitogenic 
response by cells, such as MSCs, fibroblasts and HUVECs, when exposed to FGF-2 in 
the presence of heparin [180, 183]. This response can be due to the protection from 
proteolytic degradation which results from heparin binding or the requirement that 
binding of heparin is necessary for binding to the cell surface receptor [184]. Overall, 
heparin binding plays an important role in FGF-2 bioactivity and signaling.    
 Heparin is also known to interact with the growth factor TGF-β1 [185-187]. 
Traditionally known as protein that induces chondrogenesis in MSCs, TGF-β1 has also 
been identified as a heparin-binding protein. Heparin is can bind to TGF-β1 near the N-
terminal along the β-strand loop, a position that is also close in proximity to the receptor 
binding site [186, 188]. It has been shown that sulfated HS in the liver can potentiate the 
activity of TGF-β1, indicating that there is no competition between the GAG binding site 
and receptor binding site [188]. Recent studies have also identified that interaction 
between heparin and TGF-β1 requires the presence of the N- and 6O-sulfate groups 
[186]. However, upon desulfation at these positions, downstream signaling molecules of 
TGF-β1 (Smad2/3) in human MSCs were not decreased compared to fully sulfated 
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heparin treatment [186]. This demonstrates that the specific sulfate groups along the 
polysaccharide chain required for binding are the same as those required for signaling by 
TGF-β1 [186].  
 
2.2.4 Heparin Binding Peptides  
FGF-2 binding to cell surface receptors requires interactions with heparin sulfate 
[189]. A specific peptide sequence derived from the heparin binding site on FGF-2 has 
been identified and can be used to selectively sequester heparin from standard fetal 
bovine serum [190]. The result of this heparin sequestration facilitated cell to growth 
factor interaction that enhanced human MSC proliferation via FGF-2 binding and human 
MSC differentiation via BMP-2 binding [191, 192]. This heparin and heparin binding 
peptide interaction can be exploited in systems that require cell adhesion and cell-
material interactions to control cell behavior.    
 The heparin binding site isolated from FGF-2 has previously been identified as 
the sequence Lys-Arg-Thr-Gly-Gln-Tyr-Lys-Leu (KRTGQYKL) [193]. This peptide 
sequence (HEPpep) has been utilized in form of a self-assembled monolayer able to 
sequester heparin from standard fetal bovine serum [191]. Sequential exposure to a 
solution containing the growth factor FGF-2 resulted in the binding of FGF-2 onto 
HEPpep assembled surfaces. Furthermore, it has been shown that the surface containing 
the sequestered heparin is able to amply FGF-2 mediated HUVEC proliferation [191]. 
Heparin binding peptides and other shorting peptide sequences, such as an integrin-
binding peptide, have been employed in self assembled monolayer arrays to screen MSC 
behavior in response to multiple peptide presenting surfaces and media conditions [194, 
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195]. It was observed that the heparin binding peptide can support MSC adhesion and 
osteogenic differentiation (measured through ALP activity) [194]. 
 
2.3 Heparin Containing Biomaterials 
2.3.1 Heparin Biomaterials Applications 
 Due to its biological effect in culture with multiple growth factors, its interactions 
can be harnessed as heparin is incorporated into biomaterial applications. Additionally, 
due to its binding ability, heparin can be used as a carrier for sequestration and controlled 
release of growth factors to promote angiogenesis and bone regeneration. It can be 
presented in multiple forms, either by incorporation into hydrogels and microparticles, or 
presentation onto thin film surfaces. Given its binding characteristics, heparin based 
materials can be a great candidate for emerging applications that aim to regenerate and 
repair tissue.  
 
2.3.2 Growth Factor Delivery  
 Due to the strong interaction that exists between heparin and positively charged 
growth factors, heparin based systems are often used to deliver and release growth factors 
to targeted sites of interest [163, 196]. Collagen scaffolds have previously been modified 
heparin and pre-adsorbed with FGF. It was observed that heparin containing scaffolds 
exhibit enhanced proliferation of HUVECs and can sustain release of the protein for up to 
40 days, compared to collagen scaffolds without heparin released all loaded FGF by day 
15 [197]. Additionally, when heparin has been incorporated into fibrin gels, it was 
observed that the FGF release rate decreased compared to fibrin-only gels, indicating that 
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heparin can promote sustained release of FGF [196, 198]. Additionally, when implanted 
into ischemic hind limb in mice, it was observed that FGF-2 loaded heparin containing 
fibrin gels resulted in reduced muscle fibrosis and inflammatory and enhanced 
neovascularization, compared to non-heparin containing controls [196, 198]. Growth 
factor release from heparin has been utilized as a means to deliver therapeutic 
biomolecules to areas of injury for tissue regeneration.  
It has also been shown that desulfation of glycosaminoglycans can result in 
changes of the negative charge, and ultimately can have effects on protein interactions 
[165, 178, 199, 200]. For heparin, desulfation can be performed through chemical 
modification using solvolytic processes to selectively desulfated certain groups or fully 
desulfate to remove all groups [201]. Figure 2.1 provides a schematic of the heparin ring 
structure and identifies the sulfate groups that can be removed as a result of desulfation. 
Desulfation can be advantageous for in vivo applications in that the removal of certain 
sulfate groups can reduce the anti-coagulation property of heparin, and thus not inhibiting 
clotting when necessary [201].  
 
Figure 2.1 Heparin and desulfated heparin structure. Schematic adapted from 
[165]. 
  
 Heparin systems that have been selectively or fully desulfated have shown that 
incorporation of these materials into PEG hydrogel systems have resulted in different 
Heparin  Desulfated heparin  
31 
 
release kinetics of the growth factor, VEGF over time [202]. It was observed that 
cumulative VEGF release after 96 hours was greatest when using a fully sulfated heparin 
derivative. Additionally, when this hydrogel was implanted in diabetic mice, fully 
desulfated heparin hydrogels containing VEGF appeared to promote wound angiogenesis, 
seen through larger areas of granulation tissue and greater amounts of CD31 positive 
cells [202]. Additionally, it has also been shown that a fully desulfated heparin containing 
hydrogel can support greater cumulative FGF-2 release [164]. Taken together, desulfation 
provides a platform to control growth factor presentation from heparin containing 
systems by altering release kinetics.  
 
 2.3.2 Ultrathin Films  
 Heparin ultrathin films can be grafted onto surfaces using layer-by-layer 
deposition of anionic and cationic electrostatic interactions [203-206]. This layering 
deposition procedure can be repeated multiple times to control for the thickness of the 
surface film and has utilized polymers such as poly (ethyleneimine), poly (allylamine), or 
proteins such as fibronectin, or other polysaccharides such as chitosan and dextran [203-
206]. Layering of heparin on surfaces has been used on medical devices, such as coronary 
stents, to enhance strength and blood compatibility, and to accelerate the re-
endothelialization and healing process once deployed [204, 206]. Heparin ultrathin films 
also have the ability to deliver growth factors that have been sequestered or loaded onto 
surfaces for release once implanted [205]. Heparin ultrathin films have typically been 
used on titanium or other metal surfaces because it has been shown that the polycationic 




2.3.2 Hydrogel Incorporation 
 Heparin can be incorporated into hydrogels via physical crosslinking or covalent 
crosslinking [16, 17]. As a biomaterial platform, hydrogels can support the culture of 
encapsulated cells as well as potentially protect from the surrounding environment, which 
allowing for diffusion of the required nutrients [208]. Heparin containing hydrogels have 
demonstrated the ability to act as a drug delivery carrier or a culture platform to promote 
stem cell differentiation [208-210]. Physical crosslinking of heparin occurs as a result of 
entanglement between or noncovalent interactions with the polymer chains [16]. Physical 
entanglement can provide a means to deliver a hydrogel with release of heparin that can 
act as an anti-coagulant. Free radical polymerization or Michael-type addition can also be 
used to form hydrogels containing methacrylate modified heparin [16, 210].  
Heparin-functionalized poly ethylene glycol (PEG) hydrogels have demonstrated 
the ability to sequester FGF and release it in a controlled manner over the course of 5 
weeks after the initial burst. Additionally, hydrogels loaded with FGF also has shown to 
enhance encapsulated human MSC growth. Additionally, sustained release of VEGF has 
been shown to induce proliferation of human umbilical vein endothelial cells (HUVECs) 
as well as support capillary formation in vitro systems over the course of 2 weeks [211]. 
For stem cell differentiation, MSCs cultured in heparin containing hydrogels and 
osteogenic differentiation cues can increase ALP product and osteopontin and collagen I 
gene expression over the course of 5 weeks, compared to non-heparin controls [209, 
212]. Additionally, chondrocytes cultured in heparin containing hydrogels without 
exogenous growth factors or chondrogenic components support effective redifferentiation 
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and production of GAGs and ECM proteins within a week [213]. Transplantation into a 
rabbit knee partial thickness defect also demonstrated cartilage regeneration superior to 
non-heparin and chondrocyte containing hydrogels [213]. Overall, incorporation of 
heparin in hydrogels can promote cell adhesion, proliferation and differentiation, as well 
as support sustained local delivery of growth factors. However, although hydrogels are a 
promising platform for tissue engineering applications, some limitations include the use 
of extra radical initiators that can potentially be cytotoxic to encapsulated cells, and the 




 Microparticle incorporation into 3D aggregates is another approach to present 
heparin to stem cells. Microparticles are able to load growth factors with minimal excess 
material due to the high surface area to volume ratio of this platform [183]. This ability 
presents a potential method to deliver growth factor to cells that are located closer in 
proximity to the core of an aggregate to overcome diffusional barriers [214]. Finally, 
incorporation of microparticles into stem cell aggregates has shown to modulate 
pluripotent stem cell differentiation [111, 214, 215]. Heparin containing microparticles 
have been shown to efficiently bind growth factors including BMP-2, VEGF and FGF-2. 
Additionally, microparticles loaded with BMP-2 also exhibit sustained bioactivity and 





2.4 Cell Surface Engineering 
2.4.1 Cell Surface Modification 
 Surface modification of cells with natural and synthetic polymers is another 
method to present biomaterials to control cell behavior [207]. The introduction of 
function and bioactive molecules at the cell surface can be used to add biological 
function, such as blood compatibility, controlling cell transplantation by masking surface 
antigens to increase graft efficiency and controlling interactions with the surrounding 
environments [207]. Cell surface modifications can be used to study cell-cell interactions 
as well as control stem cell lineages for regenerative medicine.  
 MSC surface engineering has previously been used to chemically attach cell 
adhesion molecules to cell surfaces to improve homing efficiency to specific tissues 
[217]. Improving homing efficiency can provide an approach to infuse MSCs to local 
environments that target injured tissue sites that are difficult to access, thus overall 
increasing efficacy of the delivered therapeutic cells [30]. To achieve this, sialyl Lewis
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(SLeX) moiety, a cell rolling ligand, has been grafted onto surface of MSCs without 
compromising MSC viability adhesion proliferation and differentiation potential [218]. 
The SLeX engineered MSCs exhibit rolling response in vitro on substrates coated with P-
selection that are superior to noncoated MSCs [217, 219]. This indicates that harnessing 
interactions that control cell adhesion at cell surfaces, this strategy can be used to 
potentially target P-selectin expression endothelium at sites that exhibit inflammation 
[218].  
 To attach cell adhesion molecules onto cell surfaces, this method uses a stepwise 
layer-by-layer deposition of first, a sulfonated biotinylated N-hydroxy-succinimide 
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(NHS) that targets and covalently attaches to cell surface amines [220]. This is followed 
by the addition of streptavidin that binds to the biotin on cell surfaces, and lastly, 
attachment of the final biotinylated ligand that promotes cell adhesion to the targeted 
substrate [217, 219]. This system has been shown to efficiently graft molecules onto cell 
surfaces without adverse impact on the native MSC phenotype.  
 Other methods to modify cell surfaces have used hydrophobic interactions with 
amphiphilic polymers [221-224]. These polymers, such as PEG-conjugated phospholipids 
or poly(vinyl alcohol) bearing a hydrophobic side alkyl side chains (PVA-alkyl), can be 
spontaneously anchored into the lipid bilayer of cell membranes and can be controlled by 
the length of the alkyl chain, or the molecule’s hydrophobicity [221-224]. This occurs 
without compromising the integrity of the cells, however, over time, it has been seen that 
PEG-lipids gradually disappear from the cell surfaces without uptake inside the cells 
[221, 222]. This technique has previously been used to mask cell surface markers on 
pancreatic islet cells and increase engraftment for treatment of type I diabetes [221, 222].  
Another method to modify cell surfaces employs electrostatic interactions 
layering anionic and cationic polymers [225-228]. Some polymers used include poly-L-
lysine, poly(ethyleneimine), poly(styrene sulfate) and poly (allylamine hydrochloride) 
[225, 226, 228]. Using layer-by-layer technique alternating between positively charged 
and negatively charged layers results in the ability to control surface presentation at the 
outermost layer as well as surface thickness [226]. While this technique is simple, most 
polycations, such as poly-L-lysine are cytotoxic and can severely damage cell membrane 





2.4.2 Heparin Cell Coating 
 Using the previously mentioned layer-by-layer strategy, heparin can also be 
grafted onto cell surfaces, as is observed with pancreatic islets [229-232]. This strategy 
utilizes the electrostatic interaction with between the intermediate streptavidin or avidin 
layer that is positively charged to bind the negatively charged heparin. Additionally, 
heparin can similarly be biotinylated to attach to the avidin layer. Heparin grafted onto 
pancreatic islets can be used for numerous applications [220, 229, 230, 233, 234]. First, a 
heparin coating can be used to prevent the instant blood mediated inflammatory reaction 
during islet transplantation, thus protecting the delivered cells to increase engraftment 
efficiency [230]. It has also been used to anchor VEGF onto pancreatic islet surfaces to 
stimulate angiogenesis and anchor thrombomodulin to regulate thrombosis and 
inflammation upon islet transplantation for type 1 diabetes treatment [229, 232]. Utilizing 
these interactions to modulate inflammation and the surrounding environments has been 
beneficial for developing pancreatic islet treatments that can increase engraftment 
efficiency and promote vascularization [229, 230]. Prior to the work presented in this 
thesis, heparin has not previously grafted onto MSC surfaces, thus presenting an 
opportunity to examine the effects of GAG coatings and how exploiting those 





CHARACTERIZATION OF A MULTILAYER HEPARIN COATING 
FOR BIOMOLECULE PRESENTATION TO HUMAN 
MESENCHYMAL STEM CELL SPHEROIDS1 
 
3.1 Introduction 
 Mesenchymal stem cells (MSCs) have been used as a cell therapy to regenerate 
injured tissue and treat inflammation resulting from a wide range of pathologies such as 
cardiovascular disease, myocardial infarction, osteoarthritis, brain and spinal cord injury, 
diabetes, Crohn’s disease and graft versus host disease [2, 3]. These multipotent adult 
progenitor cells are capable of differentiating into bone, cartilage, fat, muscle, 
tendon/ligament, and other connective tissue cell types, which can be mediated through 
local soluble factors and/or mechanical stimulation [1]. In addition to their differentiation 
capacity, MSCs have the ability to secrete cytokines and growth factors that can promote 
angiogenesis, modulate extracellular matrix (ECM) remodeling, affect immune cell 
activation or suppression (immunomodulation) and promote cell recruitment [1-4]. 
Recently, there is growing evidence that, when aggregated into spheroids, MSCs have 
enhanced anti-inflammatory properties over single MSCs grown in monolayer [21]. 
These anti-inflammatory effects are useful in treating inflammatory pathologies and 
regulating the damage that can be caused by inflammation in an acute injury.  
                                                 
1
 Portions of this chapter were taken from Lei, J., McLane, L., Curtis, J.E., Temenoff, J.S. (2014). 
“Characterization of a multilayer heparin coating for biomolecule presentation to human mesenchymal 




Upon injection or placement into an injured environment, MSCs are able to 
respond to the milieu surrounding them and secrete the appropriate mediators to repair 
the tissue or begin to differentiate to a tissue-specific cell type [4, 29].  However, MSC-
based therapies may be rendered ineffective due lack of control over cell fate upon 
administration into a complex, pathological environment. Further compounding the 
problem is the fact that that the injured environment may contain many proteases or 
highly inflammatory molecules that can harm the injected cells [235].  
 Controlled differentiation of stem cells has been achieved by cell seeding on 
scaffolds that mimic the architecture and mechanical properties of native extracellular 
matrix in tissues in the presence of soluble factors.[236] However, fibrous scaffolds do 
not retain ECM secreted by cells, which can limit their ability to fully repair tissue [237]. 
Additionally, processing that requires specialized equipment to synthesize scaffold 
materials (i.e. electrospinning) make this method difficult to scale up for cell therapies. 
Finally, scaffold-based technologies cannot be utilized as a minimally invasive injectable 
treatment, and thus, require a full surgical implantation for cell delivery [237, 238]. 
 Another method of controlled differentiation is by encapsulating cells in 
injectable hydrogels [209, 239, 240]. Hydrogels can be functionalized to be 
biodegradable, contain motifs that drive differentiation, and provide a 3D environment 
that can retain secreted extracellular matrix molecules [239]. However, limitations of 
using a hydrogel system include the polymerization requirement that typically involves 
an extra radical initiator that could potentially be cytotoxic to encapsulated cells, the 
excess void space of the material which increases the required volume injected and the 
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lack of temporal and spatial control of degradation, which may be required for full tissue 
integration [241].  
In response to these shortcomings, we aim to develop a thin, conformal coating 
method for MSC spheroids to allow simultaneous injection of both cells and a therapeutic 
agent to a site of injury. This system uses multilayer deposition of biotin and avidin to 
graft heparin onto cell surfaces [230, 234]. Heparin is a negatively charged 
glycosaminoglycan that can sequester and release positively charged proteins [242]. It 
has been used as an anti-coagulant, as a drug delivery system and as a component of 
hydrogels to help drive differentiation in multiple cell types, including MSCs and 
embryonic stem cells [243-245]. It is envisioned that the negative charge on this coating 
will allow for preloading of a growth factor of interest to both guide stem cell 
differentiation, as well as release the loaded biomolecule to facilitate local tissue repair. 
These coating layers are advantageous over using scaffolds or bulk hydrogels for guiding 
cell fate because of their simple assembly through nontoxic interactions (i.e. noncovalent, 
electrostatic) and precise tuning of thickness, composition and permeability, ultimately 
allowing for control over coating degradation (and concomitant biomolecule release) 
[246-248]. Moreover, such cell coating technologies would greatly enable injectable 
therapies, as there is no excess material that needs to be delivered with the cells. Toward 
developing this coating methodology, the objectives of this study were to characterize the 
coating and loaded protein via fluorescence microscopy and a particle exclusion assay, 
determine cell viability after coating, investigate MSC anti-inflammatory properties after 






3.2.1 Cell culture 
 MSCs derived from bone marrow aspirates were obtained from The Texas A&M 
Health Sciences Center. Cryopreserved MSCs were thawed and expanded in alpha 
Minimum Essential Medium (α-MEM, Mediatech, Herndon, VA) containing 16.5% fetal 
bovine serum (FBS, Atlanta Biological, Atlanta, GA), 2 mM L-glutamine (Mediatech), 
100 units/mL penicillin and 100 µg/mL streptomycin (Mediatech). Media was changed 
every 2-3 days until 80% confluent and used at passage 3 or 4. Human THP-1 monocytes 
(ATCC, Manassas, VA) were expanded in RPMI 1640 (Mediatech) containing 10% FBS, 
2 mM L-glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin and 0.05 mM 
2-β-mercaptoethanol (Sigma, St. Louis, MO). Media was replaced every 4 days until 
seeding in co-culture systems. Mink lung epithelial cells (MLECs, ATCC) were thawed 
and expanded in Dulbecco’s Modification of Eagle’s Medium (DMEM) with 4.5 g/mL 
glucose, 10% FBS, 2 mM L-glutamine and 200 μg/mL Geneticin® (G418, Gibco, Grand 
Island, NY). Media was exchanged ever 2-3 days until cells were at 80% confluent and 
used at passage 29.  
3.2.2. MSC spheroid formation 
To make spheroids, cells were forced into aggregation via centrifugation.[249] 
Briefly, a single cell suspension (3-6 x 10
6
 cells/mL) was added to AggreWell agarose 
microwell inserts (400 µm wide wells; ~6000 wells/insert) and centrifuged (200 rcf; 5 
minutes) to aggregate cells within the microwells. After 24 hours, MSC aggregates were 
rinsed from the microwells and cultured thereafter either encapsulated in a 1.5% alginate 
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layer (approximately 3 mm thick) crosslinked in 100 mM calcium chloride contained in 
10 cm petri dish (Corning, Tewksburg, MA) for up to 14 days or in rotary orbital 
suspension culture for up to 3 days to inhibit agglomeration of individual aggregates 
(approximately 1500 spheroids/10 mL media/petri dish; 65 rpm for rotary suspension 
only). 
 
3.2.3 Multilayer coating and subsequent cell viability 
MSCs and MLECs were cultured until 80% confluent and lifted using 0.05% 
trypsin (Mediatech). Cells were washed in phosphate buffered solution (PBS, Life 
Technologies, Grand Island, NY) 2 times and then modified with heparin by multilayer 
assembly of biotin and avidin layers [230, 234]. Cells were first cultured in 4 mM EZ-
Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL) in PBS, followed by 0.5 mg/mL 
avidin in PBS (Life Technologies, Carlsbad, CA), and lastly in 5 μg/mL, 1 mg/mL or 5 
mg/mL biotin-conjugated heparin in PBS. Each incubation step was performed in an 
Ultra-Low Attachment Surface plate (Corning) for 30 minutes at 37ºC. For imaging 
studies, cells were incubated in a biotin-heparin solution that has been tagged with 
AlexaFluor 633 (Invitrogen). To load coated surfaces with a protein after the heparin 
layer, cells were incubated for 30 minutes in a 90 μg/mL fluorescein isothiocyanate 
(FITC)-tagged histone (Sigma) solution for imaging studies or 3 ng/mL or 3 μg/mL TGF-
β1 (Peprotech, Rocky Hill, NJ) solution for MLEC luminescence studies. Once 
multilayer deposition of all layers was complete, all cells were washed in PBS and 
formed into spheroids (500 or 1000 cells/spheroid) as previously described. Spheroids 
were stained with LIVE/DEAD solution (1 μM calcein AM and 1 μM ethidium 
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homodimer-1) to assess cell viability. Images were taken using a Zeiss LSM 700 LSM 
confocal microscope and channels were merged and projections were flattened in ImageJ 
(NIH, Bethesda, MD). 
3.2.4 Particle exclusion assay 
To characterize the pericellular matrix (PCM), 3 μm passivated (covalently 
modified with methoxypolyethylene glycol amine) polystyrene microspheres (Life 
Technologies, supplied by Curtis laboratory) were used in a particle exclusion assay on a 
monolayer of MSCs [250]. Beads with diameter size of 3 μm are of the same order of 
magnitude in size as other particles excluded by the pericellular matrix, as seen in 
previous experiments.[250] MSCs were seeded at 500 cells/cm
2
 on 12 mm glass 
coverslips and cultured for 24 hours. Cells were then modified via multilayer deposition 
with 5 mg/mL biotin-heparin as described above and then suspended in PBS. Control 
samples were handled identically, but not treated with the multilayer coating. After 
coating, 20 μL of the bead solution and 180 μL of PBS were added to a custom imaging 
mold (Teflon) containing seeded MSCs. Beads were allowed to settle for 10 minutes. 
Bright field imaging was performed using a using a Zeiss LSM 700 LSM confocal 
microscope. The effective thickness of the PCM was measured as a separation between 
the beads and cell surface and was measured using ImageJ (3 measurements per cell).  
3.2.4 Monocyte anti-inflammatory co-culture assay 
To examine anti-inflammatory effects of spheroid culture with and without 
coating, MSCs were co-cultured with LPS-activated human monocytes [21, 251, 252].  
MSCs were coated and formed into spheroids as previously described and cultured in 
rotary orbital suspension for 3 days. MSC monolayer and 1000-cell spheroids (coated and 
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noncoated) were then indirectly co-cultured with THP-1 monocytes in a 12-well 
transwell system (Corning) at a ratio of 100,000 MSCs to 400,000 THP-1 monocytes. All 
cells were suspended in RPMI 1640 media. Monocytes were activated by addition of 
lipopolysaccharide (LPS, 400 ng/mL) to the media. After 16 hours, MSC monolayer and 
spheroid supernatant was collected and tumor necrosis factor (TNF)-α levels were 
quantified via ELISA (R&D Systems, Minneapolis, MN). 
 
3.2.5 Mink lung epithelial cell luminescence assay 
MLECs were used as a reporter cell line to study the effects of the coating on 
TGF-β1 signaling to cells. MLECs were coated with heparin at the concentration of 5 
mg/mL and then loaded with TGF-β1 at the concentrations of 0 ng/mL, 3 ng/mL and 3 
μg/mL by incubating heparin-coated cells in TGF-β1 solutions for 30 minutes, similar to 
the previously discussed coating experiment. Noncoated controls were also exposed to 
TGF-β1 at the previously mentioned concentrations using identical methods. After 
coating and growth factor loading, all cells were formed into aggregates (500 
cells/aggregate) using the technique previously described. At 24 hours, cells were 
transferred to a 96-well plate (150,000 cells/well) and ONE-GloTM Luciferase Assay 
buffer was added to each well using manufacturer’s protocols. Luminescence was 
measured using a plate reader (BioTek Synergy H4 Hybrid Multi-Mode Microplate 
Reader, Winooski, VT). Simultaneously, to study bioactivity of released protein, 
supernatant from aggregates was also collected 24 hours after aggregate formation. 100 
μL aliquots of each supernatant sample suspended over noncoated MLECs plated in 
monolayer at 50,000 cells/cm
2
 in a 96-well plate and cultured for 24 hours. The following 
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day, 100 μL of ONE-GloTM Luciferase Assay buffer was added according to 
manufacturer’s protocols and luminescence levels were measured using a plate reader 
(BioTek).   
3.2.6 Statistical analysis 
All values were reported as mean + standard deviation. For statistical analysis, 
one or two factor analysis of variance (ANOVA) was used to determine statistical 
significance of groups, and Tukey’s post hoc multiple comparison test with significance 
set at p<0.05 indicated a significance between individual samples. Analysis was 
performed using Minitab (v.15.1, State College, PA).  
 
3.3 Results 
3.3.1 MSC spheroid coating 
MSCs were successfully coated by using a multilayer technique with deposition 
of biotin and avidin to graft molecules of interest (heparin and a protein) onto their 
surfaces and subsequently formed into spheroids (Figure 3.1). Using a dimethyl 
methylene blue assay, it was seen that biotinylated heparin was 90.2% + 3.9% sulfated 
when compared to native heparin. Additionally, nuclear magnetic resonance analysis 




Figure 3.1.Characterization of heparin coating and histone loading via layer-by-
layer deposition on cell surfaces. (a) Schematic of coating. (b) High cell viability in 
both coated and noncoated spheroids as visualized with flattened image of 
LIVE/DEAD staining. (c) Flattened images of Alexafluor 633-tagged heparin 
coating at 5 μg/mL, 1 mg/mL and 5 mg/mL coating concentrations over 14 days. (d) 
Quantification of fluorescence/spheroid from tagged heparin over 14 days. (e) 
FITC-histone loaded on heparin-coated cells at day 1 (left) and day 7 (middle) and 
non-heparin coated control cells at day 1 (right). *Statistically different from day 1 




The viability of the resulting coated spheroids does not appear to be affected when 
compared to the viability of noncoated spheroids, as most of the cells in the aggregates in 
all cases were with calcein dye, indicating that the cells are live (Figure 3.1B). A higher 
initial coating concentration results in more heparin being grafted to cell surfaces 
throughout the entire spheroid when compared to spheroids coated with heparin at a 
lower concentration, seen by fluorescent quantification via image analysis (Figure 
3.1C&D). Heparin fluorescence decreases over 14 days, resulting in approximately a 
40% loss of heparin from all three groups when compared to the amount of heparin found 
on surfaces at day 1 (Figure 3.1D). After coating, a model positively-charged protein, 
histone (~19 kDa, pI = 8.5), tagged with FITC, was loaded onto spheroid cell surfaces. It 
was seen that histone was present on cell surfaces at day 1 and remained up to day 7. 
Without the intermediate biotin and avidin layers, heparin was not grafted to cell 
surfaces, resulting minimal protein loading on cell surfaces (Figure 3.1E).  
3.3.2 Particle exclusion assay  
Many cell surfaces are decorated with surface bound hyaluronan (a long, linear 
glycosaminoglycan) that acts to densely aggregate native proteoglycans (aggrecan, 
versican) that possess a very high negative charge. This hierarchical assembly of 
bottlebrushes of bottlebrushes anchored to the cell surface makes up the PCM [253, 254]. 
We performed a particle exclusion assay to determine if the native PCM is altered after 
multilayer coating of cell surfaces. Immediately after coating MSCs in monolayer (day 
0), there was no PCM observed around coated cell membranes, as evidenced by the lack 
of separation between the beads and cell membrane, as opposed to the noncoated MSCs 
in which a PCM thickness of approximately 6 μm thick was observed (Figure 3.2A). 24 
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hours after coating (day 1), coated samples still did not indicate the presence of any 
PCM, while noncoated samples remained similar to the previous day. 
 
Figure 3.2 Particle exclusion analysis of coated and noncoated MSCs. (a) Phase 
images of coated and noncoated MSCs in monolayer with 3 μm passivated 
polystyrene microspheres. White lines outline cell surfaces. (b) Quantification of 
PCM thickness (distance between cell surface and microsphere layer). *Statistically 
different from coated samples on the same  day; p < 0.05; n = 18. 
 
Both immediately after coating and 24 hours after coating, noncoated samples had a 
significantly thicker PCM than coated samples (Figure 3.2B).   
3.3.4 Monocyte anti-inflammatory co-culture assay 
  In this experiment, the effects of the heparin coating on MSC spheroid anti-
inflammatory properties were studied through a monocyte co-culture assay. Both 
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noncoated and coated spheroids were able to attenuate the level of secreted TNF-α from 
LPS-activated monocytes significantly more than MSCs seeded in monolayer, 
 
Figure 3.3 Degree of attenuation of TNF-α secretion by LPS-activated monocytes in 
co-culture with MSCs in monolayer, coated MSC spheroids, or noncoated spheroids 
(reported as a change from levels of TNF secreted from activated monocytes not in 
co-culture with MSCs divided by MSC amount in each culture as determined by 
picogreenTM assay). *Statistically different from MSC monolayer; p < 0.05; n = 5. 
 
as seen by greater changes in TNF-α levels normalized to MSC DNA content (Figure 
3.3). No difference was seen between the two spheroid groups.  
3.3.5 TGF-β1 bioactivity (MLEC assay) 
To study the biological activity of a protein localized to cell surfaces via heparin 
coating, MLECs were used as a biological reporter of loaded TGF-β1 activity. MLECs 
are a cell type that has been transfected with a luciferase reporter gene fused to 
plasminogen activator inhibitor-1 (PAI-1), which is expressed in response to TGF-β1. It 
has been seen that TGF-β1 activity results in a dose-dependent increase in the quantified 
luciferase activity [255]. First, it was seen that MLECs can be coated with heparin and 
formed into aggregates using the previously utilized methods, without having detrimental 
effects on cell viability (Figure 3.4A&B). When heparin was not present, there is minimal 
protein localized to cell surfaces (Figure 3.4C), however, when the heparin layer was 
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present, a positively charged model protein (histone) was observed on the surfaces of the 
cells (Figure 3.4D). Noncoated MLECs exhibited a dose-dependent response to  
 
Figure 3.4 Coated MLEC aggregates loaded with TGF-β1. (a) Flattened image of 
Alexafluor 633-tagged heparin coating on MLEC aggregates after layer-by-layer 
deposition of biotin and avidin. (b) High cell viability in coated aggregates as 
visualized with flattened image of LIVE/DEAD staining. (c) No FITC-tagged histone 
is observed on control MLEC aggregates without heparin coating (phase image). (d) 
Flattened image of FITC-tagged histone loaded on heparin-coated aggregates. (e) 
Luminescence response of noncoated and coated MLEC aggregates after loading. (f) 
Luminescence response resulting from released supernatant from noncoated and 
coated MLEC aggregates collected 24 hours after TGF-β1 loading and aggregate 
formation. *Statistically different from noncoated samples at the same 
concentration; #statistically different from all other concentration samples within 
the same coating treatment; p < 0.05; n = 4. 
 
TGF-β1 exposure. Coated MLECs had significantly higher luminescence reported when 
compared to noncoated samples at each loading concentration after 24 hours (Figure 
3.4E). In a second bioactivity assay, supernatant collected from noncoated and coated 
MLEC aggregates 24 hours after protein loading was suspended over a different set of 
MLECs plated in 96-well plates. Supernatant collected from all noncoated spheroid 
groups 24 hours after formation elicited a low level of luminescence response that was 
not significantly different from each other. However, supernatants taken from TGF-β1 
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loading concentrations of 3 ng/mL or 3 μg/mL elicited a luminescence response 
significantly higher than their noncoated counterparts (Figure 3.4F).  
 
3.4 Discussion 
 In this study, a multilayer assembly technique was applied to form a conformal 
coating of heparin on MSCs, with the ultimate goal of grafting a biomolecule of interest 
on cell surfaces that may control cell behaviors, such as differentiation. A similar 
technique has been used previously to graft unmodified heparin or thrombomodulin onto 
the surface of pancreatic islets to prevent blood-mediated inflammation or coagulation 
upon injection into the bloodstream [230, 234]. We have used a modification of this 
system to sequester a protein of interest onto the surface of cells that may act as a 
stimulus to guide cell fate after delivery. In this method, biotin is functionalized with a 
NHS group that targets cell surface amines. The grafted biotin can then bind avidin with 
high affinity and specificity. In the following layer, while heparin can electrostatically 
interact with the positively charged avidin, heparin has also been further functionalized 
with a biotin group that can interact with the presented avidin with higher affinity. As the 
outer layer, heparin’s highly negative charge, resulting from the presence of multiple 
sulfate groups, facilitates the sequestration of positively charged biomolecules via 
electrostatic interactions [244]. 
 The amount of heparin grafted on cells can be tuned by using different initial 
concentrations in solution. Given a fixed number of cells/spheroid, the coating 
concentrations chosen for this study represented levels that were below the theoretical 
saturation of heparin loaded onto the cell surfaces as a packed single layer (5 μg/mL), 
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close to saturation level (1 mg/mL), and well above saturation level (5 mg/mL) 
(calculations based on a cell diameter of 7.5 μm, cell surface area and heparin diameter of 
10 nm) [256]. While it may be expected that the amount of heparin grafted would plateau 
near saturation at the 1 mg/mL concentration, the fact that increase in fluorescence 
beyond saturation concentration was observed (Figure 3.1C) suggests that multiple layers 
of heparin can be deposited onto the surface, perhaps mediated through both the avidin-
biotin-heparin interactions and electrostatic interactions between avidin and heparin. 
These results indicate that it is possible to tune the amount of heparin that can be grafted 
to cell surfaces, and thus, ultimately control the amount of biomolecules being 
sequestered.  
 Over time, the heparin coating appeared to be removed from cell surfaces, as seen 
by lower levels of quantified fluorescence at later timepoints. While this loss could be 
attributed to several factors, we have observed that fluorescence of the same heparin 
coating in an acellular system does not decrease over time when placed in media 
(Supplemental Figure B.1). This leads us to believe that the loss of heparin is cell-
mediated via secretion of enzymes that cleave heparin or via cell membrane turnover. 
Non-biotin-tethered heparin molecules could also be released due to diffusion into the 
surrounding media or exchange of ions with other charged molecules [257]. For all three 
concentrations, there was a 40% loss of heparin by day 14 when compared to the original 
amount on day 1. However, the rates of decrease were different, as a higher percentage of 
heparin was lost on earlier days for cells coated with 5 μg/mL, indicating that the kinetics 
of heparin loss are different depending on starting concentrations (Figure 3.1D). This 
discrepancy in release kinetics lends support to the idea of multiple heparin layers being 
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present when coated with a concentration above the theoretical saturation concentration, 
some of which may be less tightly bound through electrostatic interactions and therefore 
diffuses away from cell surfaces more quickly. To further characterize the heparin 
coating, the model protein, fluorescent histone, was used to image protein sequestration. 
Heparin coating facilitates the localization of a model positively charged protein, seen 
through imaging of histone, indicating that a biomolecule can be presented to MSCs via 
the heparin coating that may then act on to direct cell fate.  
 The PCM is composed predominantly of chondroitin sulfate-rich proteoglycans 
and hyaluronan. In its native form, the PCM can extend several microns from the cell 
surface and can play a role in cell interaction with the environment and cell adhesion 
[250, 254, 258]. It is important to study to presence of the PCM after the coating 
procedure to better understand what is being presented on the surface of the cells and 
how that may affect cell behavior [259]. The decrease in PCM thickness seen in coated 
cells compared to noncoated cells, observed in the particle exclusion assay, suggests that 
the coating procedure removed or collapsed (via crosslinking) the natural PCM found on 
cell surfaces.  
 It was also observed that, 24 hours after coating, an appropriate amount of time to 
allow the PCM to grow to its natural state in media [250], the native PCM did not grow 
back on coated cells (Figure 3.2B). This finding confirms that using our method, the 
resulting heparin coating can exist on cell surfaces for at least 1 day without being 
overwhelmed by the natural matrix, potentially allowing for control of what loaded 
biomolecules are presented to the cells during that time, while simultaneously 
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maintaining a high concentration of the loaded biomolecule near cell surface receptors for 
efficient signaling.  
 It has been shown that MSCs have anti-inflammatory properties and are able to 
act as modulators of lymphocyte [30, 260]. MSCs in spheroid form have enhanced anti-
inflammatory characteristics when compared to single MSCs from monolayer culture 
[21]. The results from the co-culture experiments demonstrate the intrinsic anti-
inflammatory properties of the MSCs are not affected during the coating process or by 
the coating itself as both spheroid samples exhibited enhanced properties over MSCs in 
monolayer (Figure 3.3). It has been shown that aggregation of MSCs results in the 
production of prostaglandin E2 (PGE2), tumor necrosis factor-inducible gene 6 protein 
(TSG-6) and stanniocalcin-1 (STC-1), molecules that can act on activated monocytes to 
decrease TNF-α secretion [252, 261]. PGE2 is a small molecule derivative of arachidonic 
acid and TSG-6 and STC-1 are large anti-inflammatory proteins (29 kDa and 25 kDa, 
respectively) that are not expected to penetrate through multilayers of negatively charged 
heparin [262-264]. However, in this assay, the highly negatively charged coating did not 
alter the MSC’s ability to attenuate TNF-α production by monocytes, suggesting that 
sufficient anti-inflammatory signaling was still able to occur. On the other hand, clinical 
evidence has also shown that heparin administration has benefitted patients with 
pathologies that are associated with strong inflammatory response, such as asthma, 
ulcerative colitis and burns [265, 266]. A proposed mechanism of this anti-inflammatory 
property is inhibition of the transcription factor nuclear factor-κB (NF-κB) that promotes 
the expression of pro-inflammatory cytokines in monocytes [267]. Surprisingly, it was 
observed that a heparin coating on MSC spheroids does not increase the anti-
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inflammatory properties in this study when compared to noncoated spheroids. A potential 
explanation is that heparin may not be released from cell surfaces in high enough 
concentrations after 3 days in culture to act on activated monocytes [267], or that the 
decrease in MSC anti-inflammatory secretion was compensated for by a direct anti-
inflammatory effect of heparin, resulting in no overall change from noncoated spheroids. 
Further studies need to be performed to in order to fully study the effects of the heparin 
coating on changes to the anti-inflammatory secretome of MSC spheroids. 
  For this coating system to be effective in promoting cell differentiation, the 
protein must remain bioactive to act on cells or the surrounding environment. Therefore, 
after ascertaining that the coating was not deleterious to viability or anti-inflammatory 
properties of MSCs, we used a reporter cell line to study bioactivity of a growth factor 
(TGF-β1) sequestered to the heparin. MLECs are a cell line that is known to express PAI-
1 in response to the specific presentation of TGF-β1 in the media or on cell surfaces. In 
these cells, the PAI-1 gene has been fused with a luciferase firefly reporter. Addition of 
TGF-β1 results in a dose-dependent increase of luciferase activity in the lysed cells, 
rendering this assay to be highly specific and sensitive [255, 268]. Utilizing the heparin 
coating, TGF-β1 was localized to the surfaces of MLECs and aggregates were formed 
with the coated cells (Figure 3.4A-D). When noncoated, aggregated MLECs were 
exposed to TGF-β1, the short term exposure during coating process resulted in a dose-
dependent increase in luminescence, representing a cellular response to TGF-β1. This 
phenomenon reveals that aggregation of these cells does not impair their inherent 




 While it is noted that the heparin coating itself, without TGF-β1 exposure, can 
upregulate luciferase activity (Figure 3.4E), it has not been previously studied if heparin 
directly affects the MLEC cell type. It is known that biotin (used in the coating 
procedure) can act as a coenzyme that is involved fatty acid synthesis, glucogenesis and 
catabolism of branched amino acids, but is unlikely to affect PAI-1 expression due to its 
specificity to TGF-β1 [269, 270]. When assaying the aggregates themselves, it is evident 
that the combination of TGF-β1 loading and heparin coating results in a luminescence 
response from the cells within the aggregate that is significantly higher than the 
luminescence response from noncoated samples and coated, non-loaded samples (Figure 
3.4E) and that there are no effects of soluble heparin on activation of this cell line 
(Supplemental Figure B.2). While promising, further studies with a cell type that are not 
activated by the coating procedure are necessary to fully confirm the ability of the coating 
to facilitate signaling of a loaded growth factor to the cells.  
 With the coating present, the supernatant collected from coated aggregates that 
were loaded with either concentration of TGF-β1 can elicit a luminescence response from 
reporter MLECs that is significantly higher than noncoated samples treated at the same 
loading concentration (Figure 3.4F). These results provide evidence that presence of 
heparin may help preserve the bioactivity of the TGF-β1, as previous studies have shown 
that heparin complexes can protect proteins from enzymatic degradation and may 
potentiate presentation to its target receptor [244, 271, 272]. Such results are striking 
because in a control experiment, it was seen that when soluble heparin was present in the 
media during MLEC exposure to TGF-β1, luminescence response by the cells was 
significantly lower (Supplemental Figure B.3), suggesting that soluble heparin may not 
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preserve bioactivity of TGF-β1 in this assay and may even interfere with or inhibit 
signaling to the cells. Taken together, these data indicate that TGF-β1 can be released 
from the heparin coating in a bioactive form. This coating technique is advantageous over 
delivering soluble heparin with growth factors because the coating allows release over a 
longer period (in this case, at least 1 day), thus providing a sustained effect of preserving 
bioactivity of growth factors over time to interact with surrounding tissue. In contrast, the 
addition of soluble heparin will likely diffuse away and only have an effect immediately 
upon administration.  
 Based on these results, it is envisioned that the bioactive protein may be able to 
“signal out” to the neighboring cells and the surrounding environment to encourage 
regeneration, as well as potentially ”signal in” and act on the cells to which it is 
sequestered to promote differentiation or other functions. Thus, this multifaceted system 
may be used to both prime cells for cell-mediated tissue regeneration and modulate the 
damaged tissue environment after implantation.  
 
3.5 Conclusions 
 Through these studies, we have developed a multilayer coating system to graft 
heparin and facilitate protein sequestration onto cell surfaces. Results demonstrate that 
MSC spheroids can be coated without negatively affecting cell viability and anti-
inflammatory properties. Positively-charged proteins bind preferentially to the coated 
cells and an assay with a reporter cell line suggests that TGF-β1 remains bioactive after 
sequestration and release. In the future, this simple and efficient method of presenting 
growth factors to stem cell aggregates may have significant implications in enabling local 
57 
 
signaling between transplanted cells and surrounding tissue post-injection. Moreover, the 
ease of the chemistries employed makes this technique amenable to attaching other 
bioactive molecules (antibodies, enzymes) to stem cell aggregate surfaces. As such, the 
methods presented here represent an exciting platform with sufficient flexibility to 
maximize the therapeutic effect of injected stem cells in ways that could be tailored to the 





RESPONSE OF HUMAN MSC AGGREGATES TO GROWTH 
FACTORS IS AFFECTED BY THE SULFATION LEVEL OF 
HEPARIN USED AS A CELL COATING 
 
4.1 Introduction 
 Mesenchymal stem cells (MSCs) are currently being utilized in over 350 National 
Institute of Health-registered clinical trials treating pathologies ranging from graft versus 
host disease and diabetes to bone and cartilage injuries [5, 6]. Their ability to differentiate 
down multiple lineages and/or secrete trophic factors makes MSCs a promising cell 
source to regenerate tissue and treat a variety of diseases [1, 2, 162]. However, in these 
trials, one to five doses of 2,000,000-8,000,000 cells are required for administration; thus, 
for these multipotent cells to be a viable option, mass expansion is needed [6]. 
Additionally, for certain applications, precise control of differentiation of these 
multipotent cells is required to ensure that a homogenous cell population is delivered [4]. 
To achieve cell proliferation and differentiation, growth factors such as fibroblast growth 
factor-2 (FGF-2) and transforming growth factor-β1 (TGF-β1) can be employed. FGF-2 
is a common mitogenic growth factor used to promote proliferation for multiple cell 
types, including MSCs, fibroblasts and endothelial cells and plays a crucial role in MSC 
self-renewal [273-276], while TGF-β1 is a growth factor typically used to induce 
chondrogenesis in MSCs [111].  
In addition to growth factor supplementation, different MSC culture platforms can 
affect both MSC proliferation and differentiation. For example, pellet systems (25,000 
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cells) have traditionally been used to study chondrogenic differentiation of MSCs, 
however, recent interest in smaller MSC aggregates (500-1000 cells) with smaller 
diameters has increased because of their ability to be used as injectable therapies 
treatment of cartilage injuries and disease [79, 107, 277]. Additionally, it has been shown 
that MSCs aggregated into spheroid form ranging from 500-250,000 cells have the ability 
to attenuate inflammatory cytokine secretion and secrete higher levels of anti-
inflammatory molecules when compared to their monolayer counterparts [21, 85]. 
Although MSC aggregates such as these seem like a promising platform for effective 
cell-based therapies, the challenge of lack of proliferation in spheroid culture may hinder 
the scale-up of MSC aggregate systems [14]. Additionally, due to the 3D structure of 
formed aggregates, exogenous growth factors supplemented to the culture medium may 
not be exposed the entire cell population, especially the cells found on the interior of the 
aggregate. 
To address these potential limitations in MSC aggregate culture, incorporation of 
sulfated glycosaminoglycans (GAGs), such as heparin, within an aggregate can be used 
as a potential vehicle to promote growth factor availability due to the GAGs’ high 
negative charge that facilitates local electrostatic interaction with positively charged 
proteins [16, 158, 178, 210, 278]. Such a concept would mimic the actions of heparin 
sulfate proteoglycans (HSPGs) typically found on the plasma membrane of a cell and 
within the ECM [19, 166]. HSPGs play a role in regulation of signaling factor activity 
and can act as co-receptors for various growth factor receptors to lower receptor 
activation or alter duration of the signaling reactions [19, 166]. Because the interaction 
between heparin and its growth factors depends on the presence of the negatively charged 
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sulfate groups, desulfation of the GAG can modulate the interaction with a positively 
charged protein [158]. Specifically, it has been seen that desulfation of heparin can affect 
affinity for FGF-2 and TGF-β1 and the growth factors’ subsequent bioactivity [178, 186, 
199], but it remains unclear what effects GAGs of different sulfation levels may have on 
aggregate cell culture with growth factor supplementation.  
To incorporate GAGs into a 3D aggregate, we have previously developed and 
characterized a GAG cell coating that sequesters positively charged proteins onto cell 
surfaces [279]. We have shown that through layer-by-layer deposition of biotin and 
avidin, biotinylated heparin has been grafted onto cell surfaces at different concentrations 
without negatively affecting cell viability and inherent anti-inflammatory properties of 
MSC aggregates. When loaded onto aggregates of heparin-coated cells, TGF-β1 remains 
bioactive and has the ability to signal to surrounding cells upon release [279]. While 
characterization of this heparin coating has been performed, effects of a heparin coating 
on cell response to growth factors in long-term culture have not been explored. 
Moreover, because the electrostatic interactions between heparin and growth factors are 
necessary for binding and signaling, decreasing the sulfation level of the coating may 
provide insight into how these interactions can play a role in the subsequent cellular 
response. 
Thus, the objective of this paper is to characterize heparin MSC coatings of two 
different sulfation levels (native sulfation and fully desulfated) and study the effect of 
these coatings on MSC response in the presence of two different growth factors 
supplemented to the culture media, as would be found in traditional cell culture 
approaches for stem cell therapies. To evaluate the coating effect, MSC aggregates were 
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coated with either heparin or desulfated heparin and then cultured in serum-free media 
containing FGF-2 or TGF-β1. Over 21 days in vitro, cell morphology was characterized 
using histological staining, cell number was determined using a DNA assay, and 
chondrogenic differentiation was evaluated using quantitative reverse transcription 
polymerase chain reaction (RT-PCR) and immunohistochemical (IHC) staining for 
chondrogenic extracellular (ECM) components. In these studies, we hypothesize that the 
strong electrostatic interaction between heparin and the positively charged growth factors 
in the vicinity of the cells will promote growth factor availability, and therefore, the fully 
sulfated heparin coating will result in higher cell number in response to FGF-2 and to 
greater chondrogenic differentiation in response to TGF-β1, compared to the desulfated 
heparin coating and a noncoated control. 
4.2 Materials and Methods 
4.2.1 Heparin derivative synthesis  
Desulfation of heparin was performed using a previously published protocol 
[165]. Briefly, heparin was mixed at 5 mg/mL in methanol (VWR, Radnor, PA) 
containing 0.5% v/v acetyl chloride (Thermo Fisher Scientific, Grand Island, NJ). A 
methyl ester of heparin product was synthesized by acidic methanol treatment for 6 days. 
The product was dissolved in H2O and precipitated in an excess of 95% ethanol on ice. 
The methyl ester product was then precipitated in ethyl ether (Thermo Fisher Scientific) 
and vacuum dried using lyophilization (-40ºC at 0.120 mmHg). Demethylation was 
performed by 0.1 M potassium hydroxide treatment for 24 hours to produce the final 
desulfated heparin, which was precipitated in ethanol and ethyl ether and vacuum dried 
via lyophilization. To produce biotinylated GAGs, heparin was dissolved in water at 2 
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mg/mL and conjugated with biotin by reacting N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide (EDC) (Sigma Aldrich, St. Louis, MO), hydroxybenzotriazole (HoBT) 
(VWR) and biotin-hydrazide (Sigma Aldrich) at a molar excess compared to heparin of 
0.4 for all reagents for four hours at pH5. Desulfated heparin was dissolved at 2 mg/mL 
and reacted with EDC, HoBT and biotin-hydrazide at a molar of 3:3:8, respectively, for 
four hours at pH 5. Each reaction solution was dialyzed for two days in 3500 MWCO 
dialysis tubing (Spectrum, Rancho Dominguez, CA) followed by flash freezing and 
vacuum drying via lyophilization for two days. All heparin products were stored at -20ºC.  
4.2.2 Proton nuclear magnetic resonance (
1
H NMR) characterization 
 
1
H NMR was used to assess level of sulfation after solvolytic desulfation of 
heparin and used to determine conjugation efficiency following biotinylation of heparin 
derivatives. Approximately 5 mg/mL of each product was dissolved in deuterated water 
and 
1
H NMR experimented were conducted on a Bruker Avance III 400 spectrometer at 
400MHz. The resulting spectra were analyzed with ACD NMR Processor software 
(Version 12). Spectra can be seen in Appendix D.  
4.2.3 MSC expansion 
MSCs derived from human bone marrow aspirates were obtained from the Texas 
A&M Health Sciences Center. Cryopreserved MSCs from three different donors (2 
males, 1 female; ages 22, 24 and 37) were thawed and expanded in α-Minimum Essential 
Medium (Mediatech, Herndon, VA) containing 16.5% fetal bovine serum (FBS, Atlanta 
Biological, Atlanta, GA), 2 mM L-glutamine (Mediatech), 100 units/mL penicillin and 
100 μg/mL streptomycin (Mediatech) under normoxic conditions (37ºC, 5% CO2 and 
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20% O2) . Media were changed every 2–3 days until 80% confluence and were used at 
passage 3. 
4.2.4 Cell coating, aggregate formation, and culture  
After lifting with 0.05% trypsin (Mediatech), MSCs were washed in phosphate 
buffered saline (PBS, Life Technologies, Grand Island, NY) two times and then modified 
with a glycosaminoglycan by multilayer assembly of biotin and avidin layers, as 
previously described [279]. Briefly, cells were first cultured in 4 mM EZ-Link Sulfo-
NHS-LC-Biotin (Pierce, Rockford, IL) in PBS, followed by 0.5 mg/mL avidin in PBS 
(Life Technologies, Carlsbad, CA), and lastly 5 mg/mL biotin-conjugated heparin (Hep) 
or biotin-conjugated desulfated heparin (Hep-) in PBS (Process outlined in Figure 1A). 
Each incubation step with cells was performed in a 24-well Ultra-Low Attachment 
Surface plate (Corning) for 30 minutes at 37°C on a rotary orbital shaker plate at 65rpm. 
Once cells were coated with their respective glycosaminoglycan layers, 2000 cells in 200 
µL were pipetted into each well of a 5% Pluronic-coated 96-well V-bottom plate to form 
individual aggregates. Plates were spun down at 200 rcf to promote spheroid formation in 
serum free media composed of Dulbecco’s Modified Eagle Medium, 1% nonessential 
amino acids, 1% antibiotic/antimycotic, 1% insulin, human transferrin and selenous acid 
premix (BD Biosciences, San Jose, Calif., USA) and 50 μg/ml ascorbate-2-phosphate 
(Sigma-Aldrich). Aggregates were cultured in serum free conditions in the V-bottom 
wells with either 10 ng/mL of FGF-2 (R&D Systems, Minneapolis, MN) for DNA 
content assay or 10 ng/mL or TGF-β1 (Peprotech, Rocky Hill, NJ) and 100 nM 
dexamethasone (Sigma-Aldrich) for chondrogenic differentiation assays. Aggregates for 
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chondrogenic differentiation were cultured under hypoxic conditions (37ºC, 5% CO2 and 
3% O2 and N2). 
4.2.5 Chromatography analysis of cell coating solutions  
 To quantify amount of GAG grafted to cell surfaces, supernatants were obtained 
immediately after GAG incubation of single cells prior to aggregate formation. 
Quantification of Hep or Hep- that was remaining in the supernatant was analyzed using 
a high-performance liquid chromatography system (Shimazdu, Columbia Maryland). 
Duplicate samples were run in a 150 mM magnesium sulfate and 10 mM Tris base buffer 
through a TSK-GEL G4000PWX1 column (Tosoh Bioscience, King of Prussia, PA) for 
30 minutes at a flow rate of 1 mg/mL. Eluted samples were detected using a UV detector 
at the wavelength of 256 nM. GAG concentration in each sample was calculated using a 
standard of known concentrations ranging from 0.05 mg/mL-5 mg/mL for both Hep and 
Hep- polymers. The amount of Hep or Hep- grafted onto cells was normalized to the cell 
number for that coating group (n=3).  
4.2.6 Histological staining 
At appropriate timepoints, MSC aggregates were collected and washed with PBS 
to remove excess media. Aggregates were fixed in 10% neutral buffered formalin 
(Thermo Fisher Scientific) for 15 minutes and embedded in Histogel (Thermo Fisher 
Scientific) before subsequent incubation in increasing sucrose solution concentrations up 
to 15% under vacuum (–25 in Hg). Samples were then vacuum infiltrated with increasing 
concentrations of 20% sucrose:optimal cutting temperature compound solutions (4:1 to 
1:2 volume ratios). After overnight infiltration, samples were embedded in optimal 
cutting temperature compound and frozen in mixture of dry ice and 100% ethanol [111]. 
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Samples were stored at –80°C and cryosectioned at 10 μm thickness (Cryostar NX70; 
Thermo Fisher Scientific) prior to staining with hematoxylin & eosin (H&E). 
4.2.7 DNA quantification 
At appropriate timepoints, MSC aggregates were collected and washed with PBS 
three times to remove excess media. Aggregates were dissociated by incubation in 200 
µL 0.05% trypsin for 20 minutes and mechanical disruption by pipetting. Samples were 
spun down at 6000 rcf and collected cells were washed with PBS 1x before storing in 500 
µL of water containing 0.1% Triton-X100 (Sigma Aldrich) at -20ºC. Samples were 
subjected to three freeze-thaw cycles, in which samples were placed in a sonicating bath 
containing ice for 30 minutes, followed by freezing in the -80ºC freezer for 1 hour. Upon 
removal from the freezer, samples were thawed to room temperature for 30 minutes 
before repeating sonication and freezing cycle. Once samples were ready, DNA content 
was assayed using a CyQUANT® Cell Proliferation Assay (Life Technologies), 
according to manufacturer’s protocol. Samples were read at excitation 485 nm, emission 
525 nm by a plate reader (Biotek Synergy H4 Hybird Multi-Mode Microplate Reader, 
Winooski, VT) and DNA amount was determined using a standard curve of DNA. Data is 
reported as the DNA amount normalized to each group’s initial amount at day 1 (n=8).  
4.2.8 Gene expression analysis (RT-PCR)  
Over the course of 21 days, MSC aggregates were collected for gene expression 
analysis and lysed with RLT lysis buffer (Qiagen, Hilden, Germany). Each sample (n=1) 
contained three individually cultured aggregates to provide enough RNA for analysis. 
Cell lysates were filtered with QIAshredder tissue homogenizer and RNA was extracted 
with RNAeasy kit (Qiagen). Reverse transcription was performed using SuperScript III 
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Reverse Transcriptase (Invitrogen) with Oligo(dT)15 primers and nucleotides (Promega, 
Madison, WI). Primers were custom designed to target human mRNA for β-actin, 18s 
ribosomal protein, Sox9, collagen II, aggrecan, collagen I, collagen X, Runx2 and 
PPARγ2 (Table 1). Quantitative RT-PCR amplification for each gene was performed on a 
StepOnePlus System (Applied Biosystems, Carlsbad, CA) with SYBR Green Master Mix 
(Applied Biosystems). Raw amplification values were processed in LinReg software 
(v13.1, Amsterdam, Netherlands) to individually determine PCR efficiency and fold 
regulation relative to noncoated day 1 samples was determined for each sample with β-




Table 4.1. Human primer sequences for quantitative PCR. 
 
4.2.9 Immunofluorescent staining for matrix molecules 
Immunostaining for ECM deposition in cryosectioned samples was performed 
using primary monoclonal antibodies for collagen II, aggrecan, collagen X and collagen I 
(Abcam, Cambridge, UK; collagen X from Sigma Aldrich). Antigen retrieval was 
performed for all sections by incubating in 20 μg/ml proteinase K (Sigma-Aldrich) for 10 
minutes at 37°C. Samples for aggrecan and collagen X immunostaining were 
deglycosylated with 0.75 U/ml chondroitinase ABC (Sigma-Aldrich) for 1.5 hours at 
37°C. Samples were blocked with Image-iT FX signal enhancer (Life Technologies) and 
incubated with the primary antibodies overnight at 4°C (1:20 dilution for all primary 
antibodies). Secondary antibody binding with Alexa Fluor 488-conjugated goat 
polyclonal anti-mouse IgG (Molecular Probes, Carlsbad, California) at room temperature 
Target  Marker   Primer Sequences (5’→ 3’) GenBank 





18s Housekeeping F CGATGGGCGGCGGAAAATAGCCTTTGC NM_022551 
  
R CAGTGGTCTTGGTGTGCTGGCCTCGG 


















Chondrocyte F GGCCCAGCAGGAGCAAAGGG NM_000493 
  
R GTGGCCCGGTGGGTCCATTG 




PPARγ2 Adipogenic  F TCCATGCTGTTATGGGTGAA 
NM_015869 
    R GGGAGTGGTCTTCCATTACG 
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for 1 hour (1:200 dilution). Lastly, samples were stained with Hoechst (Sigma-Aldrich) 
for 5 minutes at room temperature to visualize cell nuclei (n=12).  
4.2.10 Statistical Analysis   
Quantitative data was transformed to fit a normal distribution using Box-Cox 
transformations, followed by a one-way and two-factor analysis of variance with Tukey’s 
post hoc multiple comparisons test (p<0.05) to determine statistical significance between 
samples in Minitab (v.15.1, State College, PA). Quantitative data are reported as mean + 
standard deviation.  
 
4.3 Results 
4.3.1 Coating characterization on MSC aggregates 
Using 
1
H NMR analysis, it was confirmed that solvolytic treatment of heparin 
resulted in removal of all sulfate groups. Furthermore, post biotinylation conjugation, 
1
H 
NMR also determined that both heparin and desulfated heparin species were both 
biotinylated with a conjugation efficiency of approximately 20%. Based on 









 mg GAG/cell of Hep- 
was grafted onto cell surfaces.  
4.3.2 Histological staining of MSC aggregates  
H&E staining revealed that the morphology of coated aggregates is distinct from 
noncoated aggregates. MSCs within aggregates coated with Hep and Hep- exhibited 
rounded cell morphology (Figure 4.1B, black arrows). This behavior persisted through 
day 14, at which rounded cell morphologies were still observed. Coated aggregates 
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cultured in media containing the growth factors FGF-2 or TGF-β1 also exhibited similar 
rounded cell morphology that persisted through 14 days in culture (data not shown).  
 
Figure 4.1. Hep and Hep- coated cells exhibit rounded cell morphology within 
aggregates. A) Schematic of layer-by-layer coating technology and MSC aggregate 
formation. B) H&E staining demonstrates rounded cell morphology observed in 
coated aggregates at day 1, 7 and 14. Arrowheads indicate cells with rounded 




4.3.3 Effect of GAG coatings on DNA content in MSC aggregates 
 DNA content assay of noncoated and coated aggregates revealed that the addition 
of FGF-2 caused an initial increase in DNA amount 7.2+1.9 fold for Hep coated 
aggregates, which was significantly higher than the other two groups (2.54+0.3 fold and 
4.11+0.8 fold for Hep- and noncoated aggregates, respectively) at day 4 (Figure 4.2).  
 
Figure 4.2. DNA content of Hep coated aggregates cultured with FGF-2 is 
significantly greater at day 4 and day 14 compared to other groups cultured with 
FGF-2. * indicates significant difference from respective coating group without FGF 
on same day; & indicates significant difference from noncoated and Hep- coated 
cultured with FGF on same day; # indicates significant difference from same group 
at day 1. Data reported as average mean + standard deviation, p<0.05, n=8. 
 
At day 14 with FGF-2 exposure, while noncoated aggregates only had a 2.1+0.9 fold 
increase in amount DNA, Hep coated aggregates increased 8.5+1.6 fold, and Hep- coated 
aggregates increased 4.3+1.4 fold, both of which were significantly higher compared to 
their respective group without FGF-2 and their respective group at day 1. At day 14, 
MSCs cultured without FGF-2 had DNA increases of 2.1+0.9 fold in noncoated 
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aggregates, 3.6+1.6 fold in Hep coated aggregates and 1.1+0.5 in Hep- coated aggregates, 
all of which were not significantly higher compared to their respective day 1 value. 
4.3.4 Effect of GAG coatings on chondrocytic gene expression in MSC aggregates 
Gene expression revealed that when noncoated and Hep and Hep- aggregates 
were cultured with TGF-β1 under hypoxia, MSCs from Hep- coated aggregates 
demonstrated an 86.5+7.5 fold upregulation of collagen II expression, which was 
significantly greater than the 37.7+10.6 fold increase for Hep coated aggregates and the 
15.1+4.7 fold increase in noncoated  aggregates at day 21 (Figure 4.3A). At day 14, 
collagen II expression in Hep- coated aggregates was significantly increased compared to 
noncoated aggregates, while this was not observed Hep coated aggregates. Aggrecan 
expression was significantly upregulated compared to the day 1 level at day 7 in Hep 
coated aggregates only (8.26+4.3 fold), however, it did not significantly increase further 
over time (19.3+5.4 fold at day 21). For Hep- coated aggregates, aggrecan expression 
was significantly upregulated (15.9+7.7 fold) only at day 21 (Figure 4.3B) and was not 
significantly different than the expression levels observed in Hep coated aggregates. 
Interestingly, Sox9 expression was not detected over the course of the 21 days for all 




Figure 4.3. MSC aggregates coated with Hep- upregulate gene expression for 
collagens II and X compared to noncoated and Hep coated controls. Summary of 
gene expression for (A) collagen II and (B) aggrecan gene expression, markers for 
chondrocytic differentiation, (C) collagen X gene expression, a marker for 
chondrocyte hypertrophy and D) collagen I gene expression, a marker for 
fibroblast/fibrochondrocyte differentiation. * indicates significantly greater than 
respective coating group at day 1. & indicates significantly greater than noncoated 
on same day. $ indicates significantly greater than Hep coated on same day. Data 
reported as average mean + standard deviation, p<0.05, n=3-4. 
 
Collagen I expression, indicative of fibroblastic differentiation, initially increased 
by day 7 but by day 21 was only expressed at 1.2+0.1 fold in noncoated groups, 1.8+0.5 
fold in Hep coated groups and 0.8+0.6 fold in Hep- group (Figure 4.3D), all of which 
were not significantly different from each other or compared to day 1. At day 7, Hep and 
Hep- coated aggregates had significantly upregulated expression of collagen I (3.14+0.5 
fold and 3.68+0.2 fold, respectively) when compared to noncoated aggregates (2.37+0.2 
fold). Collagen X expression, an ECM marker of hypertrophic chondrocytes, gradually 
increased over time for all groups but was significantly upregulated in Hep- coated 
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aggregates over both noncoated and Hep coated aggregates at day 21. Hep- coated 
aggregates exhibited a 37.1+4.7 fold upregulation on day 21 compared to an 18.4+8 fold 
regulation in Hep coated and 11.8+4.4 fold regulation in noncoated (Figure 4.3C). By day 
14, all groups had significantly upregulated expression of collagen X compared to its 
respective day 1 level (13.1+1.8 for noncoated, 15.91+0.3 for Hep coated and 28.9+7.7 
for Hep- coated), however, only Hep- coated aggregates exhibited significant 
upregulation compared to the other two groups at that timepoint and its day 1 level as 
early at day 7 (14.28+1.4 fold). No trends in expression levels were observed for Runx2, 
an osteogenic marker, and PPARγ2, an adipogenic marker, over time for all groups (data 
not shown). 
4.3.5 Effect of GAG coatings on chondrocytic ECM deposition in MSC aggregates 
 Immunostaining was performed to visualize specific ECM component deposition. 
On day 14, coated groups exhibited similar levels of staining for collagen II and appeared 
slightly stronger compared to noncoated aggregates (Figure 4.4). This increase in 
deposition for coated groups was observed as early as day 14. Additionally, at day 14, 
there appeared to be increased aggrecan staining in all samples, however, at day 14 and 
21, coated groups seemed to demonstrate stronger positive staining compared to 
noncoated samples (Figure 4.5). Positive staining for collagen X was obvious for all 
groups by day 14, at which time, differences could already be discerned between 
noncoated and coated aggregates. By day 21, Hep- coated aggregates exhibited pockets 
of pericellular collagen X, which was not observed for noncoated and Hep coated 
aggregates (Figure 4.6, insets). Collagen I staining was detected throughout all noncoated 
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and coated aggregates, however, the staining intensity was not observed to change over 
the course of 21 days within each group (Supplemental Figure B.8).  
 
Figure 4.4. Positive immunofluorescent staining of collagen II observed over 21 days 
for all aggregates, however Hep and Hep- coated aggregates exhibited stronger 
staining compared to noncoated aggregates at day 21. Collagen II is seen in green 





Figure 4.5. Positive immunofluorescent staining for aggrecan observed at day 14 for 
all aggregates. Aggrecan is seen in green and cell nuclei are stained blue. Scale bar = 





Figure 4.6. Positive immunofluorescent staining for collagen X observed at day 14 
for all aggregates, and Hep- coated aggregates exhibited stronger staining compared 
to Hep coated and noncoated aggregates at day 21. Collagen X is seen in green and 




 In this study, we have demonstrated the ability to coat MSC surfaces with 
different heparin species (Hep and Hep-) using an established layer-by-layer technology. 
Via chromatography analysis, the same GAG concentration (5 mg/mL) in the coating 
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solution resulted in similar amounts of each heparin species grafted onto cell aggregates. 
Moreover, using confocal microscopy imaging, over time, both fluorescent coatings 
decreased at similar rates (Supplemental Figure B.4). Therefore, we believe that similar 
amounts of Hep or Hep- are grafted on cell surfaces within the aggregate at any timepoint 
and that the different effects observed between heparin species are thus not a result of 
differing amounts of GAGs present in the system.  
After coating, H&E staining over time revealed rounded cell morphology within 
coated aggregates (Figure 4.1B). This phenomenon is specific to the presence of a GAG 
layer, as seen by the lack of rounded cell morphology in aggregates coated only with 
biotin and avidin (Supplemental Figure B.5). Additionally, when soluble heparin is 
introduced into the media, the morphology looks similar to that of the noncoated group 
(Supplemental Figure B.6A). While the mechanism is unknown, we conclude that Hep 
and Hep- coatings on cell surfaces can affect the organization and packing of the cells 
within the aggregate to produce the unique rounded cellular morphology observed in 
areas of the aggregate. 
 It is known that MSCs have limited proliferation capacity when cultured as 
aggregates in long-term suspension systems [8]. Because cell-based therapies require 
high dosages, developing a system that utilizes the mitogenic growth factor FGF-2 to 
improve proliferation may be necessary. Increased cell number over time was observed in 
MSC aggregates when both the Hep coating and FGF-2 were present in the system. 
Because heparin is known to preserve the bioactivity of FGF-2 [180, 182], it is possible 
that the presence of a Hep coating may simply be maintaining higher levels of active 
growth factor in the culture media. However, because this effect was not observed in 
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MSC aggregates cultured with FGF-2 and heparin added to the culture media 
(Supplemental Figure B.6B), the response of increased cell number is unique to the 
pairing of the cell surface presentation of heparin and the presence of the mitogenic 
growth factor.  
FGF-2 signaling occurs when dimerization of the growth factor and cell surface 
receptor, facilitated by heparin interactions between the 2-O and N-sulfate groups and 
growth factor, occurs [20, 176, 280]. Thus, the presence of the Hep coating could 
facilitate the sequestration of FGF-2 within the aggregate, as well as could promote 
signaling through dimerization of the receptor, together resulting in the increased cell 
number observed in these studies (Figure 4.2). Similar results have been observed when 
heparin was immobilized onto 2D surfaces and cultured with exogenous growth factors 
found in serum. The cultured cells on this 2D system exhibited increased proliferation 
when compared to MSCs cultured on surfaces without heparin [191]. Additionally, when 
heparin is crosslinked into a 3D hydrogel and loaded with FGF-2, the encapsulated MSCs 
undergo increased angiogenesis and proliferation when compared to hydrogels not 
containing heparin and loaded FGF-2 [191, 281]. While the Hep- coating may still be 
able to sequester FGF-2 locally in the aggregate, due to an overall negative charge that 
exists because of the remaining carboxyl groups, it may lack the sulfate groups necessary 
for signaling of FGF-2 to cause cell proliferation [178], resulting in DNA content more 
similar to the noncoated controls in this system. Taken together, these results suggest that 
a heparin coating combined with mitogenic growth factors in the media may help address 
the reduced proliferation capacity and thus could be used as a system for expansion of 
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MSC aggregates for subsequent administration in cell-based therapies such as treating 
graft versus host or autoimmune diseases.  
However, for other applications of MSCs, such as cartilage repair, cell expansion 
alone may not be sufficient, and systems that aim to differentiate MSCs down a 
chondrogenic pathway may be required to develop effective therapies. TGF-β1 is a potent 
growth factor known to induce chondrogenic differentiation [282]. Thus, the effects of 
our GAG coatings on the response of MSC aggregates to TGF-β1 in the media was 
examined to better understand how this system can be utilized for stem cell-based 
therapies to treat cartilage injury or disease. When coated and cultured in the presence of 
TGF-β1, Hep- coated aggregates exhibited more upregulation of the chondrogenic gene 
marker collagen II (nearly 90-fold) by day 21 compared to both noncoated and Hep 
coated aggregates, indicating that a Hep- coating can promote increased chondrocytic 
differentiation in MSC aggregates. Additionally, both noncoated and Hep coated 
aggregates had significantly higher collagen II expression at day 21 when compared to 
day 1, thus while the Hep coating may not promote high expression levels of collagen II, 
as seen with Hep- samples, it does not diminish the ability of the MSC aggregates to 
differentiation down a chondrogenic lineage. Overall increase in gene expression was 
matched by an apparent increase in staining for collagen II over time, however, intensity 
for the two coated groups looked similar at day 21 (Figure 4.4). 
Gene expression for aggrecan, another chondrogenic ECM molecule, was 
upregulated in Hep coated aggregates at day 14, followed by upregulation in Hep- coated 
aggregates at day 21 (Figure 4.3B). In contrast, increase in aggrecan deposition was seen 
as early as day 14 for all groups (Figure 4.5) via immunostaining, and both types of 
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coated aggregates appeared to exhibit stronger positive staining for aggrecan at day 21, 
compared to noncoated aggregates. These inconsistencies can be attributed the transient 
gene expression of aggrecan in this system that could have been upregulated earlier than 
day 14, as was observed in another MSC and GAG platform from our laboratory [111].  
The differences observed in gene expression and. immunostaining are somewhat similar 
to previous work in our laboratory with chondroitin sulfate microparticles incorporated in 
human MSCs aggregates, in which differences in aggrecan gene expression, but not 
immunostaining, were observed between groups treated with GAG vs. untreated [111]. 
This could be due, in part, to post-transcriptional regulation of ECM production that was 
not captured in the PCR results [283]. Although Sox9 expression was not detected in this 
system, it has been shown that collagen II expression is not correlated to levels of Sox9 
expression in adult chondrocytes [284], and that Sox9 expression is a regulator of 
chondrogenic differentiation typically expressed early during the differentiation process 
[285]. Therefore, it may be possible that differentiation in this system is occurring during 
the 21 day culture time and end points earlier than day 7 may need to be performed to 
capture the initial upregulation of Sox9 expression.  
While collagen I expression was upregulated for coated groups at day 7 and 14 
and decreased by day 21 (Figure 4.3C), minimal differences in positive staining for ECM 
deposition was observed over time in each group (Supplemental Figure B.8). This 
discrepancy can be explained by the fact that the magnitude of fold regulation increase in 
the system (around 3-fold) may not be enough to elicit a visual increase in deposition of 
the ECM protein. Additionally, the level of collagen I expression and staining is 
consistent with what has previously been shown in our laboratory with this cell type 
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[111], and may be a result of basal-level production of this molecule throughout culture. 
When the collagen II/collagen I ratio, a measure used to assess chondrocytic 
differentiation in MSCs [286], was calculated, all aggregates exhibited an upregulation 
(18.2+3.23 fold for noncoated, 19.7+8.0 fold for Hep coated, 182.2+40-fold for Hep- 
coated) at day 21. While collagen I is expressed in this system, the increased ratio 
between collagen II to collagen I indicates that MSCs in this system are favoring a 
chondrocytic pathway, rather than a more fibroblastic pathway.  
Expression of collagen X, a marker for MSC hypertrophic chondrogenic 
differentiation, increased over time for all groups, however, it was the greatest for Hep- 
aggregates by day 21 (Figure 4.3D). This was also observed in the staining for ECM 
deposition, in which bright pockets of pericellular collagen X were observed in Hep- 
coated aggregates on day 21 (Figure 4.6). Taken together, this indicates that coated MSC 
aggregates may become hypertrophic in our system, a result that has been previously 
observed in our laboratory [111, 200] and reported in other studies with human MSCs, 
including those with larger cell aggregates [106, 287]. This demonstrates that while many 
different platforms of MSC chondrogenesis exist, preventing hypertrophy remains a key 
challenge in cartilage tissue engineering, and additional culture methods, such as 
exposure to parathyroid hormones or co-culture with chondrocytes may be required to 
prevent hypertrophic differentiation during in vitro culture [105, 138, 288]. Although 
collagen X upregulation was measured in this MSC aggregate system, gene expression of 
other lineage markers, Runx2 (osteogenic) and PPARγ2 (adipogenic), were minimally 
changed or not expressed (data not shown), suggesting that those differentiation pathways 
were not favored in this system.  
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Although Hep coatings were seen to promote proliferation in response to the 
growth factor FGF-2 in MSC aggregates, upregulated chondrogenic marker expression 
was observed in Hep- coated aggregates in response to TGF-β1. It has previously been 
shown that the addition of GAG species with decreased sulfation level compared to 
heparin (such as hyaluronan and chondroitin sulfate) can activate or bind CD44, a cell 
surface receptor known to complex with the TGF-β1 receptor and activate downstream 
effector functions without the presence of TGF-β1 [289-291]. This demonstrates that 
multiple GAG species have potential to elicit TGF-β1 signaling in a manner that does not 
require binding between the GAG and growth factor. Another factor that can play a role 
when negatively charged GAGs are introduced is the change in osmotic swelling pressure 
within the aggregate. Previous studies have shown that increasing osmolarity can increase 
chondrogenic marker expression and matrix synthesis in MSC and progenitor cell 
systems undergoing chondrogenic differentiation [292, 293].  
While these possibilities may play a role in the observed effects with the Hep- 
coating, it was seen that coated aggregates cultured without TGF-β1 did not exhibit 
chondrogenic differentiation (data not shown), suggesting that the effects observed are a 
result of the coating interacting with the chondrogenic growth factor to promote a cellular 
response. It has been shown that the 6-O and N-sulfate groups play a role in the 
interaction of heparin with TGF-β1, and upon desulfation of certain groups, the affinity 
for the growth factor decreases [186]. We speculate that in this coating system, the strong 
binding of TGF-β1 to heparin may have prevented growth factor interaction with its 
receptor, resulting in reduced chondrogenic effects when compared to Hep- coated 
MSCs. The effect of desulfation has also been observed in another system in our 
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laboratory, in which in the presence of TGF-β1, MSCs encapsulated in desulfated 
chondroitin hydrogels had significantly greater expression of collagen II, aggrecan and 
collagen X when compared to MSCs in natively sulfated chondroitin sulfate hydrogels 
[200]. This provides evidence that although the desulfated forms of different GAGs may 
have a lower affinity for TGF-β1, their effect on cellular response is not dictated by that 
binding interaction. While these results support the concept that GAG cell coatings can 
be used to improve the effect and presentation of growth factors in culture, it is important 
to consider that a “one GAG fits all” strategy may not be optimal for all MSC culture 
applications and that non-native sulfation patterns may have the capability to potentiate 
the activity of specific growth factors. Thus, our coating technology represents a versatile 
platform to design MSC culture systems with pairings of GAGs and growth factors that 




These studies have demonstrated that GAG coatings have the ability to modulate 
growth factor interactions with MSC aggregates. By using layer-by-layer technology, 
biotinylated GAGs can be grafted onto cells within the MSC aggregate at similar 
amounts, thus enabling control over both the amount and sulfation level of heparin at cell 
surfaces. When cultured in the presence of the mitogenic growth factor FGF-2, natively-
sulfated Hep coatings were able to increase cell number over the culture period of two 
weeks greater than both Hep- coated and noncoated aggregates. On the contrary, when 
cultured in the presence of the chondrogenic growth factor TGF-β1, Hep- coated 
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aggregates exhibited the greatest expression of collagen II and collagen X, gene markers 
for chondrogenic and hypertrophic differentiation. The finding that heparin coatings of 
two different sulfation levels can result in different responses to two distinct growth 
factors indicates that this novel cell coating platform that enables specific pairings of 
growth factors with GAG sulfation patterns could be a potent future means of modifying 





DEVELOPMENT OF HEPPEP AND HEPARIN COATINGS FOR 
MSC SPHEROID MICROTISSUE ASSEMBLY 
 
5.1 Introduction 
 Microtissues formed from smaller tissue constructs or cells have been used in 
both in vitro model and in vivo tissue repair applications [10, 129]. Microtissue models 
can recapitulate tumor microenvironments for drug screening and have been typically 
executed in cellular arrays or microfluidic devices that provide a means to culture cells in 
either two-dimensions or three-dimensions (3D). These arrays are used to study effects of 
different conditions, such as drug dosage, on the resulting cellular response, such as 
viability, to determine safety and toxicity. In more complex systems, tissue matrix arrays 
that combine extracellular matrix (ECM) and cells can be used to investigate cell 
function, such as proliferation and differentiation, in response to different environments. 
Such approach enables high-throughput analysis of many factors to determine optimal 
conditions to achieve a desired cellular response [129, 133, 134].  
For tissue repair purposes, assembled 3D microtissues aim to exhibit similar 
characteristics as the complex physiological microenvironments for efficient integration, 
both functionally and morphologically, with the defect tissue [9, 74, 130]. For example, 
cardiac spheres formed from aggregating cardiomyocytes and cardiac muscle tissue has 
been used to form contractile constructs that can be implanted for treatment of 
myocardial infarctions [23]. Microtissues are advantageous in tissue repair applications 
because they are not as prone to clearance compared to single cells and can produce 
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proangiogenic factor that enable pre-vascularization or induce angiogenesis post 
implantation, ultimately, can improve engraftment when delivered [128].  
Microtissues are also often composed of multiple cell types in order to better 
mimic the complex structure of tissues. For example, functional myocardial microtissues 
can be formed from a combination of fibroblasts and cardiomyocytes to produce a 
contractile tissue that recapitulates in vivo extracellular matrix (ECM) organization and 
blood vessel microtissues that are composed of layers of artery derived fibroblasts and 
umbilical cord vein endothelial cells can be configured into a microtissue that resembles 
the spatial structure of the in vivo artery [10]. With the complexity using multiple cell 
types, forming cell contacts of proper cell type and spatial organization can be crucial to 
properly mimicking an in vivo microenvironment. Such is the case when recapitulating 
the complex bone marrow niche that contains multiple cell types, such as hematopoietic 
stem cells (HSCs), MSCs and endothelial cells, to study HSC maintenance and 
proliferation [96, 294, 295].  
Additionally, introducing multiple cell types into a microtissue structure requires 
an added factor of controlling interactions between the same cell types (homotypic cell 
interactions) and interactions between different cell types (heterotypic cell interactions). 
These cellular interfaces within a microtissue can provide contact-dependent signals 
between cells and can provide cues to induce cells to perform a certain function [131]. 
This has been shown during hepatocyte culture with mesenchymal stem cells (MSCs) or 
fibroblasts, during which, the combination of homotypic and heterotypic interactions 
between cell populations can affect the resulting hepatocyte function [139, 142, 148, 149, 
296]. Specifically, increasing the heterotypic cell interaction between hepatocytes and 
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fibroblasts while maintaining homotypic cell interactions has been shown to increase 
albumin production and urea secretion and ultimately maintain functional hepatocyte 
phenotype [148, 149, 296]. Control over cellular contacts is an important factor in 
developing microtissues that properly mimic in vivo tissues.  
To assemble microtissues with multiple cell types, previous methods have used 
encapsulation in hydrogels, scaffold-free technologies and microfluidic devices. 
Hydrogel encapsulation has been used to control organization of cell populations by 
encapsulating different cell types into separate sections of a hydrogel or seeding all cell 
types in a mixed population in one single hydrogel [144-146]. The other option of 
scaffold-free technologies uses centrifugation or gravity to force cells into aggregate 
form. Multiple cell types are typically mixed together and cultured together in one 
aggregate [148, 149]. Scaffold-free microtissues containing small spheroids of different 
cell types as the building block can also be formed by the incorporation of magnetic 
microparticles that direct the assembly of spheroids upon application of a magnetic field 
[150]. Lastly, microfluidic systems have been used to form high throughput arrays of 
small microtissues. Spatial organization of different cell types is typically achieved by 
introducing different cell types into the small specialized devices sequentially to allow for 
each cell type to interact and bind with each other [24, 134, 155, 156]. This platform 
facilitates control over the formation of the construct and culture parameters of media 
exchange and flow rate and can ultimately resemble a complex and accurate in vivo tissue 
environment [153, 154]. 
While these methods have all shown have the ability to produce multicellular 
microtissues, some aspects that are not addressed in these techniques include formation 
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of populations, the lack of self-assembly of the different cell populations, and production 
in dynamic culture. In encapsulation and scaffold-free technologies, formation is 
typically performed at a single microtissue scale, in which one hydrogel or one aggregate 
is produced. While microfluidic devices have the ability to produce multiple microtissues 
in a high throughput manner, the number formed is limited by the number of devices that 
need to be used. Therefore, current methods do not address assembly of microtissues at a 
larger population scale that can be achieved in culture system. Another shortcoming is 
that formation of microtissues with multiple cell types requiring physical placement of 
populations adjacent to each other or direction via an external driving force to bring cells 
together. These methods often require external biomaterials, such as hydrogels or 
microparticles, or specialized devices, such as microfluidic devices that support 
assembly. Finally, previous methods have all developed microtissues under static 
conditions. This can be a disadvantage because dynamic culture often provides the 
mixing and diffusion of nutrients and oxygen that can promote higher viability of the 
cells within the microtissue construct. Overcoming these shortcomings can result in the 
development of a platform for self-assembled microtissue that is amenable to future large 
scale bioprocessing culture, a property of microtissue assembly that has not previously 
been addressed.  
Given limitations of microtissue assembly in current technologies, the overall 
goal of this study is to develop a platform that supports self-assembly of 3D microtissues 
containing multiple cell types in a dynamic suspension system. The introduction of a 
dynamic system facilitates the formation of multicellular microtissues in a novel system 
that can eventually be translated to large scale bioprocessing technologies. MSC 
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spheroids were as the starting building block material and the model cell type in these 
studies because this cell type has been extensively used in numerous microtissue 
applications, including cartilage, hepatic, vascularized tissues and bone marrow niches 
[23, 130, 135-137].  
To achieve this self-assembly of microtissues, we utilized a cell coating that has 
been previously developed in this laboratory that uses layer-by-layer technology using 
biotin, and avidin to graft a biotinylated glycosaminoglycan (GAG), heparin, onto cell 
surfaces prior to formation of small spheroids [279]. Heparin is a negatively charged 
naturally derived polysaccharide that is known to interact electrostatically and 
specifically the positively charged growth factor fibroblast growth factor-2 [176, 280]. 
This binding site has been identified and has been synthesized into a short sequence 
known as a heparin binding peptide (HEPpep). It has been previously used in a self-
assembled monolayer that is able to sequester heparin from culture media [152, 191]. The 
sequestration of heparin from serum then facilitates the binding of growth factors such as 
FGF-2, which subsequently directs behavior of the cells cultured on that surface.   
We believe that this interaction between HEPpep and heparin can be exploited to 
control interactions between two different cell populations in a dynamic 3D culture 
system. Thus, the objective of this study is to investigate the use of HEPpep and heparin 
coatings on MSC spheroids assembly with a focus on how these coatings can affect the 
interactions between two cell populations. It is hypothesized that HEPpep coated 
spheroids will interact and assemble with heparin coated spheroids to form multi-cell 
type constructs in dynamic rotary culture. In this study, we have characterized both the 
HEPpep and heparin coating on MSC spheroid surfaces and their effects on cell viability 
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through confocal imaging. Additionally, we determined the specificity of these coatings 
and how investigated how modulating system parameters, such as ratio of cell 
populations and theoretical binding area, can affect the assembly of HEPpep coated and 
heparin coated spheroids and their interactions within the system by measuring 
assembled construct size, composition, and interfacial area between two populations.  
 
5.2 Materials and Methods 
5.2.1 MSC expansion 
MSCs derived from human bone marrow aspirates were obtained from the Texas 
A&M Health Sciences Center. Cryopreserved MSCs from three different donors (2 
males, 1 female; ages 22, 24 and 37) were thawed and expanded in α-Minimum Essential 
Medium (Mediatech) containing 16.5% fetal bovine serum (FBS, Atlanta Biological), 2 
mM L-glutamine (Mediatech), 100 units/mL penicillin and 100 μg/mL streptomycin 
(Mediatech) under normoxic conditions (37ºC, 5% CO2 and 20% O2). Media were 
changed every 2–3 days until 80% confluence and were used at passage 3. 
5.2.2 Heparin derivative synthesis and biotin conjugation  
To produce biotinylated GAGs, heparin was dissolved in water at 2 mg/mL and 
conjugated with biotin by reacting N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
(EDC) (Sigma Aldrich), hydroxybenzotriazole (HoBT) (VWR) and biotin-hydrazide 
(Sigma Aldrich) at a molar excess (compared to heparin) of 0.4 for all reagents for four 
hours at pH 5. For desulfated heparin, desulfation of heparin was first performed using a 
previously published protocol [165]. Briefly, heparin was mixed at 5 mg/mL in methanol 
(VWR) containing 0.5% v/v acetyl chloride (Thermo Fisher Scientific). A methyl ester of 
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heparin product was synthesized by acidic methanol treatment for 6 days. The product 
was dissolved in H2O and precipitated in an excess of 95% ethanol on ice. The methyl 
ester product was then precipitated in ethyl ether (Thermo Fisher Scientific) and vacuum 
dried using lyophilization (-40ºC at 0.120 mmHg). Demethylation was performed by 0.1 
M potassium hydroxide treatment for 24 hours to produce the final desulfated heparin, 
which was precipitated in ethanol and ethyl ether and vacuum dried via lyophilization. 
For biotinylation conjugation, desulfated heparin was dissolved at 2 mg/mL and reacted 
with EDC, HoBT and biotin-hydrazide at a molar ratio of 3:3:8, respectively, for four 
hours at pH 5. Each reaction solution was dialyzed for two days in 3500 MWCO dialysis 
tubing (Spectrum) followed by flash freezing and vacuum drying via lyophilization for 
two days. All heparin products were stored at -20ºC.  
5.2.3 NMR Characterization of biotinylated heparin products  
 
1
H NMR was used to assess level of sulfation after solvolytic desulfation of 
heparin and used to determine conjugation efficiency following biotinylation of heparin 
derivatives. Approximately 5 mg/mL of each product was dissolved in deuterated water 
and 
1
H NMR experimented were conducted on a Bruker Avance III 400 spectrometer at 
400MHz. The resulting spectra were analyzed with ACD NMR Processor software 
(Version 12). Spectra can be seen in Appendix D.  
5.2.4 HEPpep/heparin coating and spheroid formation  
 After lifting with 0.05% trypsin (Mediatech), MSCs were washed in phosphate 
buffered saline (PBS, Life Technologies) two times and then modified with a 
glycosaminoglycan or peptide sequence by multilayer assembly of biotin and avidin 
layers as per [279]. Briefly, cells were first cultured in 4 mM EZ-Link Sulfo-NHS-LC-
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Biotin (Pierce) in PBS, followed by 0.5 mg/mL avidin in PBS (Life Technologies), and 
lastly 5 mg/mL biotin-conjugated heparin (Hep) or 5 mg/mL biotin-conjugated desulfated 
heparin (Hep-) or 1mg/mL biotinylated heparin binding peptide (HEPpep, Biotin-NH2-
(CH2)4-GKRTGQYKLG-NH2, Aapptec) or a scrambled peptide sequence with a similar 
overall charge as the HEPpep sequence (Scramble, Biotin-NH2-(CH2)4-GTYRKKGLQG-
NH2, Aapptec) in PBS (Figure 5.1). Each incubation step with cells was performed in a 
24-well Ultra-Low Attachment Surface plate (Corning) for 30 minutes at 37°C on a 
rotary orbital shaker plate at 65 rpm. Once cells were coated with their respective GAG 
or peptide layer, 200-cell spheroids were formed via forced aggregation in an array of 
AggreWells
TM
 inserts made from 3% agarose (Pierce). Inserts were spun down at 200 rcf 
in serum free media composed of Dulbecco’s Modified Eagle Medium, 1% nonessential 
amino acids, 1% antibiotic/antimycotic, 1% insulin, human transferrin and selenous acid 
premix (BD Biosciences) and 50 μg/mL ascorbate-2-phosphate (Sigma-Aldrich). After 
24 hours, cell spheroids were transferred to 10 cm low attachment petri dishes (Fisher) 
and cultured on rotary at 65 rpm under normoxic conditions (37ºC, 5% CO2 and 20% O2) 




Figure 5.1. Schematic of layer-by-layer coating procedure and spheroid formation. 
 
5.2.5 HEPpep and heparin coating characterization  
 To image grafted coatings on cell surfaces within the spheroids, HEPpep and 
heparin were fluorescently tagged with Alexa-Fluor 633. Briefly, this conjugation was 
performed by EDC coupling in 0.1 M sodium bicarbonate buffer containing 10 mg/mL 
HEPpep or heparin, 10mM AlexaFluor®-633-hydrazide (Invitrogen), 20 µM EDC. The 
solution reacted for 1.5 hours at room temperature while protected from light before 
dialysis in 3500 MWCO tubing for two days and lyophilization for two days. Cells were 
coated as previously described and formed into 200-cell spheroids (HEPpep coated) or 
500-cell spheroids (Hep coated) and serum free media. At days 1 and 3 after coating, 
spheroids were collected, washed in PBS and stained with LIVE/DEAD staining solution 
(calcein AM at 1 µM and ethidium homodimer-1 at 1 µM, Invitrogen) and imaged under 
confocal microscopy at excitation wavelength 633 nm and emission wavelength 647 nm 
(Zeiss LSM 700 LSM confocal microscope) for the HEPpep or heparin coating and 
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excitation wavelength 494 nm/517 nm and emission wavelength of 517 nm/617 nm, 
respectively, for LIVE/DEAD staining (n = 3 plates). 
5.2.6 Specificity of coated assembled spheroids 
5.2.6.1 Assembly via soluble heparin  
Coating specificity was first observed by culturing peptide coated spheroids in 
media containing GAGs in solution. MSCs were coated with 1 mg/mL HEPpep or 1 
mg/mL Scramble using the coating method outlined previously. Coated cells were then 
formed into 200-cell spheroids through forced aggregation in AggreWells
TM
 and allowed 
to form spheroids for 24 hours. Coated spheroids were cultured in serum-free media 
supplemented with 5 mg/mL Hep, 5 mg/mL Hep- or without any additives (basal). 
Control samples included 200-cell noncoated spheroids cultured in the serum-free media 
supplemented with 5 mg/mL Hep, 5 mg/mL Hep- or no additives. Each plate was 
cultured with a total of 900 spheroids and in rotary suspension at 65 rpm for 24 hours 
under normoxic conditions. After 24 hours, samples were collected, fixed with 10% 
neutral buffered formalin and imaged under phase microscopy (Inverted Nikon TE 200 
microscope) (n = 3 plates with approximately 900 spheroids per plate). For imaging 
purposes, plates were combined and images taken represented the entire population for 
that group. All images were analyzed in ImageJ for diameter for the entire population of 
spheroids in each group. 
5.2.6.2 Assembly via coated spheroids  
 Coating specificity was also observed by culturing peptide coated spheroids with 
spheroids with GAG molecules that can express binding to those peptides. MSCs that 
would be coated with 1 mg/mL HEPpep or 1 mg/mL Scramble were stained with 
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CellTracker Orange (Molecular Probes) prior to coating steps. Other MSCs were coated 
with 5 mg/mL Hep or 5 mg/mL Hep-. Staining with CellTracker Orange was performed 
per manufacturer’s protocols. In short, after cell expansion and prior to lifting, MSCs 
were cultured in serum-free media containing α-Minimum Essential Medium, 2 mM L-
glutamine, 1% antibiotic/antimycotic and 10 µM of the CellTracker Orange dissolved in 
dimethyl sulfoxide (DMSO). After 30 minutes, media containing the CellTracker was 
removed and replaced with serum-free media without CellTracker. After 30 minutes, 
cells were lifted and coated with either HEPpep or Scramble peptide using layer-by-layer 
deposition.  
Once all cells were coated and formed into 200-cell spheroids using the 
AggreWell system, 900 total spheroids were cultured together in serum-free media at a 
ratio of 1:1 (peptide coated spheroids:GAG coated spheroid) on rotary for 24 hours under 
normoxic conditions (n = 3 plates with approximately 900 total spheroids per plate). 
Control groups contained HEPpep coated or Scramble coated spheroids with noncoated 
spheroids at a 1:1 ratio or only noncoated, heparin-coated and desulfated heparin-coated 
spheroids at a total of 900 spheroids per plate (n = 3 plates). After 24 hours, samples were 
collected, fixed with 10% neutral buffered formalin, and imaged under phase and 
fluorescent microscopy. For imaging purposes, plates were combined and images taken 
represented the entire population for that group. All images were analyzed in ImageJ for 
diameter for the entire population of spheroids in each group. Peptide coated spheroids 





5.2.6.3 Statistical analysis of spheroid assembly 
Images were taken of the entire spheroid population and diameters of the 
spheroids in these images were measured via ImageJ. To statistically compare these 
populations a cutoff size that represented larger constructs containing assembled 
spheroids was determined. To calculate cutoff size, the diameter at the upper 5% of the 
population for each control group was identified. The control groups included 
populations that contained all noncoated, heparin coated, desulfated heparin coated 
spheroids, seen in Figure 5.4 and Figure 5.5. The diameters that were determined at the 
upper 5% of the population for all control groups were averaged and set as the cutoff 
size. For experimental groups, seen in Figure 5.6 and Figure 5.7, the cutoff size was 
applied to each population and the percentage of measured diameters above that size was 
reported. The sub-population of diameters for each group that was larger than the cutoff 
size was statically compared using a one-way analysis of variance with Tukey’s post hoc 
multiple comparisons test (p<0.05) to determine statistical significance between groups in 
Minitab (v.15.1). 
To compare the percentages, the resampling method of bootstrapping was used to 
produce variance for each population [297, 298]. This was performed because the 
calculated percentage values represented the entire population of spheroids in that group, 
therefore only one value was produced and standard deviation could not be determined. 
When bootstrap resampled was performed in MATLAB (v.7.11), 900 diameters were 
chosen at random from the original population to create a new set of measurements. This 
was performed 3 times to create triplicates (as performed in the actual experiment with 3 
cultured plates), for each experimental group. Percentage of diameters above the cutoff 
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size from each resampled population was then determined. Average percentages for each 
experimental group was calculated and statistically compared using a one-way analysis of 
variance with Tukey’s post hoc multiple comparisons test (p<0.05) to determine 
statistical difference between groups in Minitab (v.15.1).  
5.2.7 Assembled spheroid competition assay 
 To study stability of assembled spheroids, 200-cell HEPpep coated spheroids that 
were stained with CellTracker Orange and 200-cell Hep coated spheroids were cultured 
together for 24 hours in serum-free conditions with no additives at 65 rpm on rotary. 
After 24 hours, an appropriate time to allow for spheroids to assemble, the media was 
replaced with serum-free media supplemented with 1 mg/mL HEPpep, a concentration 
that represents a 2X molar excess of the maximum amount of heparin grafted on cell 
surfaces (See Appendix C.2 for calculations). After 6 hours and 24 hours of culture in 
rotary suspension culture at 65 rpm, samples were collected, fixed with 10% neutral 
buffered formalin and imaged with both phase and fluorescent microscopy (n = 2 plates 
with approximately 900 spheroids).  
5.2.8 Assembly of coated spheroids at different ratios  
 To study assembly of spheroids when populations were cultured at different 
ratios, HEPpep coated spheroids were stained with CellTracker Orange and Hep coated 
spheroids were stained with CellTracker Green. Following staining and coating with 1 
mg/mL HEPpep or 5 mg/mL Hep, 200-cell spheroids were formed in AggreWells
TM
 and 
cultured at ratios (HEPpep coated:Hep coated) of 1:1, 2:1, 3:1, 6:1, 10:1 on rotary at 65 
rpm (n= 3 plates with approximately 900 spheroids). After 6 hours, 24 hours and 72 
hours in culture, groups were collected, fixed with 10% neutral buffered formalin and 
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imaged under confocal microscopy. ImageJ was used to analyze images for percent 
assembly, assembled spheroid size, composition, and cell interface area. Aggregate size 
and composition was measured at the center image of the stack collected and cell 
interface area was calculated using trapezoidal approximation through the z-stacked 
images taken at 5 µm apart. ImageJ was also used to construct confocal images of 
assembled spheroids containing HEPpep coated spheroids that are seen in green and Hep 
coated spheroids that are seen in red. 
5.2.9 Assembly of coated spheroids of different sizes  
 Spheroids of different sizes were cultured together for 24 hours to represent 
systems that contained high and low theoretical binding areas between the two 
populations. This was performed to examine how altering the potential binding area 
between two different cell populations can affect spheroid assembly. To study the effects 
of binding area without changing other parameters in the system, total cell number of 
each population of coated spheroids remained constant between the groups. Size was 
varied by forming spheroids containing different numbers of cells, ranging from 100 
cells/spheroid to 2000 cells/spheroid. Differently sized spheroids were paired together so 
that each group contained a smaller and larger spheroid. Theoretical binding areas for 
each pairing were calculated based on the surface area of the larger spheroid and the 
number of smaller spheroids that could pack tightly on that area. Calculations for binding 
area can be seen in Appendix C.2. 
The first group cultured 100-cell HEPpep coated spheroids with 500-cell Hep 
coated spheroids at a ratio of 420:560 (HEPpep:Hep) to represent low theoretical binding 
area in the system (Low BA). The second group cultured 200-cell HEPpep coated 
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spheroids with 2000-cell Hep coated spheroids at a ratio of 600:400 to represent high 
theoretical binding area (High BA) (n= 3 plates containing approximately 900 spheroids). 
HEPpep coated spheroids were stained with CellTracker Orange and Hep coated 
spheroids were stained with CellTracker Green, as previously described. A total number 
of 900 spheroids were cultured together for both groups for 6, 24 and 72 hours, at which 
time, spheroids were collected fixed with 10% neutral buffered formalin and imaged 
under confocal microscopy. ImageJ was used to analyze images for percent assembly, 
assembled spheroid size, composition, and cell interface area. Aggregate size and 
composition was measured at the center image of the stack collected and cell interface 
area was calculated using trapezoidal approximation through the z-stacked images taken 
at 5 µm apart. ImageJ was also used to construct confocal images of assembled spheroids 
containing HEPpep coated spheroids that are seen in green and Hep coated spheroids that 
are seen in red.  
5.2.10 Statistical analysis for area measurements  
Measurements collected from images (diameter, assembled spheroid size, 
composition, cell interface area) were analyzed using a one-way or two-way analysis of 
variance with Tukey’s post hoc multiple comparisons test (p<0.05) to determine 
statistical significance between groups in Minitab (v.15.1). Quantitative data are reported 
as mean + standard deviation.  
 
5.3 Results 
5.3.1 Coating characterization  
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 Confocal imaging revealed that, by using a layer-by-layer coating procedure, the 
biotinylated HEPpep peptide and biotinylated heparin was grafted on cell surfaces and 
did not disturb spheroid formation. At day 1 and day 3 after coating, both fluorescently 
tagged HEPpep and Hep were visualized in red on cell surfaces throughout the entire 
spheroid (Figure 5.2A&B, D&E). Additionally, LIVE/DEAD staining revealed that after 
3 days, cells in spheroids remained viable (Figure 5.2C&F). When intermediate layers of 
biotin and avidin were not present in the coating process, fluorescently tagged HEPpep 
was not observed on cell surfaces via confocal imaging (Figure 5.3A&B).  
 
Figure 5.2. HEPpep and Hep coating remains on cell surfaces for up to 3 days and 
does not negatively affect cell viability. Confocal images of HEPpep coating (red) at 
(A) day 1, and (B) day 3. (C) LIVE/DEAD of staining   HEPpep coated spheroids at 
day 3. Hep coating (red) at (D) day 1, and (E) day 3. (F) LIVE/DEAD staining of 
Hep-coated spheroids at day 3. Scale bar = 100µm, n = 100 spheroids. 
 
 
Figure 5.3. HEPpep coating (red) not observed on cell surfaces without intermediate 
biotin and avidin layer present. (A) Phase image and (B) confocal image of 
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spheroids coated with HEPpep without biotin and avidin. (C) LIVE/DEAD staining 
of spheroids at day 3. Scale bar = 100µm, n = 100 spheroids. 
 
 
5.3.2 Specificity of coating interactions  
5.3.2.1 Specificity of coating interactions: Assembly via soluble heparin  
To quantify the specificity of the HEPpep coating and its effects on spheroid 
assembly, coated spheroids were cultured in media containing soluble GAG and after 24 
hours, diameter of all spheroids in each population was measured. After 24 hours, none 
of the control groups exhibit spheroid assembly and the average diameter of each 
population was not significantly different from each other; thus, the cutoff size was set as 
the average upper 5% measurement for all control groups at 257.4 µm (Figure 5.4 and 
5.5). 
 
Figure 5.4. Noncoated spheroids did not assemble when cultured for 24 hours in 
media containing exogenous Hep, Hep- or under basal serum-free conditions. Phase 
image (top) and histogram of aggregate diameters (bottom) of noncoated aggregates 
cultured in serum-free media containing (A) 5mg/mL heparin, (B) 5mg/mL 
desulfated heparin, or (C) in basal conditions. Scale bar = 100µm, n = ~1500 





Figure 5.5. Hep coated, Hep- coated and noncoated spheroids cultured by 
themselves did not assemble after 24 hours in culture. Phase image (top) and 
histogram of aggregate diameters (bottom) of (A) heparin-coated spheroids, (B) 
desulfated heparin-coated spheroids, and (C) noncoated spheroids. Scale bar = 
100µm, n = ~1500 spheroids in total, red line indicates cutoff size. 
 
Imaging revealed that HEPpep coated spheroids cultured in media containing 5 mg/mL 
Hep or Hep- resulted in larger spheroids (Figure 5.6A&B). Additionally, 34+6% or 
37+5% of the entire population for HEPpep coated spheroids cultured in Hep or Hep- had 
diameters larger than the cutoff size, respectively, both of which were significantly 
different when compared to the percentage of spheroids with diameters larger than the 
cutoff size in the combined control populations (Table 5.1). Percentage of population 
with spheroids lager than the cutoff size was not significantly different than the control 
population percentage when HEPpep coated spheroids were cultured in basal serum-free 
media (6+5%) or when Scramble-coated spheroids were cultured under any conditions 
(13+7% in Hep, 10+2% in Hep-, and 8+6% in basal) (Table 5.1). Additionally, when the 
diameter measurements greater than the cutoff size for each group was compared to the 
measurements from the combined control groups, only HEPpep coated spheroids cultured 
in Hep or Hep- were significantly different (Figure 5.6.A&B).  
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Table 5.1 Resampled percentage of spheroids with diameters above cutoff size for 
HEPpep and Scramble-coated spheroids cultured in media containing GAGs in 
solution. Resampling produced triplicate (n=3) populations containing 900 
spheroids for each group. Statistical analysis was performed on percentages 
calculated from resampled populations. * indicates significantly different from the 
percentage calculated from combined control group populations, p<0.05. 
 
 
Figure 5.6. HEPpep-coated spheroids increased in diameter when cultured for 24 
hours in serum-free media containing soluble Hep or Hep-. Phase image (top) and 
histogram of aggregate diameters (bottom) of HEPpep-coated aggregates cultured 
in serum-free media containing (A) 5mg/mL heparin (B) 5mg/mL desulfated 
heparin or (C) basal conditions. Phase image (above) and histogram of aggregate 
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diameters (below) of Scramble-coated aggregates cultured in serum-free media 
containing (D) 5mg/mL heparin, (E) 5mg/mL desulfated heparin, or (F) basal 
conditions. Scale bar = 100µm, n = ~1500 spheroids in total, red line indicates cutoff 
size. Statistical analysis performed on measurements above cutoff size. & indicates 
significantly different from measurements above the cutoff size in the combined 
control group population, p<0.05. 
 
5.3.2.2 Specificity of coating interactions: Assembly via coated spheroids 
 The next experiment performed quantified the specificity of the HEPpep coating 
and its effects on spheroid assembly by culturing peptide-coated spheroids with GAG-
coated spheroids for 24 hours. Imaging revealed that after 24 hours, HEPpep coated 
spheroids cultured with Hep coated or Hep- coated spheroids contained assembled 
aggregates that were composed of different coated spheroid populations (Figure 
5.7.A&B).  
Table 5.2 Resampled percentage of spheroids with diameters above cutoff size for 
peptide-coated spheroids cultured with GAG-coated spheroids. Resampling 
produced triplicate (n=3) populations containing 900 spheroids for each group. 
Statistical analysis was performed on percentages calculated from resampled 
population. * indicates significantly different from the percentage calculated from 
combined control group populations, p<0.05. 
 
When HEPpep coated spheroids were cultured with Hep coated spheroids, the percentage 
of aggregates with diameters above the cutoff size was 70+11% and was significantly 
larger than the percentage calculated from the combined control population. Additionally, 
27+4% of the spheroids had larger diameters when HEPpep coated spheroids were 
cultured with Hep- coated, which was also significantly different when compared to the 
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control groups. However, only 12+5% of the spheroids were larger when HEPpep coated 
spheroids were cultured with noncoated spheroids (Table 5.2). When Scramble coated 
spheroids were cultured with the Hep coated, Hep- coated or noncoated spheroids, 
10+4%, 9+6%, and 6+2% of each population, respectively, had diameters above the 
cutoff size (Table 5.2), all of which were not significantly different when compared to the 
percentage of spheroids with diameters greater than the cutoff size in the combined 
control populations. When the population of spheroids above the cutoff size for each 
group was compared to that of the combined control groups, significant difference was 
observed in the diameters from populations that contained HEPpep coated and Hep 




Figure 5.7. HEPpep coated spheroids cultured with Hep coated spheroids exhibit 
larger assembled aggregates containing both cell populations after 24 hours. Phase 
image (top) and histogram of aggregate diameters (bottom) of (A) HEPpep coated 
(red) spheroids cultured with Hep coated spheroids, (B) HEPpep coated with Hep- 
coated, (C) HEPpep coated with noncoated, (D) Scramble coated (red) with Hep 
coated, (E) Scramble-coated with desulfated heparin-coated, and (F) Scramble-
coated with noncoated. Labels written as peptide-coating:GAG-coating. All groups 
were cultured at a ratio of 1:1. Scale bar = 100µm, n = ~1500 spheroids in total, red 
line indicates cutoff size. Statistical analysis performed on measurements above 
cutoff size. & indicates significantly different from measurements above the cutoff 
size in the combined control group population, p<0.05. 
 
5.3.4 Stability of assembled spheroids  
 To study the stability of assembled spheroids, assembled HEPpep and Hep coated 
spheroids were cultured in media containing 1 mg/mL HEPpep competitor in solution. 
After 6 hours and 24 hours of culture with the soluble HEPpep competitor, imaging 
revealed that assembled aggregates containing both HEPpep (red) and Hep coated 
spheroids were still observed (Figure 5.8).  
 
Figure 5.8. HEPpep-coated and Hep-coated aggregates do not disaggregate (once 
aggregated after 24hr) when cultured in media containing 1mg/mL HEPpep. Images 
taken at 6hr and 24hr after addition of soluble HEPpep. HEPpep-coated spheroids 
seen in red. Scale bar = 100µm, n = ~1000 spheroids in total. 
 
5.3.5 Aggregation of spheroids at different ratios  
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 To study how ratio of the two populations can affect coated spheroid assembly, a 
ratio of 1:1 increasing up to 10:1 of HEPpep coated:Hep coated spheroids were cultured 
together for over 72 hours. First, we observed that when Hep coated and HEPpep coated 
spheroids were cultured by themselves, assembly of spheroids did not occur at 6, 24 or 72 
hours (Figure 5.9).  
 
Figure 5.9. HEPpep and Hep coated 200-cell spheroids cultured by themselves do 
not aggregate over 72hrs. Confocal images of HEPpep coated (green) and heparin 
coated (red) spheroids cultured at 6hr (top), 24hr (middle) and 72hr (bottom) at 
ratios (HEPpep:heparin) of (A) 0:1, (B) 1:0, and (C) 10:1. Scale bar = 100µm, n = 
~1500 spheroids in total. 
 
For groups cultured at higher ratios, spheroids had not appeared to assemble with each 
other after 6 hours in rotary culture (Figure 5.10). After 24 hours in dynamic culture, 
HEPpep coated spheroids (seen in green) assembled with Hep coated spheroids (seen in 
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red) when cultured at ratios of 1:1, 2:1, 3:1, and 6:1 and formed constructs containing 
both cell populations.  
 
Figure 5.10. HEPpep coated spheroids cultured with Hep coated spheroids at 
different ratios do not aggregate after 6 hours. Confocal images of HEPpep coated 
(red) and Hep coated (green) spheroids cultured at ratios (HEPpep:Hep) of (A) 1:1, 
(B) 2:1, (C) 3:1, (D) 6:1, and (E) 10:1. Scale bar = 100 µm, n=~1500 spheroids in 
total. 
 
These aggregates containing multiple cell populations were also present at 72 hours 
(Figure 5.11A). At 24 and 72 hours, assembly of coated spheroids did not occur in the 
group with 10:1 spheroids (Figure 5.11A). In groups containing cell populations at ratios 
of 1:1 to 6:1, approximately 9-14% of the imaged spheroids had assembled with different 
coated spheroids after 24 hours. At 72 hours, approximately 12-19% of spheroids had 




Table 5.3. Percentage of assembled spheroids in groups containing different ratios 
(1:1 – 6:1) of HEPpep coated and Hep coated spheroids at 24 and 72 hours. 
 
When assembled aggregate size was measured, size of aggregates was not significantly 
different among any group at both 24 and 72 hours (Figure 5.11B). Additionally, percent 
composition HEPpep coated within these aggregates was not different among all groups 
at both timepoints (Figure 5.11C). Lastly, interfacial area between the two populations 
also was not different among all groups at both timepoints (Figure 5.11D).  
 
Figure 5.11. HEPpep coated spheroids cultured with Hep coated spheroids at ratios 
of 1:1, 2:1, 3:1, and 6:1 exhibit assembly at 24 and 72 hours. (A) Confocal images of 
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HEPpep coated spheroids (green) and Hep coated spheroids (red) cultured at ratios 
of (from left to right) 1:1, 2:1, 3:1, 6:1, and 10:1 at 24 and 72 hours. Quantified 
measurements of (B) assembled aggregate size, (C) % HEPpep coated within 
aggregate, and (D) interfacial area between two populations at 24 and 72 hours. 
Scale bar = 100 µm, n = ~1500 spheroids imaged, n = 100-200 spheroids analyzed for 
area measurements.  
 
5.3.6 Aggregation of spheroids of different sizes  
 To study how binding area in the system affects assembly of coated spheroids, 
spheroid diameter was altered by changing cell number per spheroid. Assembly of 
spheroids was observed at both 24 hour and 72 hours, however, at the later timepoint, 
mixing of the two cell populations was also seen (Figure 5.12A). Percent of assembly in 
the Low BA group was measured at 11% after 24 hours and increased to 51% after 72 
hours. Additionally, it was observed in High BA spheroid culture that percent assembly 
increased from 17% after 24 hours to 26% after 72 hours (Table 5.2).  
 
Table 5.4. Percentage of assembled spheroids in low and high BA culture conditions 
at 24 and 72 hours. 
 
When assembled aggregate size was measured, after 24 hours, spheroids cultured with 
high BA, was significantly higher than the assembled aggregate size measured in 
spheroids cultured with low BA. Additionally, size of assembled spheroids in the high 
BA group appeared to decrease significantly compared to both the low BA group at 72 
hours and the high SA aggregate size at 24 hours (Figure 5.12B). Composition of these 
assembled aggregates was not significantly different between both groups at both 
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timepoints (Figure 5.12C). However, similar to trends observed with assembled spheroid 
size, interfacial area between the two populations was significantly increased in the high 
BA group compared to the low BA samples at 24 hours (Figure 5.12D).  
 
Figure 5.12. HEPpep coated spheroids and Hep coated spheroids in high binding 
area (BA) culture conditions resulted in larger assembled aggregates and increased 
interfacial area at 24 hours. (A) Confocal images of HEPpep coated spheroids 
(green) and Hep coated spheroids (red) cultured in low SA conditions and high SA 
conditions. Quantified measurements of (B) assembled aggregate size, (C) % 
HEPpep coated within aggregate, and (D) interfacial area between two populations 
at 24 and 72 hours. Scale bar = 100 µm, n = ~1500 spheroid in total, n = 100-200 
spheroids analyzed for area measurements.  
 
Lastly, to further examine how binding area can affect assembly via coatings, binding 
area was reduced by culturing spheroids of the same size together at the ratio used for the 
112 
 
high BA group for 72 hours. Over 72 hours, assembly of spheroids was observed, 
however did not form large constructs that resulted in mixing of cell populations after 72 
hours (Figure 5.13).  
 
Figure 5.13. HEPpep and Hep coated 200-cell spheroids cultured at a ratio of 3:2 
aggregate after 72hrs. Confocal images of HEPpep coated (green) and Hep coated 
(red) spheroids cultured at 6hr (top), 24hr (middle) and 72hr (bottom). Scale bar = 
100µm, n = ~1000 spheroids in total. 
 
5.4 Discussion 
In this study, we have examined the effects of HEPpep and Hep coatings on MSC 
spheroid assembly to form multicellular constructs in a 3D dynamic system. To date, this 
113 
 
is the first reported study of microtissue assembly from smaller MSC building blocks in a 
dynamic system of culture [74, 130]. Through coating characterization, we first 
confirmed that using the layer-by-layer technology previously utilized in this laboratory 
(Figure 5.1), results in grafting of both the peptide sequence HEPpep and the heparin 
onto cell surfaces. After coating, these cells were able to form into spheroids and after 3 
days in culture, the HEPpep and Hep layers were still present and the cells within the 
spheroids remained viable, indicating that the coating process and the HEPpep and 
heparin layers do not have detrimental effects on cell viability. While other systems have 
grafted the HEPpep sequence to 2D surfaces [191], this technology to our knowledge, is 
the first reported example of grafting this peptide sequence onto cell surfaces.  
Assembly of spheroids with a HEPpep coating can occur in two forms: culture in 
environments containing soluble GAGs or culture with Hep coated spheroids. When 
cultured in media containing soluble Hep or Hep-, only HEPpep coating spheroids 
appeared to increase diameter size, indicating that spheroids were assembling to form 
larger constructs (Figure 5.6A). Because the HEPpep contains a lysine residue, and 
therefore is positively charged in addition to  presenting the sequence specific for heparin 
binding, we believe that soluble Hep can act as a crosslinker to bring together these 
HEPpep coated spheroids while in rotary culture. This specific interaction has been 
observed previous reports that have shown that HEPpep grafted to a 2D surface is able to 
sequester heparin from culture supplements [191]. While HEPpep and heparin can 
specifically interact, the similar results observed with Hep- in the media indicates that 
Hep- may contain an overall negative charge able to bring together the positively-charged 
HEPpep coated spheroids to form larger assembled spheroids (Figure 5.6B). 
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Additionally, when using a scrambled peptide that has the same charge as the HEPpep 
sequence but does not express a specific heparin binding site, Scramble coated spheroids 
did not appear to assemble when cultured in media containing any soluble GAG (Figure 
5.6D-F). This indicates that any nonspecific electrostatic interaction between the 
Scramble coating and Hep or Hep- was not sufficient to promote spheroid assembly and 
that there may actually be some degree of specific binding between the HEPpep coating 
and Hep- in addition to electrostatic interactions.  
The specificity of assembled spheroid populations with different coatings was 
also observed to be specific to HEPpep–Hep interactions. Images confirmed that larger 
assembled aggregates contained populations of both HEPpep and Hep coated spheroids 
when assembled (Figure 5.7A). When presented in coating form, the interaction that 
drives spheroid assembly appears to require the HEPpep and Hep coating that can 
specifically interact with each other, as all scramble coated groups and HEPpep and Hep- 
coated spheroids did not result in percentages of aggregates above the cutoff size 
significantly different than the control group (Table 5.2). The differences observed 
between the two presentations of GAG, in which both Hep and Hep- in media can direct 
spheroid assembly while only a Hep coating can drive assembly with HEPpep coated 
spheroids, may be a result of the availability of the GAG in each form. When soluble Hep 
and Hep- are in media, they are readily available and surround all HEPpep coated 
spheroids, and therefore can freely interact with the coating to promote assembly. On the 
other hand, when HEPpep coated spheroids and Hep coated spheroids are cultured in 
dynamic rotary culture, random collisions between the two different spheroids are 
required to then facilitate interactions that result in assembly. The specific interaction that 
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occurs upon collision between HEPpep coated and Hep coated spheroids enables the 
binding of the different populations of spheroids to form assembled aggregates.  
Once examining the assembly of these spheroid building blocks, we examined the 
stability of these aggregates by adding a soluble competitor to the media of HEPpep and 
Hep coated assemblies. After 24 hours of culture in media containing exogenous HEPpep 
competitor, it was observed that the interaction of HEPpep and Hep that results in 
assembly is stable and will not disassemble over that period of time (Figure 5.8). This 
finding is important in applications where cells in the microtissue will secrete proteins 
that contain heparin binding sites that can interact or compete with the heparin coating to 
break apart the formed aggregate [128]. 
After establishing that this coating system can assemble smaller spheroid building 
blocks when cultured together in a dynamic system, we investigated different parameters 
in this system that could affect the assembled aggregate properties (size, composition, 
and interface). We first varied the ratio of HEPpep coated spheroids to Hep coated 
spheroids in culture from 1:1 to 10:1. At the ratio of 10:1, no assembly of spheroids was 
observed over 72 hours, indicating that there may be a maximum ratio at which no 
assembly of different spheroid populations will occur due to the decreased amount of 
Hep coated spheroids resulting in a lack of available binding site interactions (Figure 
5.11A). Percent of assembly in all other groups (1:1-6:1) was maintained approximate 
around 15% at both time points, demonstrating that once assembly occurs, the overall 
system does not promote further assembly (Table 5.1). Additionally, assembled aggregate 
size, composition and interfacial area between the two populations were not significantly 
different among the groups that aggregated and between 24 and 72 hours (Figure 5.11B-
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D). This indicates that altering population ratio in this system may not be a factor in 
controlling size, composition and binding area of assembled coated spheroids and that 
other parameters that can affect kinetic collisions within the system can play a role in the 
observed measurements such as aggregate size. For example, while observed with a 
different cell type, it has been seen that rotation speed in dynamic rotary suspension can 
dictate the size of the resulting embryoid bodies formed from single cell embryonic stem 
cells, indicating that rotation speed is a parameter that can affect aggregate formation size 
[299, 300].  
To further examine this system of coated MSC spheroid assembly, we varied the 
parameter of available binding area in the system by changing spheroid diameter and 
spheroid sizes in culture. In comparing these two groups, theoretical binding area was 
varied, while cell number of each coated populations was constant. This was performed 
in effort to mimic previous coculture systems that have varied heterotypic interactions 
between the two cell types, while holding cell number constant to maintain homotypic 
interactions [148]. As expected, with larger spheroids in culture to provide a higher 
binding area, larger assembled spheroids and higher interfacial area was observed at 24 
hours when compared to the lower surface area group (Figure 5.12B). Similar to the 
previous study, percent assembly remained around ~15% for both groups at 24 hours, 
however did appear to increase at 72 hours (Table 5.2). At 72 hours, assembled 
aggregates exhibited cell population mixing and cell rearrangement, resulting in 
decreased aggregate size for the larger binding area group (Figure 5.12A&B).  This was 
not observed for smaller aggregates in previous experiments, thus the size of the 
spheroid, and ultimately the number of cells in each spheroid, may limit the control of 
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assembly in this coating system. The difference in assembly observed between altering 
ratio and altering surface area of coated MSC spheroids demonstrate that parameters held 
constant in these studies, such as rotation speed of rotary culture or total number of 
spheroids cultured together, alter the kinetics that affects the number of collisions 
between the two different populations, thus resulting in assembled constructs of different 
sizes and compositions.  
Through these studies, we have also identified certain limitations in this 
microtissue assembly system of coated MSC spheroids. With the model MSC cell type 
utilized, it was observed that cellular rearrangement began to occur as early as 72 hours 
in culture, indicating that we may not have control over the homotypic and heterotypic 
interactions in long term culture with this adherent cell type. While only one cell type 
was used in this study, we have shown the ability to initially assemble these coated 
spheroids, and future usages of this coating technique on different cell types [229, 232, 
279], can lead to the development of multicellular microtissues that can be cultured for 
tissue model or repair applications. Additionally, in these studies, we demonstrated that 
while assembly can occur between HEPpep and Hep coated spheroids, efficiency of 
assembly remained consistently below 20%. To increase this assembly efficiency within 
the population, further examination of this system to determine other factors, such 
altering rotation speed or altering total number of spheroids, may need to be optimized.  
We have ultimately shown in these studies that using a HEPpep and Hep coating 
system on MSC spheroids can facilitate self-assembly of smaller building blocks to form 
larger aggregates in a dynamic system. Additionally, harnessing this specific interaction 
facilitates the aggregation of a population of coated spheroids in one system. These 
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qualities of this assembly method represent a technology that can be amenable to large 
scale up bioprocesses, an aspect that has not been studied in the current microtissue field. 
By exploiting the ability of heparin to bind growth factors, a novel technique to build 
microtissues from smaller building block aggregates has been developed and has the 
potential to be implemented in in vitro tissue modeling and in vivo tissue repair 
applications.   
  
5.5 Conclusions 
 These studies demonstrate a novel technique to assemble small building blocks 
using HEPpep and Hep coatings on MSC spheroids. By using layer-by-layer deposition, 
biotinylated HEPpep and Hep can be grafted onto MSC surfaces for up to 3 days without 
having detrimental effects on cell viability. We have shown that the HEPpep coating 
specifically interacts with the Hep coating to promote assembly of two different spheroid 
populations and that controlling assembly can be performed by altering available binding 
area. These results establish a new method that is scalable for large bioprocessing 
applications to form a population of self-assembled microtissue in dynamic culture by 
exploiting heparin interactions with growth factor derivatives for future uses of in vitro 










 Heparin, a highly sulfated GAG, has anti-coagulant activity, plays a role in 
organizing basement membrane and can act as a co-receptor to bind and sequester 
positively charged growth factors, cytokines, and chemokines and enhance ligand-
receptor signaling [244]. It can be produced by mast cells throughout the entire body or 
found tethered to cell membrane proteoglycans [157, 166]. Due to its negative charge, 
heparin can be manipulated as a biomaterial with the ability to sequester and bind 
positively charged growth factors to cells to guide behavior [16]. In the work presented in 
this thesis, the unique properties of heparin-protein interaction and binding has been 
exploited and presented to cells via an engineered coating and the effects of this heparin 
coating were examined on mesenchymal stem cell (MSC) aggregates and spheroids.  
MSCs are multipotent stem cells with the ability to differentiate down bone, 
cartilage and muscle lineages and secrete trophic factors that promote regeneration and 
repair of injured tissue [1, 4]. While MSCs are a promising cell source and are currently 
being used in over 300 clinical trials, an approved therapy using MSC does not exist [5, 
6]. To improve MSC-based therapies, biomaterial strategies, such as a heparin cell 
coating, can be used to provide cues in the surrounding environment to guide cell 
behavior [16, 17, 103, 209]. Therefore, the combination of using MSCs with heparin 
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biomaterials can potentially be used in future cell-based therapies for the treatment a 
wide variety of injuries and pathologies.  
The overall goal of this dissertation was to engineer a heparin coating that 
exploits the interactions with surrounding growth factors or binding peptides to influence 
MSC behaviors, such as cell proliferation, differentiation and aggregation. To investigate 
how heparin coatings can modulate cellular response, MSCs were coated using a layer-
by-layer method with heparin, desulfated heparin or a heparin binding peptide. Together 
these studies provide valuable insight into the unique ability of engineered heparin 
coatings on cell surfaces to promote a desired cell behavior in different environments for 
future development of MSC-based therapeutics.  
 In Chapter 3, heparin coatings for MSC cell surfaces were developed for MSC 
spheroids. A multilayer technology was used to graft a range of 5 μg/mL–5 mg/mL 
heparin onto the surface of MSC aggregates. Results revealed that heparin coating did not 
affect cell viability (seen through LIVE/DEAD staining) and cell anti-inflammatory 
properties (seen through co-culture with activated monocytes) and facilitated 
sequestration by coated cells of a growth factor (transforming growth factor- β1, TGF-β1) 
that remained bioactive. Together, these studies provide insight into a system that could 
potentially maximize the therapeutic potential of MSC-based treatments because the 
loaded protein can both signal to influence transplanted cell fate and be released into the 
surrounding environment to help repair injured tissue. 
In Chapter 4, the response of heparin-species coatings to positively charged 
growth factors were studied within an MSC aggregate. Due to the importance of the high 
negative charge density in the interactions with growth factors, both heparin and 
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desulfated heparin were grafted onto cell surfaces within the aggregate using the 
developed coating technology and the following were examined: 1) cell number in 
response to fibroblast growth factor-2 (FGF-2) and 2) chondrogenic differentiation in 
response to TGF-β1. Results revealed that in the presence of FGF-2, by day 14, heparin-
coated MSC aggregates increased in DNA content 8.5+1.6 fold compared to day 1, which 
was greater than noncoated and desulfated heparin-coated aggregates. In contrast, when 
cultured in the presence of TGF-β1, by day 21, desulfated heparin-coated aggregates 
upregulated gene expression of collagen II by 86.5+7.5 fold and collagen X by 37.1+4.7 
fold, which was higher than that recorded in the noncoated and heparin-coated 
aggregates. These observations indicate that this coating technology represents a versatile 
platform to design MSC culture systems with pairings of GAGs and growth factors that 
can be tailored to overcome specific challenges in scale-up and culture for MSC-based 
therapeutics. 
 In Chapter 5, the interaction between heparin and a growth factor derived binding 
sequence (HEPpep) was used to promote assembly of MSC spheroids into small 
microtissue constructs in a dynamic culture environment. This technology demonstrated a 
novel method to self-assemble a population of microtissues out of smaller building blocks 
in suspension culture. The heparin and HEPpep coating interaction was observed to be 
specific for each other and resulted in assembly of spheroids to form constructs 
containing multiple cell populations. It was observed that at different cell population 
ratios and different levels of binding area within the system, the interactions between the 
heparin and HEPpep coatings resulted in assembly of the two cell populations after 24 
hours and remained present up to 72 hours, However, altering these factors did not affect 
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the interfacial area between the two cell populations and cellular rearrangement within 
the assembled aggregates was observed at 72 hours. Together, these results present a new 
method to assemble building blocks in a “bottom-up” approach to form small 
microtissues with multiple cell populations by exploiting the interaction of GAG and its 
corresponding binding sequence in a coated presentation.  
 Together, these findings presented in this dissertation suggest that heparin in a 
coating form can promote MSC response to growth factors and MSC aggregation. These 
engineered GAG molecular interactions at the cell surface can be used as a powerful and 
promising tool to promote a desired cell response or direct cell aggregation in future 
MSC-based therapies.   
  
  6.2 Conclusions 
The research presented in this dissertation advances the understanding of how 
engineered GAG interactions at MSC surfaces can be utilized to direct cell behavior. 
Based on the native proteoglycan structure seen at cell surfaces, coating cells with 
heparin is a novel technology to present both native and non-native GAGs to cell to alter 
the local microenvironment. These studies have examined 1) the effects of the heparin 
coating on protein loading, inherent MSC anti-inflammatory properties and native 
pericellular matrix, 2) the effects of heparin on modulate response to positively charged 
growth factors in the environment, and 3) the effects of heparin interactions on promoting 
cell aggregation. Together, these results indicate that heparin-based coatings can be used 
to as a potential tool to promote a desired cell response in MSC-based therapies.  
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The approach in this dissertation involves engineering the interactions that occur 
at the cell surface through a coating technology, as developed and characterized in 
Chapter 3. In this chapter, this approach presented a potential a dual-delivery system, in 
which a biomolecule of interest can be released from cell surfaces to help regenerate and 
repair tissue without the use of excess biomaterials. This coating technology exploited 
growth factor interactions with heparin, as it is the most sulfated native GAG and is 
known to interact and bind numerous positively charged proteins through electrostatic 
and sequence specific interactions.  
Heparin coating was grafted onto surfaces using layer-by-layer deposition of 
biotin and avidin. As the outer layer, heparin’s high negative charge, resulting from the 
presence of multiple sulfate groups, facilitated the sequestration of positively charged 
biomolecules via electrostatic interactions [244]. The amount of heparin grafted on cells 
was tuned using different initial concentrations in solution. Given a fixed number of cells 
per spheroid, coating concentrations ranging from 5 µg/mL to 5 mg/mL resulted in an 
increased amount of heparin visualized on cell surfaces. While it was expected that the 
amount of heparin grafted would plateau near the theoretical saturation level of the 1 
mg/mL concentration, the fact that increased fluorescence was observed at 5 mg/mL 
suggested that multiple layers of heparin can be deposited onto the surface, perhaps 
mediated through both the avidin–biotinylated heparin interactions and electrostatic 
interactions between avidin and heparin. Over time, the removal of the heparin coating 
from cell surfaces could be attributed to secretion of enzymes that cleave heparin, or cell 
membrane turnover or non-biotinylated heparin release into surrounding environments 
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[257]. Overall, characterization of this coating revealed that it was possible to tune and 
control the amount of heparin that could be grafted on to cell surfaces.  
To study the effects of this heparin coating on MSC properties, the pericellular 
matrix (PCM) and anti-inflammatory properties of MSCs were also examined in Chapter 
3. The PCM is composed predominantly of chondroitin sulfate-rich proteoglycans and 
hyaluronan can play a role in cell interaction with the environment and cell adhesion 
[250, 258, 259]. It was important to study the presence of the PCM after the coating 
procedure to better understand what was being presented on the surface of the cells after 
coating. The decreased PCM thickness and lack of regrowth after 24 hours suggested that 
the heparin coating procedure removed or collapsed (via crosslinking) the natural PCM 
found on cell surfaces. This implied that the heparin coating could exist on cell surfaces 
for at least 1 day without being overwhelmed by the natural matrix. For anti-
inflammatory properties, the ability of MSC spheroids to attenuate tumor necrosis factor-
α (TNF-α) secretion by activated monocytes was observed [3, 84]. Using a co-culture 
assay, the highly negatively charged heparin layer did not alter the ability of MSCs to 
attenuate TNF-α production by monocytes, suggesting that sufficient anti-inflammatory 
signaling by MSCs was able to occur. These results indicated that the addition and 
modification of cell surfaces did not alter the inherent ability of MSC spheroids to 
attenuate monocyte pro-inflammatory cytokine secretion.  
Lastly, in Chapter 3, assessment of a loaded protein bioactivity was performed 
using a reporter mink lung epithelial cell (MLEC) cell line known to express 
plasminogen activator inhibitor (PAI-1) fused with a luciferase firefly reporter in 
response to TGF-β1 in a dose dependent manner [255, 268]. After assaying the 
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supernatant containing any released TGF-β1 that was loaded onto heparin coated cells, it 
was seen that the presence of the heparin coating could help preserve the bioactivity of 
the TGF-β1. Based on these results, it was envisioned that the bioactive protein could be 
able to “signal out” to the neighboring cells and the surrounding environment to 
encourage regeneration. This multifaceted system could potentially be used in cell-based 
therapies to both prime cells for cell-mediated tissue regeneration and release 
biomolecules to modulate the damaged tissue environment. 
 To characterize the interactions of how this GAG coating could facilitate a 
bioactive protein’s ability to “signal-in” to the cells, in Chapter 4, coated MSCs were 
cultured in environments containing different growth factors. Because the high negative 
charge density of heparin is attributed to the sulfation groups found along the GAG 
backbone [20], desulfation of heparin was performed to study how electrostatic 
interactions can modulate cell response to growth factors in the surrounding environment. 
Once heparin was desulfated through solvylytic removal of sulfate groups [165], layer-
by-layer deposition was used to graft biotinylated heparin species of native and no 
sulfation onto cell surfaces. Via chromatography analysis, the amount of heparin and 
desulfated heparin was measured and confirmed to be approximately the same amount 
when the same coating concentration was used. Therefore, by using this technique, 
different species of GAGs were grafted onto cell surfaces at similar amounts, and 
presented a controlled method to study the effects of GAG interactions with soluble 
growth factors in coated MSC aggregates.   
 To potentially overcome the challenge of limited proliferative capacity in MSC 
aggregates, the addition of the mitogenic protein FGF-2 has been used to improve 
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proliferation in MSCs [183]. Using the developed technique of grafting heparin species 
of native and no sulfation, the response of coated MSCs in aggregate form to FGF-2 in 
the media was observed. Only when both a heparin coating of native sulfation and FGF-2 
were present in the system, increased cell number in MSC aggregates occurred. It is 
known that FGF-2 signals through the dimerization of the growth factor and cell surface 
receptor, facilitated by heparin interactions between the 2-O and N-sulfate groups and 
growth factor, occurs [20, 176, 280]. Thus, the presence of the heparin coating could 
facilitate the sequestration of FGF-2 within the aggregate, as well as could promote 
signaling through dimerization of the receptor, together resulting in the increased cell 
number observed. While the desulfated heparin coating may still be able to sequester 
FGF-2 locally in the aggregate due to an overall negative charge that exists because of 
the remaining carboxyl groups, it may lack the sulfate groups necessary for signaling of 
FGF-2 to cause cell proliferation [178], and therefore resulted in DNA content more 
similar to that of the noncoated controls. Taken together, these results suggested that a 
heparin coating combined with mitogenic growth factors in the media could help address 
the reduced proliferation capacity and thus could be used as a system for expansion of 
MSC aggregates for subsequent administration in cell-based therapies such as treating 
graft versus host or autoimmune diseases [6, 8].  
On the other hand, when cultured with TGF-β1, a growth factor that is commonly 
used for chondrogenic differentiation, desulfated heparin coated aggregates exhibited 
more upregulation of the chondrogenic gene marker collagen II and the hypertrophic 
gene marker collagen X by day 21 compared to noncoated aggregates and heparin coated 
aggregates. This indicated that a desulfated heparin coating could potentiate the 
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chondrogenic response of TGF-β1 to promote increased chondrocytic and hypertrophic 
differentiation in MSC aggregates. In contrast to heparin coatings that were seen to 
promote proliferation in response to FGF-2 in MSC aggregates, upregulated 
chondrogenic marker expression was observed in desulfated heparin coated aggregates in 
response to TGF-β1. It has been shown that the 6-O and N-sulfate groups play a role in 
the interaction of heparin with TGF-β1, and upon desulfation of those groups, the affinity 
for the growth factor decreases [186]. However, desulfation did not affect the ability of 
TGF-β1 to signal to MSCs, indicating that while desulfated forms of different GAGs 
could have a lower affinity, the effects of TGF-β1 on cellular response is not dictated by 
that binding interaction [186]. In this coating system, it was speculated that the binding of 
TGF-β1 to heparin could have prevented growth factor interaction with its receptor, 
resulting in reduced chondrogenic effects when compared to the desulfated coated MSCs.  
While these studies from Chapter 4 support the concept that GAG cell coatings 
could be used to improve the effect and presentation of growth factors in culture, the 
results indicated that it is important to consider that a “one GAG fits all” strategy may not 
be optimal for all MSC culture applications and non-native sulfation patterns may also 
have the capability to potentiate the activity of specific growth factors. Therefore, this 
coating technology represents a versatile platform to design MSC culture systems with 
pairings of GAGs and growth factors that can be tailored to overcome specific challenges 
for MSC-based therapeutics.  
Lastly, MSCs in microtissues can be a promising approach for regeneration of 
tissue or in vitro modeling [7, 135, 136]. By exploiting heparin and growth factor binding 
interactions presented in coating form, this technology could be used to self-assemble 
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cells of different populations in a dynamic system to form microtissue constructs. The 
specific heparin binding site on the growth factor FGF-2 has previously been isolated and 
synthesized into a short peptide form (HEPpep) [191]. Because this sequence could be 
produced to include a biotin group, it could also be grafted onto cell surfaces via the 
layer-by-layer technology used in this dissertation. It was observed that the biotin-avidin 
layering technique facilitated the grafting of a biotinylated HEPpep sequence onto cell 
surfaces, without disrupting the MSCs ability to form spheroids or having detrimental 
effects on cell viability. Additionally, the coating appeared to remain on cell surfaces for 
up to 3 days. Therefore, these results indicated that this versatile coating method could be 
used to graft a variety of heparin-based molecules onto cell surfaces.  
As observed in Chapter 5, self-assembly occurred when HEPpep coated spheroids 
were cultured in media containing soluble heparin in solution and when cultured with 
heparin coated spheroids. The assembly of these HEPpep coated spheroids resulted in 
larger aggregates when cultured with soluble heparin and aggregates that contained two 
different cell populations when cultured with heparin coated spheroids. Additionally, this 
interaction appeared to be specific between the two molecules as assembly of coated 
MSCs only occurred when heparin coatings were presented to HEPpep coatings, and not 
a scramble peptide coating. This scramble peptide presented a similar charge density as 
HEPpep to the spheroids, however did not contain the specific binding sequence for 
heparin [191]. Together these results presented a potential opportunity to promote 
assembly of different cell populations by using a coating system that exploited binding 
between GAGs and its corresponding binding site. This system was advantageous 
compared to current assembly methods in that assembly to form multiple microtissues 
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containing multiple cell populations can occur on its own without external direction or 
manipulation of the cell populations in a dynamic system [23, 134-136]. Additionally, 
this was believed to be the first report of microtissue assembly in a dynamic system, 
rather than a static system, and could potentially be implemented in larger scale 
processing systems.  
To further examine the properties of this self-assembled microtissue system, 
altering cell population ratio and interfacial binding areas was performed in Chapter 5 to 
study effects on the types of assembly that was occurring in the system. This included 
examining assembled aggregate size, composition of the assembled aggregate and the 
interfacial area between the cell populations. After 24 and 72 hours in dynamic culture, 
aggregate assembly was observed between HEPpep coated and heparin coated spheroids 
at varying cell population ratios and varying binding area availabilities. However, 
assembled aggregate size, composition and interfacial area did not appear to be different 
among the groups varying cell population ratio between 24 and 72 hours and 
rearrangement of the cells within the assembled aggregate was observed at 72 hours. 
These results indicated that while optimization of different parameters in the system need 
to be explored to better characterize assembly of coated spheroids, altering molecular 
interactions at the cell surface could be used as a method to self-assemble coated 
spheroids into larger constructs.  
This heparin coated-based biomaterials approach presented in this dissertation 
provides a novel system that exploits GAG interactions in a coated presentation to guide 
cell behavior for MSC-based therapies. By using the ability of heparin to interact with 
different positively charged growth factors or its binding sites, cell response to 
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surrounding growth factors and cell interactions with other coated populations were 
examined. At the cellular level, harnessing the molecular interactions of heparin species 
with different sulfation levels at the surface of MSCs allowed this system to potentiate 
specific growth factor response and direct MSCs to behave in a certain manner for future 
therapeutic applications. At a larger scale, exploiting heparin and growth factor binding 
facilitated this system to promote cell aggregation to form tissue constructs for future 
microtissue applications. Taken together, this coating technology can be a valuable and 
powerful tool to engineer molecular interactions at cell surfaces that modulate the 
environment and direct behavior for future cell-based therapies. 
 
6.3 Future Directions 
 The findings presented in this dissertation provide significant insight into the 
potential uses of exploiting GAG interactions at cell surfaces to modulate MSC aggregate 
behavior. A coating system able to graft multiple species of heparin on multiple cell types 
was developed and its effects on growth factor response and microtissue assembly were 
examined. The results of these experiments suggest that engineering cell surfaces with 
exogenous GAG introduces a level of control of what is presented to cells and the 
subsequent cellular response. The studies in this dissertation represent a broad 
examination of how these heparin coatings can be used in different MSC behaviors, 
ranging from proliferation to differentiation to aggregation. However, while this 
characterized system has shown to be versatile and can potentially be used for a variety 
of applications in MSC-based therapies, future work can expand on the insights gained 
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from this dissertation to better understand how the molecular interactions of heparin and 
growth factors at the cell surface affect cell behavior.  
 For a thorough investigation of MSC response to growth factors in media, 
molecular interactions at cell surfaces between the GAG layer and growth factor can be 
further characterized through depletion or “pull-down” studies. These experiments would 
culture heparin and desulfated heparin coated cells in the presence of a growth factor, 
such as FGF-2, and the concentrations of the growth factor would be measured over time 
to determine the amount of protein remaining in the environment [200]. For pull-down of 
FGF-2 within coated aggregates, this understanding will provide quantification of heparin 
coating sequestration of FGF-2 from the environment and ultimately, the contribution of 
the coating’s ability to promote an increase in cell number. To further parse out how 
heparin coatings can modulate response to FGF-2, visualization of the downstream signal 
molecules, such as Erk1/2, could provide insight into where signaling is spatially 
occurring within the aggregate [301], and whether cell proliferation via FGF-2 signaling 
is observed within the entire aggregate or around simply exterior surface. Together, this 
information can lead to a better understanding how and where the interaction of GAG 
coatings on cell surfaces can potentiate a growth factor response.  
These studies can also be particularly interesting and informative because of the 
results observed when heparin coatings of native and no sulfation were cultured with the 
chondrogenic growth factor TGF-β1. It was observed in Chapter 4 that MSC aggregates 
coated with desulfated heparin had upregulated gene expression of chondrogenic markers 
when cultured with TGF-β1 in the environment. It is known that the 6-O and N-sulfate 
groups on heparin are important for interaction with TGF-β1, therefore, upon desulfation 
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and removal of those groups, the affinity for the growth factor decreases. However, 
despite this decreased affinity, there is an increased response to the growth factor in 
desulfated heparin coated MSCs when compared to heparin coated MSCs. Studying the 
sequestration profile of TGF-β1 in the presence of a desulfated heparin coating and its 
subsequent signaling can therefore clarify the how that interaction can result in promoting 
chondrogenic differentiation in MSC aggregates.  
To further develop MSC coated aggregates for purposes of differentiation in cell-
based therapies, a different regimen of differentiation cues can be utilized to promote 
chondrogenic differentiation. For example, often times a cocktail of growth factors is 
used to promote effect differentiation of MSCs down a chondrogenic lineage for cell-
based therapies. Combinations of FGF-2, TGF-β1, BMP-7 and IGF-1 have been reported 
to all induce chondrogenic differentiation or support cartilage maturation [302]. Although 
contrasting results were observed with heparin and desulfated heparin coatings when 
cultured with two separate growth factors, the response of the coated cells when cultured 
with a cocktail of growth factors could provide insight how these coatings can promote 
differentiation in MSC aggregates when cultured in a complex environment containing 
multiple differentiation cues. Overall, this study can examine the effect of GAG coatings 
in response to different and multiple growth factors can offer novel potential strategies to 
engineer the environment surrounding cells to guide cell behavior.  
In addition to the ability of heparin to sequester positively charged growth factors, 
heparin also has the ability to act as a delivery vehicle and support controlled release of 
growth factors [16, 17, 199, 303]. It was observed in Chapter 3 that this heparin coating 
facilitated loading of TGF-β1 onto cell surfaces and that the released growth factor 
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remained bioactive. Further studies can be performed to examine the amount of released 
TGF-β1 and whether it is able to signal to another population of cells to promote 
chondrogenic differentiation. Additionally, this coating platform establishes an 
opportunity to explore how altering sulfation pattern can modulate the release of a loaded 
growth factor from cell surfaces. It has previously been shown that selectively desulfating 
heparin can tune the release of growth factors, in which increasing desulfation resulted in 
increased cumulative release of FGF-2 [164]. Thus, by observing the release profiles of 
growth factors from engineered cell coatings of heparin species with varying sulfation 
levels, these studies can provide insight into how GAG coatings on cells can be 
engineered into a dual-delivery system in which both cells and a released biomolecule 
can act to help regenerate and repair a site of injury.  
For translation into in vivo studies and eventually clinical settings, a coating that 
uses minimal manipulation of the cells may be preferred and beneficial. MSCs that have 
not been subjected to multiple incubations steps that are not performed in the preferred 
media environment of the cells may reduce cell loss during the coating process. 
Ultimately, the current layer-by-layer deposition of biotin and avidin, while effective in 
grafting multiple molecules onto cell surfaces, requires extensive manipulation of cells. 
Additionally, it has been shown that the use of avidin has the potential to promote an 
immunogenic response when translated to in vivo settings [304]. The removal of this 
layer combined with development of a method to graft the GAG layer directly to cell 
surfaces may lead to a coating process that is more efficient in retaining live cells and 
requires less manipulation, thus is less time consuming.  
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Two suggested methods to achieve a more optimal coating process are to utilize 
covalent conjugation to cell surface amino residues or to incorporate amphiphilic 
polymers into lipid bilayer membranes by hydrophobic interactions [207, 305]. Both 
methods require chemical modification of the GAG of interest, however there is no 
longer a necessity of having intermediate layers because of the direct conjugation onto 
cell surfaces. For covalent conjugation, heparin can be chemically modified with the N-
hydroxyl-succinimidyl ester group to form covalent bonds to amino groups of membrane 
proteins [306, 307]. Poly (ethylene glycol)-conjugated phospholipids (PEG-lipid) or poly 
(vinyl alcohol) bearing hydrophobic alkyl side chains (PVA-alkyl) have been used due to 
the spontaneous attachment to cell membranes by anchoring into the lipid bilayer 
membranes through hydrophobic interactions [308-310]. Both methods require 
modification of heparin or the GAG of interest with these added side groups that directly 
target moieties on cell surface membranes. Using these direct coating methods, the 
removal of layer-by-layer deposition can provide a less manipulative process to coat cells 
and ultimately can be easily translated for clinical scale up.  
 Aside from having the ability to potentiate growth factor response, heparin 
coatings and their interactions with growth factors can be exploited to promote cell 
aggregation, as observed in Chapter 5. By presenting heparin and HEPpep onto cell 
surfaces, the interaction can be harnessed to bring together the two differentially coated 
populations as assembly of small building blocks. This assembly can be used to build 
microtissues in a self-aggregating manner that does not require manual manipulation of 
seeding different cell populations around each other. While assembly of coated MSC 
spheroids was performed in Chapter 5, this coating technology is applicable and 
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translatable to other cell types, as has been observed in both literature and Chapter 2 
[229, 230, 279]. Thus, this coating technology for assembly of microtissues can be used 
to study complex systems with multiple cell types, such as hepatocyte and fibroblast co-
cultures to maintain cell phenotype and function, as well as model complex stem cell 
environments, such as the bone marrow to understand how MSCs, endothelial cells and 
osteoblasts can interact to maintain HSC phenotype [96, 148, 149, 294]. Furthermore, 
HEPpep and heparin coatings can be applied to nonadherent immune cells to promote 
aggregation of lymphocytes and platelets because it is known that cell-cell contacts 
between these cell types can enhance adhesion and cell migration of T and B cells [311, 
312]. This can be used to study heterotypic interactions and cross talk between 
lymphocytes and platelets to examine the important regulatory mechanisms from 
aggregation in thrombosis, inflammation and atherosclerosis processes [311, 312]. 
Furthermore, by using HEPpep coatings cultured in soluble heparin, homotypic 
lymphocyte aggregation can also be engineered, as cell-cell interactions play a central 
role in T and B cell activation as well as migration of cells during the inflammatory 
response [313-315]. Because of the versatility of this technology, the usage of these 
coatings is not limited to the forming MSC microtissues in a self-assembled manner, and 
this platform can be translated to other cellular systems to study behaviors, such as 
functional phenotype, migration, and immune cell activation.  
The studies performed in this dissertation with this coating system were 
performed in a dynamic system in which MSC spheroids were cultured in suspension. 
While in this suspension system, heparin coated MSC spheroids were able to interact 
with HEPpep coated MSC spheroids to form small constructs containing multiple cell 
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populations. While further parameters of the system should be optimized to control how 
these coated cells assemble in terms of bringing together two different populations in 
direct contact with each other, the dynamic platform to promote aggregation of a 
population of building blocks can be translated to larger scale processes to form large 
populations of microtissues. This could be useful because many of the proposed MSC-
based therapies require high and multiple dosages of cells, therefore, large expansion and 
culture of these cells are necessary [5]. The assembly of coated MSC spheroids in a 
dynamic rotational system establishes the basis for a future platform to construct a 
population of small microtissues in a system that is amenable to large scale production 
that could be translated into clinical use.  
 Combined with the results from Chapter 3, this technology has the potential to not 
only assemble cell populations for microtissue construction, but also deliver growth 
factors to a specific population. It was shown that the interaction between heparin and 
FGF-2 can promote a potentiated growth factor response in the coated cells. Therefore, 
incorporating that aspect with microtissue assembly, this coating technology could be 
used to not only promote self-assembly within a coated population of cells, but also 
deliver biomolecules of a specific population of coated cells to promote a subsequent 
behavior and response. In the case of culturing hepatocytes for the use of liver-assist 
devices, coated hepatocytes and MSCs could be assembled together using this system to 
form a population of tissue constructs with controlled homotypic and heterotypic 
interactions to produce a hepatocyte population that is phenotypically functional (urea 
and albumin production). Once those parameters are optimized and achieved, a growth 
factor, such has HGF, can be delivered to the heparin-coated MSC populations in the 
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constructs to promote differentiation down the hepatic lineage to form hepatic tissue 
constructs that could be implemented for liver repair or in a liver-assist device [141]. This 
system exploits both the ability of heparin and HEPpep coatings to promote self-
assembly of cells, but also the sequestration properties of heparin. Additionally, because 
this system is performed in a dynamic setting that supports both the construction and 
culture of microtissues, this facilitates the ability to temporally introduce different 
components into the cultured constructs. Therefore, once microtissues have been 
constructed and cultured, it is possible to continue to build up the construct by 
introduction of another coated population. In the case of hepatocyte and MSC 
microtissues, once constructed and cultured to a desired timepoint, the addition of coated 
endothelial cells can be introduce and self-assembled to represent the in vivo sinusoidal 
structure found in functional liver tissue [316]. This platform represents a modular 
system that can promote the construction and support the culture of complex tissue 
structures by exploiting molecular interactions of heparin at cell surfaces.  
 Future work can expand on the various principles and findings presented in this 
dissertation to develop a GAG coating that is able to control the immediate 
microenvironment around a cell to guide cell behavior. The numerous applications and 
usages of GAG-based coatings establish that this enabling technology can be used to 
engineer molecular interactions at the cell surface to influence cell and tissue behavior.  
Taken together, the research presented in this thesis provides valuable insight into the 
ability to engineer molecular interactions of heparin at cell surfaces to direct the behavior 





POTENTIAL APPLICATIONS FOR ASSEMBLED AGGREGATES 
DEVELOPED IN AIM 3 
 Although the results from Chapter 5 did not reveal a robust system that can be 
used to control assembly for microtissue formation in a self-assembled manner, the 
applications of exploiting molecular interactions between heparin and HEPpep coated 
cells can also be used in other technologies, such as bioprinting. Bioprinting is a recent 
method to create biologically relevant materials and is defined as a set of techniques that 
transfer biologically important materials onto a substrate. The result of bioprinting is a 
complex, well defined three-dimensional structure that recreates multicellular tissues and 
organs de novo [317, 318]. Some examples of bioprinting methods include dip pen 
lithography and ink jet deposition, both of which place cells onto a substrate and is 
repeated to build up a hierarchical construct containing different cells in a specific 
orientation [319, 320]. However, some limitations of these methods include developing a 
nontoxic and non-damaging technique to assemble constructs rapidly to form a cohesive 
and mechanically stable tissue while maintaining the integrity of the cells. Additionally, 
printed constructs must be suitable for perfusion and be able to survive some printing 
methods that can require high shear environments [317]. Therefore, the application of the 
coating technology can be incorporated into existing bioprinting methods to help 
overcome these limitations.  
 By harnessing the interactions between heparin and HEPpep, these molecules can 
be coated onto cell surfaces or the substrates to promote rapid cohesion of each 
component. Because these coatings have been shown to promote assembly and contain a 
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level of specificity for each other, heparin and HEPpep coatings can essentially be used 
as a “glue” to keep the printed cells together and promote stable formation of the 
resulting tissue. These coatings can be incorporated into laser-induced transfer methods 
in bioprinting that aim to create grafts for wound healing applications that use both 
fibroblast and mesenchymal stem cells in a graft [321]. Coating these cell types can 
facilitate the ability to direct the organization of the cell types within the graft by 
promoting adhesion and aggregation in different orientations through the heparin and 
HEPpep coating interactions. Additionally, for bioprinting methods such as ink-jet 
delivery or laser-induced deposition, cell suspensions are often used and methods are 
often performed in fluid environments to maintain the integrity of the living cells [317]. 
Shear stresses caused by the transfer and deposition of printing may cause an unstable 
environment that the results incorrect orientation and formation of the tissue. Therefore, 
printing layers or sections of a tissue must allow for the printed materials to adhere to 
each other before proceeding to a subsequent section. Incorporation of the coating 
technology can be potentially useful because it has been shown to promote assembly 
between populations under dynamic culture settings. Therefore, it could be used in a 
shear-containing environment to help stabilize and form a printed tissue in the correct 
orientation faster by exploiting the heparin and HEPpep interaction and promoting cell 
adhesion. Overall, the application of incorporating heparin and HEPpep coatings into 
bioprinting techniques can result in promising and novel methods in bioprinting of tissues 
and organs.  
 In addition to incorporating these coating technologies into the bioprinting 
process to form these constructs, heparin and HEPpep coatings can also be used to direct 
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the shape and function of the printed tissue over time. This modular system is possible 
because the heparin coatings can be found on cell surfaces for up to 14 days and HEPpep 
coatings can be seen for at least 3 days, therefore, by harnessing their interactions to 
promote assembly, additional coated components can be aggregated onto the tissue 
construct or different orientations of the overall tissue can be changed after initial 
construction. Specifically, this can be used in one approach to form microvessels for 
vascular tissue engineering. Typically, bioprinted capillaries can be formed by using bio-
ink particles (cells or cell aggregates) that are deposited on a cylindrical template. 
However, one limitation is the need for the particles to form adhesion junctions with each 
other through cell-cell contacts or ECM deposition to form a stable vessel [318]. The use 
of this coating technology allows bioprinting processes to form the tissue construct in an 
initial configuration, such as a cell sheet that facilitates a stable formation of the complex 
microstructure and layers in a vessel [322, 323], followed by the subsequent 
transformation into a cylindrical vessel by exploiting the interactions with heparin and 
HEPpep coatings to direct formation of adhesive junctions at the edges of the cell sheet. 
Therefore, incorporation of this coating technology into bioprinting applications 
potentially allows for modulating tissue shape and subsequent function over time after 
initial construction.  
 While further optimization of the coating system used in Chapter 5 is needed to 
fully develop a self-assembled microtissue formation technique, the exploitation of the 
heparin and HEPpep interactions can be used to form microtissue systems that are used to 
model complex in vivo environments. One example includes promoting aggregation via 
heparin and HEPpep coatings between lymphocytes and platelets to examine the 
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important regulatory mechanisms in thrombosis, inflammation and atherosclerosis 
processes [311, 312]. It is known that cell-cell contacts of both homotypic and 
heterotypic interactions can enhance the adhesion, cell migration and tissue infiltration of 
T and B cells [311]. Therefore, these coatings can be used as a means to promote and 
control assembly of these multicellular aggregates to potentially study how the amount 
(more or less aggregation) or type (homotypic or heterotypic) of interaction can affect 
lymphocytes and platelet activation in inflammatory responses. While this is a promising 
application, further optimization still needs to be performed to study the effects of these 
coatings on different cell types and new parameters, such as ratio, rotation speed and 
culture time, need to be determined to understand how these coatings can promote and 
control assembly or aggregation of different cell types.  
 Finally, this coating technology can potentially be used to form small tissue 
constructs containing multiple adherent cell types. The exploitation of the heparin and 
HEPpep coatings can be used to direct the spatial organization of the construct to mimic 
the in vivo tissue structure. This is particularly applicable for tissues with multiple zones 
containing different cell types and tissue structures, such as osteochondral constructs that 
interface between cartilage and bone tissue [324]. By harnessing the interactions of 
heparin and HEPpep, coated chondrocytes and osteoblasts can be assembled into 
osteochondral constructs that contain on one end, the cartilage tissue, and on the other 
end, the bone tissue. To achieve this level of controlled assembly, parameters of how 
many total cell building blocks are needed in the system, the ratio of the cell populations, 
and the dynamic and or static culture conditions need to be determined to develop a 
system that can support assembly in a controlled manner to form tissue constructs with 
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directed spatial orientations. In this example, the potential application of these coatings 
can ultimately be used to form constructs for both tissue repair for cartilage injuries and 







B.1 Alginate bead heparin coating in media 
B.1.1 Materials and Methods 
Alginate beads were used as an acellular control for MSC spheroids due to their 
ease of formation and spherical shape. Alginate beads were made using the Nisco 
electrostatic bead generator, in which 3% alginate formed ~200 μm droplets in 100 mM 
calcium chloride. Beads were coated with 0.1% poly-L-lysine, followed by 4 mM EZ-
Link Sulfo-NHS-LC-Biotin in PBS, followed by 0.5 mg/mL avidin in PBS, and, lastly, 5 
mg/mL biotin-conjugated heparin in PBS. Each layer was incubated for 1 hour with 
washing steps between layers. The volume of 0.1 mL beads was incubated at 37ºC in 
MSC maintenance media (containing 10% FBS) replaced every other day. The heparin 
coating was imaged under the same imaging parameters (laser intensity, gain, and 
exposure time) via confocal microscopy immediately after coating (day 0) and at day 7. 
Fluorescent quantification was performed in ImageJ.  
B.1.2 Results 
After alginate beads were formed and coated, confocal imaging was used to 
image the heparin layer on the surface of the alginate beads. Immediately after coating, 
heparin was seen around the bead surfaces. After 7 days in MSC maintenance media, 
beads were imaged and heparin was still observed on the surface of beads with no 





Supplemental Figure B.1. Alginate bead heparin coating in media. A) Heparin seen 
in red on alginate bead surfaces immediately after coating procedure (day 0). B) 
Heparin on alginate bead surfaces after being cultured in MSC media for 7 days at 
37ºC. C) Quantification of fluorescence on alginate bead surfaces over 7 days, p < 
0.05, n=4.  
 
 
B.2. Luminescence of MLEC aggregates without TGF-β1 exposure 
B.2.1 Materials and Methods 
Noncoated MLECs were cultured with soluble heparin (5 mg/mL or 5 μg/mL) and 
exposed to TGF-β1 (3 ng/mL) for 30 minutes to mimic the coating procedure used in this 
study, but using a non-modified heparin that should not attach to cell surfaces. Following 
the same procedure as outlined for experiments shown in Figure 3.4, cells were then 
formed into 500-cell aggregates. Subsequently, the aggregates were cultured for 24 hours 
in media without heparin or with soluble heparin at 5 μg/mL or 5 mg/mL. After 24 hours 
in culture, cells were lysed with ONE-Glo
TM
 Luciferase Assay buffer and luminescence 
was measured using a plate reader. 
B.2.2 Results 
It was observed that soluble heparin at both concentrations without any TGF-β1 
stimuli resulted in significantly lower luminescence response when compared to the 
control group of 3 ng/mL TGF-β1 exposure. With TGF-β1 exposure, there was no 
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difference observed in cells cultured with soluble heparin at either concentration 
compared to the control group. The resulting observations reveal that the luminescence 
response seen in Figure 3.4E is not a result of soluble heparin in solution.  
 
Supplemental Figure B.2. MLEC aggregates without TGF-β1 exposure had 
significantly less luminescence response compared to control with TGF-β1 exposure. 
* Statistically different than TGF-β1 only control, p < 0.05, n=5. 
 
 
B.3. Luminescence response to noncoated MLECs with increasing TGF-β1 dosage 
B.3.1 Materials and Methods 
The MLEC response curve was made by plating MLECs at 50,000 cells/cm
2
 in 
96-well plates and culturing them in media containing TGF-β1 ranging from 0 pg/mL to 
750 pg/mL with or without 5 mg/mL heparin. This concentration was chosen based on 
the coating concentration of 5 mg/mL, representing the maximum amount of heparin that 
could be released into the supernatant from the coated surface. After 24 hours in culture, 
cells were lysed with ONE-Glo
TM
 Luciferase Assay buffer and luminescence was 





Higher luminescence levels were observed with higher concentrations of TGF-β1. 
Additionally, when heparin was is present in the media (5 mg/mL), the luminescence 
response was significantly lower at higher TGF-β1 concentrations (375 pg/mL and 750 
pg/mL) when compared to samples without heparin in solution. These results confirm 
that the luminescence values reported in Figure 4F are not attributable to soluble heparin 
released from the cell coatings, even if all of heparin on the coatings was released within 
the 24 hour assay period. 
 
Supplemental Figure A.3. Luminescence response from noncoated plated MLECs 
when exposed to increasing TGF-β1 concentrations for 24 hours. # Statistically 
different than sample at same TGF-β1 concentration with no heparin, p < 0.05, n=3. 
 
 
A.4 Fluorescently tagged Hep and Hep- coatings  
A.4.1 Materials and Methods 
Biotinylated-heparin (Hep) and biotinylated-desulfated heparin (Hep-) species 
were fluorescently tagged with AlexaFluor®-633 by EDC coupling in 0.1M sodium 
bicarbonate buffer containing 10 mg/mL GAG, 10mM AlexaFluor®-633-hydrazide, 
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20µM EDC. The solution reacted for 1.5 hours at room temperature while protected from 
light before dialysis in 3500MWCO tubing for two days and lyophilization for two days. 
Cells were coated as described in the Materials and Methods section of Chapter 4 using 
the fluorescently tagged heparin derivatives, and formed into 2000-cell aggregates in 5% 
Pluronic-coated 96-well V-bottom plates and cultured in serum-free media containing 
Dulbecco’s Modified Eagle Medium, 1% nonessential amino acids, 1% 
antibiotic/antimycotic, 1% insulin, human transferrin and selenous acid premix and 50 
μg/ml ascorbate-2-phosphate. At days 1,7 and 14, aggregates were collected, washed in 
PBS, and imaged under confocal microscopy at excitation wavelength 633nm and 
emission wavelength 647nm (Zeiss LSM 700 LSM confocal microscope). Images taken 
at the center of the aggregate were extracted and fluorescence observed was quantified 
using Image J (NIH, Bethesda, MD) (n=9).  
A.4.2 Results 
The fluorescence signal (seen in red) was observed strongly at day 1, and 
decreased over the course of 14 days (Supplemental Figure A.4A). Image analysis 
revealed that by day 14, both Hep and Hep- coated aggregates had decreased ~70% in 




Supplemental Figure A.4. Fluorescently tagged Hep and Hep- coatings decrease in 
fluorescent intensity over 14 days in culture. A) Confocal images of Hep and Hep- 
coating (seen in red) at center of aggregate on day 1, day 7 and day 14. B) Image 
analysis of fluorescently tagged Hep and Hep- coatings quantified with ImageJ 
revealed that both coatings decreased in fluorescence at similar rates over 14 days. 
Scale bar = 100um, n=9. 
 
 
B.5 MSC aggregates coated with biotin and avidin  
B.5.1 Materials and Methods 
MSCs were coated as described in the Materials and Methods section, but with 
only the intermediate layers of 4 mM NHS-biotin and 0.5 mg/mL avidin prior to 2000-
cell aggregate formation in 5% Pluronic-coated 96-well V-bottom plates and cultured in 
serum-free media containing Dulbecco’s Modified Eagle Medium, 1% nonessential 
amino acids, 1% antibiotic/antimycotic, 1% insulin, human transferrin and selenous acid 
premix and 50 μg/ml ascorbate-2-phosphate without growth factor supplements. At days 
1, 7 and 14, MSCs were collected and processed for histological staining with H&E as 





When MSCs were coated with only the intermediate layers of biotin and avidin, 
the rounded cell morphology was not observed, with aggregates at day 14 exhibiting 
similar morphology to noncoated aggregates (Supplemental Figure B.5).  
 
Supplemental Figure B.5. MSC aggregates coated with only biotin and avidin layers 
(no Hep or Hep- layer) do not exhibit rounded cell morphology over the course of 14 
days. H&E stain; Scale bar = 100um, inset scale bar = 25µm, n=8.  
 
 
B.6 MSC aggregates cultured with heparin supplementedin the media  
B.6.1 Materials and Methods 
Noncoated MSCs were formed into 2000-cell aggregates in 5% Pluronic-coated 
96-well  V-bottom plates and cultured in serum-free media composed of Dulbecco’s 
Modified Eagle Medium, 1% nonessential amino acids, 1% antibiotic/antimycotic, 1% 
insulin, human transferrin and selenous acid premix and 50 μg/ml ascorbate-2-phosphate 
supplemented with 10 ng/mL FGF-2 (Noncoated + FGF), 5 mg/mL heparin (Noncoated + 
Soluble Hep), or 5 mg/mL heparin and 10 ng/mL FGF-2 (Noncoated + Soluble Hep + 
FGF). At day 1, 4 and 7, aggregates were collected and processed for histological 
staining with H&E (n=16) or DNA content analysis using the CyQUANT® Cell 





H&E staining revealed that morphology of these aggregates cultured with soluble 
heparin did not result in the formation of rounded cell morphology (Supplemental Figure 
B.6A). Additionally, at day 4, DNA amounts did not increase for aggregates cultured 
with soluble Hep without FGF-2 (0.42+0.1 fold) and with FGF-2 (0.74+0.1 fold) and did 
not increase by day 7 (Supplemental Figure B.6B). This suggests that the observed 
effects are related to the coating and not any heparin released in the system. 
 
Supplemental Figure B.6. MSC aggregates cultured with heparin supplemented in 
culture media at 5mg/mL did not exhibit rounded cell morphology at day 1 or 
increased DNA content over time. A) H&E staining of noncoated aggregates 
cultured with heparin supplemented in soluble form to culture media with or 
without FGF-2. Scale bar=100µm, inset scale bar = 25µm, n=16. B) DNA content of 
MSC aggregates with soluble heparin and FGF-2 compared to noncoated control 
with FGF-2 and aggregates with soluble heparin (no FGF-2 in media). Data 
reported as average mean + standard deviation, p<0.05, n=8. 
 
B.7. Safranin-O staining of coated MSC aggregates cultured in TGF-β1 
B.7.1 Materials and Methods 
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MSC aggregates were coated, as described in the Materials and Methods section, 
formed into 2000-cell aggregates in 5% Pluronic coated 96-well V-bottom plates and 
cultured in serum-free media containing Dulbecco’s Modified Eagle Medium, 1% 
nonessential amino acids, 1% antibiotic/antimycotic, 1% insulin, human transferrin and 
selenous acid premix and 50 μg/ml ascorbate-2-phosphate supplemented with 10 ng/mL 
TGF-β1 and 100nM dexamethasone for 21 days. At days 1 and 21, samples were 
collected and processed for histological staining with Safranin-O. 
B.7.2 Results 
Safranin-O staining, typically used to visualize GAG deposition, was detected at 
day 21 for all groups cultured in TGF-β1 (seen in light purple near cells).  
 
Supplemental Figure B.6. Safranin-O staining reveals that all aggregates cultured 
with TGF-β1 deposited GAG (light purple) after 21 days in culture. Scale bar = 
100um, inset scale bar = 25µm, n=12. 
 
B.8. Collagen I immunostaining of coated MSC aggregates cultured in TGF-β1 
B.8.1 Materials and Methods 
MSC aggregates were coated, as described in the Materials and Methods section, 
formed into 2000-cell aggregates in 5% Pluronic-coated 96-well V-bottom plates and 
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cultured in serum-free media containing Dulbecco’s Modified Eagle Medium, 1% 
nonessential amino acids, 1% antibiotic/antimycotic, 1% insulin, human transferrin and 
selenous acid premix and 50 μg/ml ascorbate-2-phosphate supplemented with 10 ng/mL 
TGF-β1 and 100nM dexamethasone for 21 days. At days 1, 14 and 21, samples were 
collected and processed for immunostaining (specific methods found in Materials and 
Methods section of Chapter 4) for the ECM molecule collagen I using a 1:60 dilution of 
the primary antibody and 1:200 dilution of the secondary antibody. 
B.8.2 Results 
Positive staining for collagen I was observed for all aggregates at the initial day 1 
timepoint. However, over the 21 day culture, the staining detected did not appear to 




Supplemental Figure B.8. Positive collagen I immunostaining was observed for all 
groups. Collagen I is seen in green and cell nuclei are stained blue. Scale bar = 







C.1 Calculations for Amount of GAG and HEPpep Grafted on Cell Surfaces 
C.1.1 Calculation Description   
To calculate the maximum amount of heparin that can be grafted onto cell 
surfaces, calculations were made based on surface area. This means that the amount of 
maximum surface area present on cell surfaces was the limiting factor in how much 
heparin could exist on surfaces. Heparin chains were assumed to be cylindrical in shape 
assembled on cell surfaces in a tightly packed configuration, as has been observed with 
protein configuration on surfaces [325]. Concentrations of heparin and GAG used in 
coating steps can be converted to the total amount of heparin molecules present in 
solution through conversions using molecular weight and Avagadro’s number.  
To calculate an appropriate concentration of HEPpep for coating experiments, the 
assumption that the binding of HEPpep to heparin requires one molecule of each. This is 
based on binding of FGF-2 to heparin, in which one pentasaccharide unit is needed to 
bind one growth factor molecule [20]. Therefore, the concentration of HEPpep was based 
on the theoretical number of heparin molecules present at 5 mg/mL coating 
concentration. The number of molecules for heparin and HEPpep were first matched, and 
then that number of HEPpep molecules was converted into a concentration. While the 
final concentration for HEPpep coating was chosen based on this calculation, it was 
assumed that not all HEPpep molecules get on cell surfaces since some may be lost 
during coating incubation steps to other surfaces, such as the coating vessel. Therefore, 
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the final concentration chosen was greater than that of the calculated concentration based 
on the number of molecules that matched.   
C.1.2 Calculation Equations 
C.1.2.1 Measurements for calculations  
Table B.1.2. Diameter and molecular weight values. 
Molecule Diameter (µm) Molecular Weight (kDa) Reference 
Mesenchymal stem cell 30 - [326]  
Heparin 0.001 20 [327, 328]  
HEPpep  - 1431.76   
 
C.1.2.2 Calculation for maximum number of heparin molecules grafted on cell surfaces 
𝑴𝒂𝒙 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒉𝒆𝒑𝒂𝒓𝒊𝒏 𝒎𝒐𝒍𝒆𝒄𝒖𝒍𝒆𝒔
=
𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑐𝑒𝑙𝑙






2 ∗ 100,000 𝑐𝑒𝑙𝑙𝑠 
Note: 100,000 cells were used as an approximate amount that would be coated 
with 1 mL of the GAG coating solution.  
C.1.2.3 Calculation for number of heparin molecules available at a given concentration 









∗ 𝐴𝑣𝑎𝑔𝑎𝑑𝑟𝑜′𝑠 𝑁𝑢𝑚𝑏𝑒𝑟 
C.1.2.4 Calculation for HEPpep coating concentration  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑒𝑝𝑎𝑟𝑖𝑛 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑎𝑡
5𝑚𝑔
𝑚𝐿





𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝐸𝑃𝑝𝑒𝑝 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠
𝐴𝑣𝑎𝑔𝑎𝑑𝑟𝑜′𝑠 𝑛𝑢𝑚𝑏𝑒𝑟 
∗ 𝐻𝐸𝑃𝑝𝑒𝑝 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑎𝑟 𝑤𝑒𝑖𝑔ℎ𝑡   
C.1.2.5 Calculation results  
Table C.1.2. Concentration and number of molecule values for heparin and HEPpep 
coating solutions 
 
Concentration # of Molecules  
Maximum heparin molecules per 100,000 cells - 3.6*10
14
 






















C.2 Calculations for Theoretical Binding Area  
C.2.1 Calculation Description  
To alter binding area (BA) in Chapter 5, different sized spheroid paired with each 
other was used to represent high and low theoretical binding area between two 
populations. To calculate theoretical surface area in the system, different sized spheroids 
were paired together while holding total number of cell type constant within the system. 
This was performed first by determining how cell number per spheroid can affect the 
diameter (Table C.2.1). Once different size spheroids were established, surface area for 
each spheroid size was calculated and different pairs of spheroids of different sizes were 
matched up. To calculate the number of smaller spheroids can bind and interface with 
larger spheroids, the assumption that the smaller spheroids would organize to pack tightly 
on larger spheroid surfaces was made. To calculate the number of small spheroids that 
would pack onto a large spheroid, the ratio of the surface area of the larger spheroid was 
compared to the projected area of the smaller spheroid. These numbers were then used to 
calculate the theoretical binding area between the two populations and the total cell 
numbers of each population. The resulting groups were referred to as low and high SA 
groups based on their resulting total binding area values.  
C.2.2 Spheroid Size Quantification  
 Spheroid size can be altered by changing the number of single cells formed into a 
spheroid. Spheroids containing cell numbers ranging from 100 to 2000 were formed and 
after 24 hours, their diameters were measured using phase microscopy and ImageJ 
analysis (n = 5 images containing approximately 30 spheroids). Table C.2.1 summarizes 
the approximate size of spheroids with increasing cell numbers.  
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Table C.2.1 Size of spheroids with increasing cell numbers 






C.2.3 Calculation Equations  
C.2.3.1 Calculation for surface area  




C.2.3.2 Calculation for projected area  
 Projected area was calculated as the projected area that a sphere would cover, 
ultimately resulting in a square shadow.  
𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑒𝑑 𝐴𝑟𝑒𝑎 =  (𝑑𝑠𝑝ℎ)
2 
C.2.3.3 Calculation for packing of smaller spheroids  
 To calculate packing of smaller spheroids, the projected area of the smaller 
spheroid was compared to the spheroid surface area of the larger spheroid. The number of 
Population A spheroids packed onto Population B spheroid surfaces is summarized in 
Table B.2.3.  
𝑅𝑎𝑡𝑖𝑜 𝐵: 𝐴 =
𝐿𝑎𝑟𝑔𝑒𝑟 𝑆𝑝ℎ𝑒𝑟𝑜𝑖𝑑 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝐴𝑟𝑒𝑎 (𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐵)
𝑆𝑚𝑎𝑙𝑙𝑒𝑟 𝑆𝑝𝑒𝑟ℎ𝑜𝑖𝑑 𝑃𝑟𝑜𝑗𝑒𝑐𝑡𝑒𝑑 𝐴𝑟𝑒𝑎 (𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐴)
  
 
C.2.3.4 Calculation for theoretical binding area between two populations  
To calculate theoretical binding area between the two populations, the assumption 
that 80% of the area of the spheroid at its diameter was interfaced and bound to the 
surface was used for each smaller spheroid (Population A) that was bound to the surface 
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of the larger spheroid. To calculate total binding area, the binding area for one spheroid 
was multiplied by the ratio of smaller spheroids that could pack onto the larger spheroid 
surface (Ratio B:A). Total theoretical binding areas for two groups are seen in Table 
C.2.3.  
𝑇𝑜𝑡𝑎𝑙 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 𝐴𝑟𝑒𝑎 = (0.8) ∗ 𝜋(
𝑑𝑠𝑝ℎ 𝐴 
2
)2 ∗ (𝑅𝑎𝑡𝑖𝑜 𝐵: 𝐴) 
C.2.3.5 Cell number calculations  
 The purpose of this calculation was to ensure that the number of cells in each 
population was approximately the same for the different experimental groups with 
different sized spheroids paired together in the orientation that the smaller Population A 
spheroids are packed tightly on the larger Population B spheroids. To do so, the cell 
number for Population B (larger spheroids) were matched between the two groups and 
the smaller spheroid number was then recalculated based on the Ratio of B:A number. 
For example, the 100:500 group, the Final Cell Number for Population B was multiplied 
by 4 to match the Final Cell Number of Population B in the 200:2000 group. Final Cell 
Number of A for the 100:500 group was then multiplied by 4 and the Ratio of B:A for 
that group resulting. Resulting cell numbers are summarized in Table C.2.4.  
 
C.2.3.6 Calculation results  
 
Table C.2.2. Surface area and projected area of spheroids of different sizes.  







100 98 30156.6 9604 
200 109 37306.3 11881 
500 149 69711.1 22201 







Table C.2.3. Number of Population A spheroids packed onto Population B spheroid 
surface (Ratio B:A) and resulting binding area.  
Cell number - Population A 
(smaller) 
Cell number - Population B 
(larger) Ratio of B:A 




100 500 7.3 43778.596 
200 2000 15.2 113582.59 
 
Table C.2.4. Final cell numbers for spheroids in Population A and B for the two 
experimental groups.  
Cell number - Population A 
(smaller) 
Cell number - Population B 
(larger) 
Final Cell 
Number A Final Cell Number B 
100 500 2903.4 2000 






H NMR SPECTRA 
 
D.1 Conjugation efficiency calculations 
 To calculate conjugation efficiency, 
1
H NMR analysis was utilized to identify 
relative amounts of heparin or desulfated heparin and biotin in each synthesized product. 
Using NMR, unique hydrogen groups on heparin, desulfated heparin and biotin were 
identified and peaks were integrated to provide relative amounts of how much each group 
is present in the sample. Using this method of analysis, the amount of biotin conjugated 
to heparin or desulfated heparin was measured after synthesis of these biotinylated 
GAGs.  
 Heparin and desulfated heparin were identified with the hydrogen group that 
exists on the hydroxyl group (-OH) of the saccharide unit [329]. The peaks were 
observed within the range of 5.1-5.6 ppm. This integration was normalized to 1 to 
represent a single heparin or desulfated heparin unit that exists in the sample. The 
following integration for other peaks is then relative to that initial normalization. To 
identify the amount of biotin present, the 2 hydrogen groups found on the carbon groups 
next to the amine group in the chain linker portion is integrated at 2.5-3.0 ppm. There are 
typically 2 peaks included within this integration and the resulting integration value is 
measured. That value is then divided by 2 to determine the amount of biotin present. This 
is performed because there are 2 hydrogens contributing to that integration value. The 
resulting value is the percentage of biotin found per one unit of heparin, and referred to in 
this thesis as the biotin conjugation efficiency. Table D.1.1 summarizes the integration 
162 
 
values and conjugation efficiencies calculated for the biotinylated products used 
throughout this thesis.  
Table D.1.1 Biotinylation Conjugation Efficiency 
Date Sample Peak Integration Biotinylation Efficiency 
1/21/2014 Desulfated heparin 5.1-5.6 1   
    2.5-3.0 0.32 16.0% 
2/7/2014 Heparin  5.1-5.6 1   
    2.5-3.0 0.28 14.0% 
11/4/2014 Heparin  5.1-5.6 1   
    2.5-3.0 0.42 21.0% 
11/4/2014 Desulfated heparin 5.1-5.6 1   
    2.5-3.0 0.48 24.0% 
4/24/2015 Heparin  5.1-5.6 1   
    2.5-3.0 0.45 22.5% 
4/24/2015 Desulfated heparin 5.1-5.6 1   
    2.5-3.0 0.41 20.5% 
8/24/2015 Heparin  5.1-5.6 1   
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